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SUMMARY
The regulation of human interferon-gamma production by 
peripheral blood mononuclear leukocytes, stimulated by 
polyclonal T-cell activators (mitogens), was investigated 
because of its possible importance as a regulator of the 
immune response and because it usually accompanies 
lymphocyte activation.
Low density lymphocytes, enriched for large granular 
lymphocytes, were shown to be capable of IFN-gamma 
production in the absence of macrophages, unlike T-cells, 
but with interaction of two subsets of this low density 
population being required for optimal production. It is 
suggested that a non-T cell low density population can act 
as accessory cells for T-cells in the absence of 
macrophages.
The action of both positive and negative modulators of 
IFN-gamma production were investigated. The importance of 
IL-1 production was demonstrated by the depressive effects 
of anti-IL-1 antibody and the ability of purified IL-1 to 
reverse the depressive effects of macrophage-depletion on 
T-cell activation.
Blockade of the IL-2 receptor by monoclonal antibodies 
inhibits IFN-gamma production, as does treatment with 
prostaglandin E2 , known to inhibit IL-2 production. The 
receptor blockade is reversible by pure IL-2 as is the 
PGE2 inhibition. IL-1 and IL-2 alone rarely induced any IFN-gamma. These data imply that for maximal IFN-gamma 
production the interaction of at least two other protein 
factors (IL-1, IL-2) with mitogen-stimulated T-cells is 
necessary, and that other factors may act as 
down-regulators.
A variety of cell-surface molecules involved in MHC 
restriction and also the Til antigen were also shown to 
have regulatory effects. Those of the. Til pathway may 
involve effects on calcium and IL-2 levels.
T-cell activation could also be triggered by calcium 
ionophore plus tumour promoter. Activation of the IL-2 and 
IFN-gamma genes by this method was shown to be coordinate 
and not to require protein synthesis. Thus many regulatory 
effects on IFN-gamma production probably act at a 
post-transcriptional level.
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CHAPTER 1.
INTRODUCTION.
The aim of this thesis is to investigate at least some 
of the major factors involved in regulating the production 
of immune interferon (IFN-gamma) by human peripheral blood 
mononuclear leukocytes (PBML). In this introduction the 
activity and possible functions of IFN-gamma, both in 
vitro and in vivo. will be briefly discussed in order to 
demonstrate its possible importance as a regulator of the 
immune response, and hence the necessity for investigating 
the control of its production. Since IFN-gamma is chiefly 
produced by T-cells in the course of normal T-cell 
responses, i.e. in an antigen-specific MHC restricted 
fashion, T-cell activation will also be reviewed.
1) WHAT ARE INTERFERONS?
IFN-gamma is a member of a group of molecules, the 
"interferons", which were initially identified and defined 
by their ability to induce in cells an antiviral state 
which inhibits viral replication (Isaacs & Lindenmann, 
1957). However, interferons (IFNs) also have a variety of 
non-antiviral effects including possible immunoregulatory 
roles (Kirchner, 1984). IFNs are a heterogeneous family of 
proteins, dividable into two groups (I and II) which 
differ in terms of structure, function, producer cell 
type, and mode of induction. The viral IFNs alpha and beta 
are related proteins, usually induced in vivo by viral 
infection of cells (Baron & Buckler,1963), whilst
IFN-gamma (type II) is induced by immune stimulation of
peripheral blood mononuclear leukocytes (PBML; 
Kirchner,1984). Alpha and beta were originally known as 
type I IFNs, but throughout this thesis will be referred 
to as IFN-alpha/beta where the exact type has not been 
specified or where a mixture of the two types exists. 
IFN-alpha and IFN-beta were originally distinguished as 
being produced by fibroblasts and lymphoid cells 
respectively, but these cells are not the only producers 
of these IFN types. For example, in mouse fibroblast 
cultures IFN-alpha and IFN-beta appear to be produced 
concomitantly, their production seeming to be linked 
(Yamamoto & Salvin,1980). IFN-gamma, also known as immune 
IFN, is the predominant form produced by stimulated PBML 
(Youngner & Salvin,1973).
IFN-gamma was first described in 1965 as being produced 
in lymphocyte cultures stimulated by the T-cell mitogen 
PHA (Wheelock,1965). IFN-gamma is distinguishable from 
IFNs alpha and beta in several ways, being sensitive to pH 
2, heat labile at 56°C, and antigenicaliy different, 
antibodies to IFNs alpha or beta failing to neutralise 
antigen-induced IFN-gamma (Youngner & Salvin,1973). 
However, while as a general rule IFN-alpha is acid stable, 
a novel human IFN has been described, though not yet 
adequately characterised, with the antigenic reactivity of 
IFN-alpha but which is acid labile (Balkwill fit al..1983). 
IFNs alpha/beta and IFN-gamma also bind to different 
receptors, human IFN-gamma not competing for binding with 
IFN-alpha-A, whereas all IFNs alpha and beta do compete 
(Branca & Baglioni,1981). The structure and position of
the IFN-gamma gene also differs from IFNs alpha and beta. 
More than ten distinct non-allelic genes coding for 
IFN-alpha proteins (80-95% homologous) are found on the 
short arm of chromosome 9, plus the gene for IFN-betat 
which is 40-50% homologous to the IFN-alpha genes and was 
thought for a long time to be the only IFN-beta gene 
(Shows et al.,1982; Trent et al.,1982). The single 
IFN-gamma gene, however, is found on the long arm of 
chromosome 12 (Trent et al.,1982). Furthermore, IFN-gamma 
has no sequence homology to either IFNs alpha or beta and 
also has three introns whereas alpha and betaj have none 
(Gray & Goeddel,1982). This suggests that while there may 
be a close evolutionary link between IFNs alpha and beta, 
IFN-gamma is not related and possesses certain properties 
distinct from IFNs alpha and beta.
Cloned IFNs alpha and beta! consist of 166 amino acids 
whilst IFN-gamma is composed of 146 amino acids (Gray & 
Goeddel,1982). Very recently a second IFN-beta type has 
been described, HuIFN-beta2 , whose gene structure is 
radically different from IFN-betaj in that it contains 
three introns and is located on chromosome 7 (Sehgal et 
al.,1986).
T-cell derived IFN-gamma, purified to homogeneity, 
consists of two active species (20kD and 25kD), but these 
were shown to have identical amino acid sequences and 
differed only in the extent of glycosylation of the 17kD 
protein (Rinderknecht at al.,1984). The asparagine residue 
at position 28 (numbering based on the recombinant cDNA 
sequence) is glycosylated in both species, but at position
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will therefore tell us more about T-cell activation as 
well.
i) Mitogens.
A considerable amount of research has been devoted to 
determining what signals are involved in initial T-cell 
activation and subsequent processes, mostly using mitogens 
(polyclonal activators of T-cells). Most studies assume 
that mitogen- and antigen-induced events are very similar. 
This appears to be the case since there is no evidence of
any qualitative difference in the biochemical and
physicochemical changes induced by specific and
non-specific activators. The differences in time and 
degree of response appear to be quantitative in nature and 
are due to the percentage of cells initially triggered by 
the activator.
The anti-human T-lymphocyte monoclonal antibody 0KT3 has 
potent mitogenic properties at nanogram concentrations, 
but is inhibitory at higher levels (Van Wauwe
al.,1980). It acts by binding to the trimolecular T3 
structure (Tsoukas e£ al.,1984) always closely associated 
with the T-cell antigen receptor (Ti) whose alpha and beta 
chains define antigen and MHC specificity (Saito et
¿1-,1984; Yaque gt si-,1985). Recently a putative second 
type of T-cell antigen receptor has been identified, 
composed of the gamma and "delta" chains, whose function 
is unknown (Brenner gt al..1986).
Other mitogens include the plant lectins (proteins which 
bind carbohydrates) PHA and Con A. Lectins which bind to
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D-mannose and D-glucose residues on T-eells are generally 
mitogenic and induce IFN-gamma production, and sometimes 
low levels of IFN-beta too (Ito et al.,1984). 
Phytohaemagglutinin (PHA) is derived from the kidney bean 
(Nowell,1960) and appears to bind to the carbohydrate 
moieties of T3 (Valentine et al.,1985) or Ti 
(Kanellopoulos et al.,1985). It may also bind to another 
T-cell marker Til, also known as the E (sheep erythrocyte) 
receptor (O’Flynn et ai.,1985a). Concanavalin A (Con A) 
also causes non-specific T-cell activation by binding to 
the T3 structure (Kanellopoulos et al-,1985). PHA and Con 
A bind to a large and partially overlapping range of 
glycoproteins (Henkart & Fisher,1975; Diller-Centerlind 
à!- >1980) only some of which are responsible for T-cell 
activation.
Human B-cells respond poorly if at all to T-cell 
mitogens (Janossy & Greaves,1971 ; Schuurman gt al.,1980). 
Human B-cells will proliferate in response to certain 
B-cell mitogens (e.g. Cowan I strain Staphylococcus aureus 
protein A) but require T-cell derived factors induced by 
T-cell mitogens to differentiate into immunoglobulin 
secreting cells (Dosch et al.,1980; Saiki & Ralph,1981; 
Falkoff £t al. ■1982 ) .
The mitogen Staphylococcal enterotoxin A (SEA), 
different from protein A, is derived from bacterial cell 
walls and has similar properties to the plant lectins. At 
picogram levels it is a more powerful inducer than PHA or 
Con A (Carlsson & Sjogren,1985). The ability of microgram 
concentrations of OKT3 to inhibit proliferation triggered
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by all these mitogens is consistent with the view that the 
T3 complex functions as a signal transducer in the early 
stages of T-cell activation (Van Wauwe et al.,1984).
PHA, Con A, and SEA also appear to interact with 
N-acetylneuraminic acid and galactose residues of 
glycoproteins, since their cleavage with enzymes blocks 
induction by these mitogens (Dianzani et al.,1982). 
Oxidation of terminal galactose residues of macrophage 
glycoproteins by galactose oxidase causes release of a 
soluble factor (possibly IL-1) which stimulates lymphocyte 
production of IFN-gamma (Antonelli et al.,1985) providing 
that a calcium flux also occurs (Dianzani et al.,1984). 
Thus interactions of mitogens with cell surface 
glycoproteins appears to be the method by which they 
trigger T-cell activation.
ii) Macrophages and IL-1.
Many workers have shown that T-cell activation requires 
two signals: firstly, triggering of the T-cell antigen 
receptor (Ti) and secondly, the presence of macrophages as 
accessory cells. Binding of mitogen to T3-Ti causes early 
changes in cytoplasmic free calcium ion concentration and 
membrane potential (Tsien et al.,1982; Weiss g t al. ■1984). 
Macrophages act in two ways, "passively" presenting 
antigen or mitogen and "actively" producing IL-1 (Bendtzen 
& Petersen,1984). In the relative but not complete absence 
of macrophages mitogens can induce the first stage of 
activation, associated with cellular enlargement or 
blastogenesis, with RNA and protein synthesis occurring as
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response -to antigen or mitogen stimulation (Archer et 
al. , 1979 ; Sonnenf eld et gl .,1979; Klein gt al .,1982; Valle 
et al.,1975). T-cell lines proliferating in vitro are also 
capable of IFN-gamma production when stimulated by mitogen 
(Matsuyama et al.,1982) or the appropriate antigen (Morris 
et al.,1982). Thus when a murine cytotoxic T-cell line is 
exposed to its specific target (influenza-infected P815 
cells) it produces IFN-gamma in an H-2 restricted fashion, 
but does not respond to free virus (Morris et al. . 1982). 
Furthermore T-cell lines do not require macrophages as 
accessory cells, unlike T-cells freshly derived from human 
peripheral blood which need macrophages for optimal T-cell 
activation (Unanue et al.,1984) and subsequent IFN-gamma 
production (Epstein et al.,1971).
Whilst human PBML mainly produces T-cell derived 
IFN-gamma, it must be remembered that some IFN-alpha may 
also be produced by macrophages (Roberts el al.,1979).
Alloantigens also stimulate IFN-gamma production, as 
demonstrated in both murine (Kirchner si al.,1979) and 
human mixed lymphocyte cultures (Perussia et al.,1980). 
Highest yields are obtained if there are differences in 
class II rather than class I surface antigens in both mice 
(Kirchner et al.,1979) and humans (Andreotti & 
Cresswell,1981). As in mitogen and conventional antigen 
stimulation, the main IFN type produced is gamma and the 
response is both more rapid and potent if the responder 
lymphocytes have already been pre-sensitised to the 
stimulator lymphocytes, i.e. a secondary MLR (Perussia gt 
al.,1980). T-cells are again the producers with
macrophages as accessory cells (Perussia gt al.,1980; Ito 
et al.,1980 ).
Tumour cells can also induce IFN production when mixed 
with fresh leukocytes from non-sensitised donors in vitro 
(mixed lymphocyte-tumour cell culture, MLTC). However, in 
the human system the main product is IFN-alpha rather than 
IFN-gamma and the producer cells are non-T, non-B null 
cells which do not require macrophage assistance 
(Trinchieri £t al.,1977 & 1978; Djeu st àl.,1980),
characterised as large granular lymphocytes (Timonen 
al.,1980).
In general it appears that IFN-gamma is produced in 
almost all cases in which T-cell activation has occurred, 
as measured by proliferation, and relies upon the prior 
induction of the lymphokines (mediators of cellular 
immunity produced by lymphocytes) IL-1 and IL-2 (Lotz et 
al.,1986a&b). Proliferation is not an absolute requirement 
for IFN-gamma production (Kirchner et al-,1979) and visa 
versa (Wilkinson et al.,1985).
In view of the apparent importance of T-cell activation 
and these other lymphokines in IFN-gamma production, these 
topics are discussed next, separately and in detail.
3) T-CELL ACTIVATION AND THE LYMPHOKINE "CASCADE".
In recent years it has become clear that a group of 
proteins called lymphokines, which transmit growth and 
differentiation signals between haematopoietic cells, play 
a central role in the immune system (Marx,1983). 
Lymphokines were originally described as non-antibody
8
mediators of cellular immunity produced by activated 
lymphocytes (Dumonde gt al.,1969). Similar substances 
produced by monocytes/macrophages should strictly speaking 
be termed monokines.
Activation of T-lymphocytes occurs when antigen is 
presented by macrophages to the appropriate T-cell antigen 
receptor. In addition to antigen-presentation, the 
macrophage also supplies an augmentary activation signal 
in the form of the monokine interleukin 1 (IL-1). This 
stimulates production of T-cell growth factor, known as 
interleukin 2 (IL-2), by activated T-cells which in turn 
stimulates IL-2 receptor bearing T-cells to proliferate. 
Since only antigen-stimulated T-cells normally express 
IL-2 receptors, IL-2 stimulated T-cell proliferation is 
clonally restricted to activated cells. IL-2 is also 
thought to stimulate production of IFN-gamma, which is 
itself a lymphokine with further stimulatory effects, some 
of which may amplify the response to the antigen.
There thus appears to be a cascading loop of lymphokine 
action, each of which amplifies the response to the 
triggering antigen. The initial response to the antigen is 
very specific and limited to the very few T-cells whose 
antigen-receptor binds the antigen. Once these cells are 
activated, however, they can respond to the non-specific 
effects of lymphokines and a large expansion of the 
antigen-specific cell population can occur. IFN-gamma is 
thus a reliable and relatively early marker of T-cell 
activation which is independent of proliferation. A 
greater understanding of the regulation of its production
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secreting cells (Dosch e£ al.,1980; Saiki & Ralph,1981; 
Falkoff et ai.. ,1982).
The mitogen Staphylococcal enterotoxin A (SEA), 
different from protein A, is derived from bacterial cell 
walls and has similar properties to the plant lectins. At 
picogram levels it is a more powerful inducer than PHA or 
Con A (Carlsson & Sjogren,1985). The ability of microgram 
concentrations of 0KT3 to inhibit proliferation triggered
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by all these mitogens is consistent with the view that the 
T3 complex functions as a signal transducer in the early 
stages of T-cell activation (Van Wauwe et al.,1984).
PHA, Con A, and SEA also appear to interact with 
N-acetylneuraminic acid and galactose residues of 
glycoproteins, since their cleavage with enzymes blocks 
induction by these mitogens (Dianzani et al.,1982). 
Oxidation of terminal galactose residues of macrophage 
glycoproteins by galactose oxidase causes release of a 
soluble factor (possibly IL-1) which stimulates lymphocyte 
production of IFN-gamma (Antonelli et al.,1985) providing 
that a calcium flux also occurs (Dianzani et al.,1984). 
Thus interactions of mitogens with cell surface 
glycoproteins appears to be the method by which they 
trigger T-cell activation.
ii) Macrophages and IL-1.
Many workers have shown that T-cell activation requires 
two signals: firstly, triggering of the T-cell antigen 
receptor (Ti) and secondly, the presence of macrophages as 
accessory cells. Binding of mitogen to T3-Ti causes early 
changes in cytoplasmic free calcium ion concentration and 
membrane potential (Tsien et al.,1982; Weiss et al.,1984). 
Macrophages act in two ways, "passively" presenting 
antigen or mitogen and "actively" producing IL-1 (Bendtzen 
& Petersen,1984) . In the relative but not complete absence 
of macrophages mitogens can induce the first stage of 
activation, associated with cellular enlargement or 
blastogenesis, with RNA and protein synthesis occurring as
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resting T-cells move into the Gi phase of the cell cycle 
(Williams et al.,,1984). However, lymphocytes do not enter 
the S phase, in which DNA synthesis occurs, unless a 
second signal is presented.
Experiments with macrophage-depleted lymphocytes show 
that the events of primary T-cell activation can be 
simulated in the absence of macrophages by using 
sepharose-bound 0KT3 plus purified IL-1 (Williams ®t 
al. ,1985; Palacios et al. ,1985a; Schwab et al. ,1985 ) . It 
is thought that the macrophage Fc receptors by binding 
soluble 0KT3 facilitate crosslinking of the T-cell antigen 
receptor, thereby causing the T-cells to internalise T3-Ti 
and be activated (Kan et al.,1984&1986). Facilitating 
crosslinking of the T-cell receptor appears to be one role 
of macrophages in T-cell activation. This Fc binding can 
be simulated by linking soluble 0KT3 to sepharose beads, 
since the required crosslinking does not occur if soluble 
0KT3 is used without macrophages or if monovalent 0KT3 Fab 
fragments are used (Ledbetter et al.,1986). Mitogen 
responsiveness appears to involve multivalent ligands, 
experiments with PHA and Con A suggesting that mitogenic 
ligands must be at least divalent (Lindahl-Kiessling,1972; 
Wands et al..,1976). For both PHA and Con A the binding of 
the ligand is virtually complete within 30 minutes (Ling & 
Kay,1975), the extent to which proliferation is optimal 
depending on mitogen concentration and length of exposure.
IL-1 seems to act as a general stimulator, initiating 
cell-cycle progression of triggered T-cells, into Gl and 
then S (Davis & Lipsky,1986), which has to precede IL-2
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driven proliferation (Sheurich et al.,1985). IL-1 
production is thought by some to be required for optimal 
IL-2 receptor expression (Kaye et al.,1984). Others 
suggest that T3-Ti crosslinking is a sufficient signal for 
IL-2 responsiveness and that IL-1 acts chiefly by 
triggering IL-2 production, since IL-2 receptor expression 
can occur in the absence of IL-1 (Tsoukas et al..1985: 
Meuer & Buschenfelde,1986). It is still not clear which of 
these two signals, crosslinking or IL-1, is the the main 
trigger for IL-2 receptor expression. Possibly both are 
involved. Recently it has been shown that recombinant IL-1 
can help induce both IL-2 secretion and IL-2 receptor 
expression by the IL-1 sensitive EL4 thymoma cell line 
(Lowenthal et al.,1986). IL-1 can synergise with either 
increased calcium ion levels, using ionomycin, or protein 
kinase C (PKC) activation, caused by a tumour promoter, to 
secrete high levels of IL-2, but only with tumour promoter 
will IL-1 induce IL-2 receptor expression. Thus Lowenthal 
suggests that IL-1 activates the EL4 cell line by a third 
intracellular pathway involving neither calcium nor PKC 
activation (Lowenthal et al., 1986).
The trigger for IL-1 release by macrophages in some 
cases is direct stimulation by antigen (and probably also 
mitogen), but other soluble antigens which also trigger 
T-cell proliferation do not cause IL-1 release (Wallis et 
al.,1986). These antigens may induce some additional 
T-cell signal or alternatively may induce production of 
membrane bound rather than secreted IL-1 (Kurt-Jones et 
al-i1985a). This may explain the observation of Haq el al.
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(1984) that macrophages, but not the less differentiated 
monocytes, can support T-cell proliferation without 
secreting IL-1 . The magnitude of the T-cell response to 
antigen has been shown to be proportional to the level of 
membrane IL—1 and class II major histocompatability 
complex (MHC) antigen (la) expression (Kurt-Jones et 
al.,1985b).
Class II MHC expression by macrophages is required for 
antigen/mitogen triggered T-cell proliferation, anti-MHC 
class II antibodies inhibiting IL-2 production (Larsson & 
Coutinho,1984). These cell surface molecules may act not 
only as restricting elements for antigen recognition by 
the T-cell receptor, a requirement overcome by mitogens, 
but may also be directly involved in mediating activation 
signals to the macrophage for IL-1 production (Larsson & 
Coutinho,1984; Durum & Gershon,1982). Class II MHC 
expression seems to be the major requirement for any cell 
type to act as an accessory cell, such as macrophages and 
B-cells (Grey & Chesnut,1985). Since class II expression 
is usually transient, regulating the level of expression 
on the cell surface may be crucial in controlling the 
level of immune response (Unanue et al..1984).
At least two forms of IL-1, alpha and beta, have been 
discovered (Allison,1985; Billiau et al.,1985; Wood £t 
ai.,1985) which are both synthesised as large (33kD) 
precursors before cleavage into active forms of about 17.5 
kD (Giri gt al.,1985). Many different cell types can 
produce and respond to IL-1, so that it appears to be an 
important communication molecule with multiple activities
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(Durum et al.,1985). Both IL-1 alpha and beta bind to the 
same high affinity plasma membrane receptor (80kD) found 
on both lymphoid and fibroblast/epithelial cell types 
(Dower et al.,1985; Kilian et al.,1986; Matsushima et 
al.,1986).
Activated macrophages also produce prostaglandins, 
another group of substances with multiple activities, 
which may act as inhibitors of both IL-1 production and 
T-cell proliferation (Kunkel et aj,., 1986a; Makoul et 
al..,1985). IL-1 and prostaglandin E2 (PGE2 ) , both produced 
by macrophages, act antagonistically (Hayari et al.,1985) 
with PGE2 seeming to depress the stimulatory effects of 
IL-1 and also inhibiting class II MHC expression (Snyder 
et al.,1982).
iii) Calcium ion flux and protein kinase C activation.
The early stages of T-cell activation, discussed above, 
can be bypassed without using conventional mitogens. 
Phorbol esters and calcium ionophores act synergistically 
by mimicking the membrane processes and signals thought to 
occur during normal T-cell activation (Truneh et 
al.,1985a; Isakov & Altman,1985). An influx of calcium 
ions across the cell membrane, causing a rise in 
cytoplasmic free calcium ion concentration, provides one 
essential signal. Activation and association with the cell 
membrane of the enzyme protein kinase C is the other 
signal. Both these events are usually triggered by 
perturbation of the T-cell receptor, either by antigen or 
mitogen (Imboden gt al.,1985). As discussed above,
Lowenthal has suggested that IL-1 acts by causing a third 
intracellular signal which can synergise with either 
calcium ion flux or PKC activation (Lowenthal et 
al.,1986).
In resting T-cells protein kinase C (PKC) is inactive. 
T-cell activation leads to a transient production of 
diacylglycerol in the cell membrane which helps activates 
PKC by increasing its affinity for calcium ions, i.e. the 
other signal. This activation pathway is described in more 
detail in chapter 5. Calcium ionophores mimic the T3-Ti 
induced calcium flux whilst phorbol esters mimic 
diacylglycerol by binding to and activating PKC (Kikkawa 
et al.,1983). The calcium ion chelator EGTA inhibits 
mitogen activation, but this effect is bypassed if the 
phorbol ester TPA is added, presumably because it replaces 
PKC’s need for calcium ions to become active (Gelfand at 
al.,1985).
IL-2 induced proliferation, however, is independent of 
any calcium ion influx (Mills et al.,1985b; O ’Flynn e£ 
al.,1985b) and ionophore/phorbol ester triggering cannot 
replace the proliferative signal of IL-2 binding to its 
receptor (Albert et al..1985).
Voltage-gated potassium ion channels, the predominant 
ion channel in T-cells, also seem to be involved in T-cell 
activation since potassium ion channel blockers inhibit 
PHA induced mitogenesis (Chandy et aJL . ,1984; De Coursey a£ 
al.,1984). The relationship between potassium and calcium 
ion fluxes across the cell membrane is not understood.
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iv) The Til antigen-independent activation pathway.
The T3-Ti complex may not provide the only T-cell 
activation pathway. The 50 kD Til cell surface molecule, 
also known as the sheep erythrocyte (E) receptor, has also 
been shown to cause T-cell activation in the absence of 
antigen and macrophages when the appropriate Til epitopes 
are bound by monoclonal antibodies (Meuer et al.,1984; Fox 
et al-,1985). Til and T3 antigens can mobilise calcium 
independently (O’Flynn et al.,1986) with the Til 
glycoprotein being functionally linked to a calcium 
channel (Alcover fit al. ,1986). The two activation pathways 
appear to be linked, however, since non-mitogenic anti-T3 
antibodies can block activation via Til (Fox et al.,1986). 
Antibodies against other Til epitopes than those that 
cause activation can similarly inhibit mitogen induced 
T-cell activation via T3-Ti (Reed et al.,1985b). Also the 
anti-Tll moab specific for the 9-1 epitope plus anti-T3 
will costimulate macrophage-depleted lymphocytes which are 
unresponsive to anti-T3 alone (Yang et al.,1986). This 
costimulation of T-cells is substantially enhanced by 
exogenous IL-1. Thus the Til pathway does seem to have 
some involvement in T-cell activation via the T3-Ti 
antigen receptor.
Recently a lymphokine has been isolated from T-helper 
cells after antigen-specific triggering that appears to 
bind to Til (Milanese fit fil •,1986a). This 10-12kD protein, 
tentatively named T-cell activating factor (TCAF), 
stimulates resting T-cells in the absence of macrophages, 
causing proliferation and IL-2 receptor expression. TCAF
18
is distinct from IL-2 in terms of size and from IL-1 which 
is not produced by T-cells. Its true role in T-cell 
activation and that of the Til activation/suppression 
pathway have yet to be determined.
v) IL-2 and IL-2 receptors.
Two distinct factors are required for induction of 
T-cell growth, namely IL-1 and IL-2 (Larsson et ad.,1980). 
Both helper and cytotoxic T-cells can produce IL-2 but 
helper T-cells may be the major source (Robb,1984). 
However, the ability of most cytotoxic T-cell clones both 
to respond to and also to produce IL-2 weakens the idea of 
a strict functional division of T-cell types (Andrus gt 
al ■.1984).
Human IL-2 consists of 133 amino acids, plus a 20 
residue cleaved signal sequence, and a single disulphide 
bond. Any heterogeneity in molecular weight seems to be 
due to variation in the degree of glycosylation of 
threonine 3 (Robb e£ ad.,1984a). IL-2 is derived from a 
single gene with three introns and a 5’ flanking region 
with homology to the promoter region of the IFN-gamma gene 
(Hardy £t al.,1985). Similarly only a single IL-2 receptor 
gene has been identified, coding for a 272 amino acid 
precursor of two domains separated by a putative 19 
residue transmembrane region (Cosman e£ al.,1984; Leonard 
et al. , 1984; Nikaido ei al. .1984).
The immune specificity of T-cell clonal expansion is 
guaranteed by the absence of IL-2 receptors from resting 
T-cells and the restriction of IL-2 receptor expression to
antigen activated T-cells (Cantrell & Smith,1983). 
Mitogens, however, by activating non-specifically cause a 
much higher percentage of the total T-cell population to 
express IL-2 receptors, which accumulate asynchronously. A 
critical threshold of IL-2 receptor density appears to be 
required before the commitment to cell cycle progression 
and DNA synthesis takes place. But once maximal IL-2 
receptor expression occurs, continued proliferation is 
proportional to IL-2 concentration and time of exposure to 
IL-2 (Cantrell & Smith,1984).
IL-2 receptor expression is usually transient, peaking 
at 48-72 hours post-induction before declining. 
Maintenance of IL-2 receptor expression depends upon 
réintroduction of antigen (Andrew si al.,1985; Kaplan et 
al..,1984; Lowenthal si si-. 1985b) or mitogen (Depper si 
al.,1984). Addition of exogenous IL-2 will not prevent the 
fall in IL-2 receptor levels. Reason dictates that IL-2 
receptor expression should be transient in order to ensure 
that an antigen-specific clone does not expand too much. 
Thus induction combined with down-regulation of IL-2 
receptor levels is likely to play a crucial role in 
controlling the cellular immune response.
In addition to its effects on T-cell growth, IL-2 also 
promotes proliferation of activated B-cells via surface 
receptors similar to those of activated T-cells (Waldmann 
et si-, 1984; Mingari ei ai-,1984; Tsudo at al. . 1984 ;■ 
though at 2000 per B-cell there are only half as many as 
on T-cells (Lowenthal ei al..,1985a). However, IL-2 is 
thought to act at a later stage of B-cell proliferation
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(48h) than B-cell growth factor (within 24h) and to play 
an auxiliary role (Boyd et al.,1985; Suzuki &
Cooper,1985). As in the case of T-cells, macrophages are 
required as accessory cells for induction of IL-2
receptors on B-cells, purified IL-1 being capable of 
partially replacing this function (Shirakawa et al. ■1986) .
The monoclonal antibody anti-Tac has been shown to bind 
to the IL-2 receptor (Leonard et al.,1982) and thereby 
inhibit various aspects of T-cell activation attributed to 
IL-2 binding (Depper et ail., 1983). But quantitative 
binding assays with radiolabelled IL-2 and anti-Tac 
indicate that activated T-cells have 10-20 times more 
binding sites for anti-Tac than for IL-2 (Robb et 
al.,1984b). By using very high concentrations of labelled 
IL-2, it has been shown that a class of low affinity IL-2 
receptors exists whose association constant is 5000 times 
lower than the high affinity receptors. Anti-Tac binds 
equally well to both, however, hence the initial 
discrepancy between IL-2 and anti-Tac binding assays. 
Despite there being many more low than high affinity 
sites, they are thought unlikely to act at in vivo IL-2 
concentrations since <1% would be occupied whilst the high 
affinity sites would be saturated (Robb et al.,1984b). 
About 50% of IL-2 bound to high affinity sites is 
internalised within 10 minutes at 37°C and thereafter 
degraded with a half-life of 60-80 minutes (Fujii et 
al.,1986).
Studies with anti-Tac indicate that IL-2 up-regulates 
the expression of its own receptor once it has been
21
induced (Welte et al. ,1984). In "the absence of mitogen 
stimulation exogenous IL-2 is mitogenic only for any Tac 
positive cells already present and does not appear to 
induce IL-2 receptors on resting cells lacking this 
molecule (Taylor al al.,1986a).
Purified macrophage-depleted T-cells can be induced to 
express IL-2 receptors if PHA and recombinant IL-2 are 
added together, but this does not trigger endogenous IL-2 
production (Katzen et al.,1985; Wakasugi et al.,1985). 
Thus IL-2 can induce its own receptor on T-cells in 
combination with PHA, but macrophages are also required to 
provide an additional signal (probably IL-1) for IL-2 
production. The mitogens Con A and 0KT3, however, are 
entirely dependent on macrophages for both IL-2 receptor 
expression and IL-2 production, even if exogenous IL-2 is 
added as well (Wakasagi al al.,1985).
The addition of exogenous IL-2 to T-cells and thymocytes 
which are already activated has been shown to increase the 
level of Tac expression by several groups (Reem & 
Yeh,1984; Welte al AX-.1984; Depper at al.,1985; Reem & 
Yeh,1985). This upregulation of Tac levels requires de 
novo RNA and protein synthesis (Depper al .al.,1985), IL-2 
augmenting IL-2 receptor mRNA expression as well as other 
messages associated with T-cell activation. Transcription 
assays on isolated nuclei show that the rise in IL-2 
receptor mRNA levels is due at least partly to activating 
transcription of the gene itself. However, as in the case 
of unstimulated PBML, IL-2 alone cannot induce IL-2 
receptor expression in unresponsive T lymphoblasts
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(previously activated T-cells), but acts by ensuring 
optimal expression when an initial activating signal such 
as PHA is also present (Depper ei iLl- .1985).
However, Smith and Cantrell (1985) have demonstrated 
that whilst the addition of exogenous IL-2 to activated 
cells leads to a possible 8-10 fold enhancement of Tac 
expression (high and low affinity receptors) there is a 
simultaneous 20-30% diminishment of detectable high 
affinity binding sites. Thus whilst IL-2 apparently helps 
upregulate its own receptor levels, in fact it seems to 
cause a rise in the ratio of low to high affinity 
receptors (Smith & Cantrell,1985). Only in the case of Con 
A activated thymocytes has it been demonstrated to the 
contrary that IL-2 also augments the level of high 
affinity receptors (Reem £t al. .1985 ) .
Both high and low affinity receptors share at least 
three different antigenic determinants, suggesting that 
they are structurally related and that any differences may 
be due to a change in configuration (Lowenthal et 
al.,1985c). This is supported by the finding that addition 
of a monoclonal antibody (PC61) for the IL-2 receptor 
causes an accelerated dissociation of IL-2 from receptors 
of both types, possibly by altering their conformation and 
hence their affinities (Lowenthal ai.,1985). Labelled 
IL-2 normally dissociates from the low affinity receptors 
with a half-life of 60 seconds (80 to 90% of total bound 
IL-2 is released by these receptors) and from high 
affinity with a half-life of 60-90 minutes. Binding of 
PC61 reduces these rates to 16 and 120 seconds
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respectively. Other peptide hormones (e.g. epidermal 
growth factor and insulin) are reported to have similar 
high and low affinity receptor systems and it is thought 
that the two types can convert from one to the other. When 
L-cells displaying only murine low affinity IL-2 receptors 
are fused with membranes from human T-cells some of the 
murine IL-2 receptors (p55 chains) are converted to 
dramatically higher affinity forms (Robb,1986). Thus the 
same molecule (p55) can form low or high affinity 
receptors depending on the environment, cofactors present 
in the IL-2 receptor positive human T-cell line possibly 
crossing species lines to combine with the murine chain 
and convert it to form high affinity binding sites.
It has been suggested that IFN-gamma also increases the 
level of IL-2 receptor expression (Johnson & Farrar,1983) 
and may even induce IL-2 receptors to appear on 
macrophages (Herrman et al.,1985; Holter et al. , 1986a). 
However, others have found no such evidence for IFN-gamma 
action in IL-2 receptor expression (Welte et al.,1984) and 
IFN-gamma does not appear to play a role in mitogen 
stimulated proliferation since anti-IFN-gamma antibodies 
have no effect on T-cell proliferation (Welte et al..1984: 
Wilkinson at al..1985).
vi) IFN-gamma production.
Binding of IL-2 to its receptor not only stimulates 
T-cell proliferation but also induces expression of at 
least 4 out of 7 cell cycle dependent genes, including 
c-myc and the IL-2 receptor (Kaczmarek at al•,1985). A
24
heat, labile protein has been isolated from the cytoplasm 
of PHA stimulated, but not resting, PBML which can induce 
DNA synthesis in isolated quiescent nuclei (Gutowski at 
al-,1984). This activator of DNA replication (ADR) may be 
a cytoplasmic transducer of IL-2, there being a close 
relationship between ADR levels and IL-2 induced 
proliferation. Thus antigen/mitogen activate resting 
T-cells causing them to shift from the Go phase of the 
cell cycle to Gl a and express IL-2 receptors. IL-2 binding 
then triggers a shift from Gl a to Gib and ADR formation. 
ADR upon reaching the nucleus would stimulate DNA 
replication (S phase).
There is also increasing evidence that IL-2 mediates 
IFN-gamma production. Blockade of IL-2/IL-2 receptor 
interactions inhibits various T-cell responses (Depper et 
ai.,1983) and this may include IFN-gamma production 
(Vilcek et al.,1985; Croll et al.,1985) since T-cells are 
thought to be the major producers of IFN-gamma (Pasternack 
et ai- , 1984; Morris at al.,1982). Exogenous IL-2 acts 
synergistically with sub-optimal doses of mitogen to boost 
IFN-gamma yields (Kasahara at al.,1983a; Vilcek et 
al ■ ,1985) but exogenous IL-2 alone induces at most only 
low levels of IFN-gamma from resting PBML and must be 
added at very high concentrations (Vilcek at al.,1985; Le 
at al- , 1986; Blanchard at al. ■1986).
It is the aim of this thesis to investigate the role of 
IL-2 and other immune mediators in the regulation of 
IFN-gamma production in the context of T-cell activation.
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4) PROPERTIES OF INTERFERON-GAMMA.
Although IFN-gamma appears to share some of the 
biological effects of IFN-alpha and IFN-beta, it also has 
certain unique properties and effects upon cells of the 
immune system and other cell types (Vilcek,1982; Vilcek et 
al.,1983; Trinchiera & Perussia,1985). The ability of 
IFN-gamma to mediate a variety of functions makes it a 
possibly important regulating factor of the immune, 
hematopoietic, and other systems. Its anti-viral activity 
may not therefore be its most important function. The 
availability of homogeneous recombinant IFN-gamma, free 
from the contamination of other lymphokines in the crude 
preparations used in earlier studies, has made possible 
most of the recent advances in the study of its 
properties. These are briefly reviewed here as an 
indication of IFN-gamma’s possible importance in the 
immune response.
When protein extracts of cells induced with IFN-alpha or 
IFN-gamma are analysed by 2D-gel electrophoresis, it is 
clear that both IFNs induce the synthesis of several 
common polypeptides. These probably include those induced 
enzymes which lead to the development of the anti-viral 
state (Baglioni,1979; Lengyel,1982). This suggests that 
they share some common mechanisms of action, but IFN-gamma 
also induces synthesis of a further 12 distinct proteins 
(Weil at al..,1983). The synthesis of those proteins that 
are induced by both types of IFN (alpha and beta) has also 
been found to be regulated differently. IFN-alpha uses 
translational inhibition to regulate the steady state
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levels of two induced proteins (mol.wts. of 67 and 56 kD) , 
whilst IFN-gamma does not (Sen & Rubin,1984). Thus even in 
the shared anti-viral function of the two IFN types, the 
molecular mechanisms involved are not identical.
All three types of IFN enhance the expression of class I 
MHC antigens and beta-microglobulin, with IFN-gamma having 
the most potent effects in vitro (Ball et a_l . ,1984), and 
in vivo (Momburg et al.,1986a). Treatment of cytototoxic T 
lymphocyte targets with either IFN-gamma or IFN-alpha/beta 
markedly augments cytotoxicity, presumably due to the 
enhancement of MHC class I antigens demonstrated by 
immunofluorescence (Blackman & Morris,1985). However, only 
IFN-gamma has significant effects on expression of class 
II antigens, IFN-alpha and IFN-beta enhancing weakly or 
not at all (Dolei el al-,1983; Rosa & Fellous, 1984) . 
Recombinant IFN-gamma increases the synthesis and 
expression of the HLA-DR (Ia-like) antigens, as well as 
beta-microglobulin, on human melanoma cells when 400 times 
higher doses of IFN-alpha had no effect (Basham & 
Merigan,1983). Recombinant IFN-alpha and IFN-beta induce 
HLA-A.B on monocytes and myeloid leukemic cell lines but 
not HLA-DR, unlike recombinant IFN-gamma (Kelley et 
al.,1984). IFN-gamma has been shown to enhance expression 
of class II antigens or induce them de novo in a large 
number of cell types, including myelo-monocytic cells 
(Koeffler £t .al.,1984; Virelizier et ai■ ,1984 ) , lymphoid 
cells (Wong el al.,1984), mast cells (Koch el al. .1984 ) . 
endothelial cells (Geppert & Lipsky,1985), fibroblasts 
(Collins al al-,1984), astrocytes (Lampaon & Fisher,1984;
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Fierz g£ al.,1985), and a large series of tumor-derived 
cell lines (Wong gt .al.,1983). IFN-gamma causes similar 
effects in vivo. injection in mice leading to widespread 
and selective induction of class I and class II antigens 
in a variety of tissues (Skoskiewicz et al.,1985; Momburg 
gt gl.,1986b).
The ability of IFN-gamma to induce the expression of 
class II antigens on a variety of cells suggests an 
immunoregulatory role when one considers the importance of 
class II molecules in antigen presentation (Unanue et 
al.,1984; Janeway et g_l.,1984). IFN-gamma treatment 
renders macrophage lines capable of antigen presentation 
(Zlotnik gt al.,1983), an effect antagonised by the 
macrophage product PGE2 , though probably by its inhibitory 
effects on T-cells rather than on macrophages (Zlotnik et 
al.,1985). IFN-gamma treatment also renders endothelial 
cells susceptible to the cytotoxic effect of class II 
specific T lymphocytes (Pober et al.,1983). IFN-gamma 
treatment of macrophages presenting antigen accelerates 
immune proliferation of responding T-cells in response to 
soluble antigen in a manner which appears dependent on the 
level of macrophage DR (class II antigen) expression 
(Becker gt gl.,1985). However, induction of la expression 
on murine macrophages by IFN-gamma is antagonised by other 
immune response products, such as IgG and IgE (Virgin IV 
et gl.,1985) and IFNs alpha and beta (Ling gt gl.,1985; 
Inaba g£ gl.,1986). Thus any regulatory effects of 
IFN-gamma ia vivo probably interact with other immune 
regulators.
All three types of IFN have also been shown to modify 
activities of several cellular components of the immune 
response in vitro. In the case of macrophages IFN-gamma 
boosts the level of IL-1 production (Arenzana-Seisdedos et 
al.,1985) and HLA-DR and DC expression (Virelizier et 
al.,1984), suggesting that it could amplify T-cell 
activation by a feedback loop to the beginning of the 
lymphokine cascade. It also boosts macrophage IgG Fc 
receptor expression (Perussia et al.,1983; Fertsch & 
Vogel,1984) which could increase the level of Fc-FcR 
interactions between T-cells and macrophages important in 
the phagocytosis of antibody coated bacterial and viral 
particles (Chang et al.,1985). IFN-gamma also appears to 
be an important macrophage activating factor (MAF), 
inducing cytotoxicity of human monocytes against tumour 
targets at levels as low as 0.3-lU/ml, IFNs-alpha/beta 
showing no MAF activity even up to levels of 200U/ml (Le 
et sl.,1983). Monoclonal antibodies against IFN-gamma 
neutralise all MAF activity in conditioned medium from 
mitogen stimulated lymphocytes in both the human (Le & 
Vilcek,1984) and murine systems (Spitalny & Havell,1984), 
suggesting that it is the major MAF in such preparations. 
Other T-cell derived factors, however, also exhibit MAF 
activity (Lee si al.,1986).
All three IFN types markedly augment T-cell cytotoxicity 
(Blackman & Morris,1985; Lindahl et al.,1972; Vose et 
al.,1983) and IFN-gamma also appears to be involved in 
enhancement of NK cell activity (Braakman et al.■1986: 
Peterman st al.,1984), although the nature of this
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involvement with respect to IL-2’s effects on NK activity 
is unclear (Trinchieri ei al.,1984; Shaw ei al.■1985: 
Lanier ei al.,1985). It is generally agreed that IL-2 
augmented NK activity is mediated at most only partly by 
IFN-gamma since it is only partially inhibited by 
antibodies against the latter (Mukaida et al..1986: 
Braakman et al.,1986). However, IFN-gamma does enhance 
IL-2 mediated generation of activated killer cells (Itoh 
et al.,1985b) and helps maintain NK-like cytotoxicity 
(Peterman et al.,1984).
In addition to its effects on cellular responses, 
IFN-gamma effects humoral responses too. Soluble T-cell 
factors induce primary splenic B-cells to proliferate and 
differentiate into antibody secreting cells (Jelachich et 
ai.,1984). Such action is partly due to IFN-gamma which 
can substitute for a late helper factor (T-cell replacing 
factor) which acts synergistically with other helper 
factors (IL-1 and IL-2) in the stimulation of a B-cell 
antibody response in vitro (Leibson et al.,1984). 
IFN-alpha also helps to stimulate immunoglobulin 
production in vitro (Nebauer et al.,1985).
IFN-gamma also directly induces maturation of resting 
B-cells in vitro. producing surface phenotype changes and 
immunoglobulin secretion (Sidman at al.,1984). But it is 
far from the only B-cell maturation factor, antibodies 
against IFN-gamma having no effect on other such factors 
produced by T-cells.
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5) THE IN VIVO ROLE OF IFN-GAMMA ?
IFN-gamma clearly exhibits a variety of immunomodulatory 
effects In vitro in addition to its antiviral properties. 
Since IFN-gamma is produced by antigen stimulated T-cells 
on an immune specific basis it seems not unreasonable to 
assume that it plays some role in the immune response 
other than purely anti-viral. IFNs alpha and beta, 
however, can be made by many cell types and appear to be 
chiefly induced by viral infection. Although they have 
definite in vitro regulatory effects, the in vivo 
relevance of these effects to immune regulation is not 
clear. The induction of IFN production of all three types 
by some bacteria and bacterial products suggests that they 
may also help fight bacterial infection in some cases. 
Thus the use of Staphylococcal enterotoxin A (SEA) in this 
study will also provide some information about bacterial 
induction of IFN-gamma.
Even in the case of IFN-gamma there is little direct 
evidence for an in vivo immunomodulatory role. What 
evidence there is has recently been reviewed (De Maeyer et 
al.,1985) but is largely inferential. For example, murine 
recombinant IFN-gamma protects mice in vivo against local 
and systemic infection by the bacterium Listeria 
monocytogenes (Kiderlen et al.,1984), so it can clearly 
help combat both viral and non-viral infection. The 
effects of in vivo defects in IFN-gamma production have 
been taken as evidence for an in vivo role. Mice strains 
which are low producers of IFN-gamma (e.g. BALB/c) tend to 
be more susceptible to many infections compared to high
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producing strains such as C57BL/6 (Virelizier,1982; 
Cheers & McKenzie,1978; Kirchner at al.,1978). The 
susceptibility of human neonates to viral and bacterial 
infections may be due to impaired T-cell immunity caused 
by defective IFN-gamma production (Wakasugi & 
Virelizier,1985). The low NK activity and HLA-DR levels of 
neonates appear to be consequences rather than causes of 
reduced IFN-gamma secretion since exogenous IFN-gamma can 
enhance both (Kaplan et al.,1982; Kelley et al..1984). 
More direct evidence about endogenous IFN-gamma’s role 
requires experiments using antibodies to IFN-gamma in 
infected animals.
Its major non-antiviral role in vivo may prove to be its 
effects on macrophages. Activation of macrophage cytotoxic 
activity may be the major mechanism for dealing with many 
bacterial infections and enhancement of MHC class II 
antigen expression may be essential in regulating T-cell 
activation by macrophages. Basal levels of IFN-gamma may 
exist prior to activation of the lymphokine cascade which 
could help initiate an immune response leading to further 
lymphokine production. It has been argued that IFN-gamma 
is produced continuously in low "physiological" amounts 
which increase occasionally when infection induces an 
acute response (Bocci,1985).
6) OBJECTIVES AND COMMENTS ON THE EXPERIMENTAL SYSTEM 
EMPLOYED IN THIS STUDY, 
i) Aims.
IFN-gamma’s anti-viral effects alone make it worthy of 
study, but if in addition it has in vivo immunomodulatory 
effects then further study of its induction will
contribute to our understanding of the immune reponse. 
IFN-gamma is thought to be produced at the end of a 
cascade of other substances. If this is indeed the case, 
how do the lymphokines and other regulatory molecules and 
pathways that make up this "cascade" interact? The primary 
aim of this study is to examine the interactions involved 
in T-cell activation using IFN-gamma production as a 
measure of their effects. This is a very active field of 
research with respect to other aspects of T-cell 
activation, e.g. T-cell proliferation, but rather less 
work has been devoted to the regulation of IFN-gamma 
production. However, some of the work on T-cell activation 
by other researchers over the past three years has had 
direct relevance to the work described here and is 
therefore discussed in that light.
Areas worthy of investigation include:
1. Can non T-cells produce IFN-gamma?
2. How are IL-1 and IL-2 involved in IFN-gamma production, 
i.e. does IFN-gamma production really rely upon the 
lymphokine "cascade”?
3. What cell surface molecules can regulate IFN-gamma 
production? The recent description of a putative 
lymphokine (TCAF) that acts via a T-cell
A
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activation/suppression pathway (Til) distinct from that 
activated by the T-cell antigen receptor makes the role of 
this pathway of increasing interest. How does it affect 
IFN-gamma production and how are these effects regulated?
4. How is transcription of the IFN-gamma gene regulated 
compared to production of the protein itself?
ii) The experimental system.
Most of the major fundamental work on the immune 
response has made use of the advantages of the murine 
system over research using human material. For example, 
the use of mice from the same inbred strain, genetically 
identical in the MHC (H2) region of the genome, was 
essential for unravelling the role of MHC antigens in the 
immune response. In comparison work on human material, as 
here, has clear disadvantages. Most work is obviously in 
vitro and may therefore not necessarily be relevant to the 
in vivo situation. There is also the problem of variation 
between immune responses of different individuals to the 
same stimulus. In this study buffy coats (i.e. peripheral 
blood mononuclear leukocytes) from many different donors 
were used with no possibility of repeating experiments 
with cells from the same MHC genotype as there would be 
with mice strains. There was considerable variation 
between the response of different donors to the same 
mitogenic stimulus under the same conditions (Table 1). 
Whilst differences between donors was a major factor in 
this variation, the practical limitation on experiments 
which made it difficult to measure only the peak level of
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Table 1.1
THE RESPONSE OF DIFFERENT DONORS PBML TO THE SAME STIMULUS
IFN-gamma Titre (U/ml)
Donor
1. 160 8. 1600 15. 40
2. 630 9. 630 16. 1200
3. 130 10. 630 17. 250
4. 160 11. 160 18 . 160
5. 40 12. 320 19. 160
6. 63 13. 55 20. 450
7. 80 14. 600 21. 2000
Range = 40-2000 U/ml.
Mean titre = 453 U/ml.
Standard deviation of titres = 524
a) PBML at 5x10s cells/ml were induced with 20ng/ml of 
SEA. The cells were incubated at 37«C and the IFN-gamma 
the supernatant measured 3 days post-induction.titre of
IFN-gamma production probably also contributed to the 
variation in titres. IFN-gamma levels were always measured 
in the cell supernatant three days after induction, since 
time courses showed that this was usually the peak period 
of production. However, there was almost certainly some 
difference in the speed of response between donors with 
some donors producing peak levels earlier than others 
(probably between 2 and 4 days, 3 days post induction 
being the mean). However, whilst optimisation of IFN-gamma 
levels, by determining the peak level from a time course, 
might have partly reduced apparent donor variation it also 
would have greatly increased the number of samples and 
assays required for each experiment. Furthermore donor 
variation was not such a problem if one concentrated on 
relative rather than absolute levels of IFN-gamma 
production in different regulatory situations, i.e. 
absolute differences in level between donors are not as 
important as whether a certain set of conditions depress 
or elevate IFN-gamma production in all donors. When this 
proves to be the case then inferences can be made about 
regulatory effects for all donors since the response will 
not be specific to a single donor, T-cell line, or mouse 
strain.
However, variation in donor responses does necessitate 
frequent repetition of experiments if small shifts/effects 
are being examined where the results are not clear-cut. In 
this study effects were usually shown to be reproducible 
for many different donors, not just two or three, before 
firm conclusions were drawn.
35
The major and decisive advantage of the human system 
lies in the increasing availability of purified and 
recombinant human interleukins, plus antibodies against 
them, and the large range of antibodies available for cell 
surface markers of different cell types and subsets. 
Clinical research and investigation has been the spur for 
developing these powerful tools for further research. Far 
fewer such developments have occurred in the murine system 
so that in consequence the human T-cell response is in 
some ways the more thoroughly defined.
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CHAPTER 2.
INTERFERON-GAMMA PRODUCTION BY LOW DENSITY LYMPHOCYTES. 
Introduction.
A variety of T-cell types have been found capable of 
producing interferon-gamma (Archer et al., 1979),
including both Lyt 2+ and Lyt 2- cells in the mouse 
(Guerne et al.,1984) and the T4 and T8 subsets in man 
(Biondi et al.,1984). However, probably all require the 
presence of accessory macrophages for significant 
interferon-gamma production (Bendtzen & Petersen,1984; 
Bruszewski et al.,1984; Chang et al.,1982; Unanue et 
al.,1984). There is also now evidence to suggest that 
non-T cells can also produce IFN-gamma. In particular, it 
has been shown that human low-density lymphocytes produce 
IFN-gamma and a variety of other lymphokines, including 
IL-1, IL-2, colony-stimulating factor, and B-cell growth
factor, in response to T-cell mitogens (Kasahara et 
.al.,1983b; Djeu,1983; Scala et al.,1984; Pistoia et
al.,1985; Procopio § t  .al.,1985). This IFN-gamma production 
i3 often ascribed to large granular lymphocytes (LGL), 
which make up a large proportion of the low density 
fraction of lymphocytes and possess natural killer cell 
characteristics (Burns si si.,1985). LGL, which make up 
less than 5% of the total peripheral blood mononuclear 
leukocytes, have a distinct morphology of high cytoplasmic 
to nuclear ratio with a granular cytoplasm. Nearly all 
natural killer (NK) cell activity can be attributed to the 
LGL population (Timonen et al.,1981), and they bear the
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surface markers Leu 7, Leu 11, and 0KM1 (Scala et 
al.,1985; Abo et al.,1984), Leu 7 being expressed later in 
the path of differentiation of NK cells (Phillips & 
Lanier,1985). NK cells have spontaneous cytolytic activity 
against a variety of cells, unlike cytotoxic T-cells whose 
action is specific, MHC restricted, and takes several days 
to develop (Herberman & Ortaldo,1981). NK cells may 
therefore play an important role in immune surveillance in 
a primary broad range defence system which can respond 
almost immediately to foreign materials, helping to 
control infection until the more potent and specific 
immune system begins to respond.
In this chapter IFN-gamma production by LGL enriched 
low-density lymphocytes, in response to the mitogen SEA, 
was examined. Unlike high density T lymphocytes, 
low-density cells were found not to require macrophages 
for IFN-gamma production. However, this IFN production 
appeared to be partially dependent upon the interaction of 
two subsets separable by sheep red blood cell rosetting.
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RESULTS.
Low density lymphocytes are high-level producers of 
IFN-gamma independent of macrophages.
Macrophage-depleted lymphocytes were prepared by 
replating PBML on plastic petri dishes, discarding 
adherent cells or retaining them as purified macrophages, 
and overnight incubation with silica to eliminate 
phagocytic cells (see methods). This method produced >99% 
pure lymphocyte preparations as judged by non-specific 
esterase staining.
Separation of lymphocytes into differing density 
sub-populations was achieved by centrifugation at 550G for 
30 minutes over a six-step discontinuous buffered 
Percoll/RPMI gradient, the steps of which varied by 2.5% 
Percoll concentrations from 40 to 52.5% Percoll (see 
methods).
As can be seen in table 1 (data provided by 
M.F.Wilkinson), when macrophage-depleted lymphocytes were 
separated on a stepped gradient the low density 
lymphocytes from fractions 1 and 2, comprising 6% of the 
total lymphocytes, were the best IFN-gamma producers on a 
per cell basis, as induced by SEA. The interferon produced 
was shown to be IFN-gamma for both total lymphocytes and 
low-density cells by its 99% neutralisation with 
anti-IFN-gamma antiserum (80U/ml and 320U/ml reduced to 
<2U/ml respectively). Addition of macrophages made little 
difference to IFN-gamma production by low-density cells, 
but boosted production five- to 10-fold for the denser and 
total lymphocytes. This has also been shown to be the case
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TABLE 2.1
PRODUCTION OF IFN-GAMMA BY LYMPHOCYTES OF DIFFERENT DENSITIES
INDUCED BY SEA.
IFN-gamma titre (U/ml)
--------------------- Alone________ With macrophages
Lymphocytes 50 2000
Macrophages <8 -
Fraction 1 (3%) 800 130
Fraction 2 (3%) 400 500
Fraction 3 (27%) 80 200
Fraction 4 (53%) 40 200
Fraction 5 (14%) 20 200
a) Macrophages were added back to the macrophage-depleted
cells in the column headed "with macrophages" at a
macrophage : lymphocyte ratio of 1:10.
b) The percentage of the total lymphocyte population present 
in each fraction is indicated in brackets.
c) All cells (5x10s cells/ml) were induced with SEA at 20ng/ml.
d) Data obtained from M. Wilkinson.
for induction by Con A and PHA (Croll et al.,1986a).
In subsequent experiments low-density cells were usually 
isolated from the top two steps of the gradient, chiefly 
from the interface between the 42.5% and 45% steps. A 
single 46% Percoll cushion was also used to isolate 
low-density cells (Ly.L). Cells isolated from the bottom 
three steps or below the 46% interface were considered 
high density, chiefly T-cells (Ly.H).
Comparison of the level of IFN-gamma production by these 
various fractions, for several different donors, confirmed 
that the low-density fraction is enriched for high level 
producers in the absence of macrophages (Tables 2 & 3). 
Addition of purified macrophages, from the same donor, to 
the fractions shows that Ly.L IFN-gamma production is 
relatively macrophage independent compared to the 
unfractionated lymphocytes and especially when compared 
with the high density fraction (Ly.H). The latter are 
particularly macrophage-dependent for significant 
IFN-gamma production. When the total lymphocyte 
populations were reconstituted from the low- and 
high-density cells, the requirement for macrophages was 
restored to that found in the unfractionated lymphocyte 
population. Thus, only low-density lymphocytes are 
macrophage-independent
The removal of B lymphocytes by nylon-wool filtration, 
which removes both macrophages and B-cells, does not alter 
the observation that it is the low-density cells that can 
produce significant IFN-gamma levels without macrophages 
(Table 3). The low-density fraction contained up to 20%
PRODUCTION OF IFN-GAMMA BY LOW AND HIGH DENSITY LYMPHOCYTES
INDUCED BY SEA.
TABLE 2.2
IFN-gamma titre (U/ml)
Donors
1 2  3
Cells Alone With Mo Alone With Mo Alone With Mo
PBML 400 800 630 1000 630 1000
Ly. 200 1000 100 250 100 800
Ly.Low 320 250 400 1000 2000 800
Ly.High 10 100 16 100 32 200
Ly.Rec. 130 1000 80 200 130 400
a) All cells (5x10s cells/ml) were induced with SEA at 20ng/ml.
b) Macrophages were added back to cell populations in the columns 
headed "With Mo" at a macrophage : lymphocyte ratio of 1:10.
c) Ly.= Unfractionated Lymphocytes.
Ly.Low = low density lymphocytes.
Ly.High = high density lymphocytes.
Ly.Rec. = recombined high and low density lymphocytes.
TABLE 2.3
PRODUCTION OF IFN-GAMMA BY LOW AND HIGH DENSITY LYMPHOCYTES 
DEPLETED OF MACROPHAGES AND B CELLS.
IFN-Gamma titre (U/ml) 
Donors
1 2
Cells Alone With Mo Alone With Mo
PBML 100 200 160 400
Ly. 40 160 50 160
Ly.Low 320 130 160 160
Ly.High 100 400 80 160
Ly.Rec. 1300 1300 80 400
NW- 130 200 8 100
NW-.Low 80 100 60 120
NW-.High 16 100 4 8
a) All cells (5x10s cells/ml) were induced with SEA at 20ng/ml.
b) Macrophages were added back to cell populations in the columns 
headed "With Mo" at a macrophage : lymphodyte ratio of 1:10.'
c) Ly.= Unfractionated Lymphocytes.
Low = low density lymphocytes.
High = high density lymphocytes.
Ly.Rec. = recombined high and low density lymphocytes.
NW- = nylon wool depleted lymphocytes.
SIg+ cells, reduced to <2% by nylon-wool treatment. 
Therefore, B lymphocytes are not involved in 
macrophage-independent IFN-gamma production by low-density 
cells.
Differing lymphocyte-macrophage ratios or mitogen 
concentration did not effect the relative lack of 
macrophage-dependence of Ly.L compared to Ly.H (Tables 4 & 
5). However, Ly.L fractions often did benefit from the 
addition of macrophages to a limited extent, IFN-gamma 
production being boosted 2-3 fold compared to 5-10 fold 
for Ly.H. This effect may have been due to high-density 
T-cells contaminating the low-density cell preparation.
When the levels of IFN-gamma production of low density 
cells and PBML were compared over a time course (Table 6) 
the low density cells were found to respond to SEA 
stimulation much more rapidly. Within 24 hours of 
induction low density cells were producing IFN-gamma 
levels (40U/ml) not attained by PBML, from which they were 
derived, until 3 days after induction. Thus Ly.L produce 
readily detectable levels of IFN-gamma much more rapidly 
than PBML, although both cell populations reach peak 
production at a similar time, 3-4 days post induction.
Co-operation between subsets of low-densitv lymphocytes is 
necessary for maximal IFN-gamma production.
In order to purify further the low-density fraction and 
remove any T-cells, which compose the majority of the high 
density population, the Ly.L were further fractionated by 
high-affinity sheep red blood cell (SRBC) rosetting into
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TABLE 2.4
IFN-Gamma titre (U/ml)
SEA concentration (ng/ml)
10 30 100
THE EFFECT OF INCREASING MITOGEN- CONCENTRATION ON IFN-GAMMA
PRODUCTION BY LOW AND HIGH DENSITY LYMPHOCYTES.
Alone With Mo Alone With Mo Alone With MoDonor 1 
Ly.Low 200 150 50 80 150 250
Ly.High 4 32 <2 50 20 250
Donor 2 
Ly.Low 130 500 100 200 63 400
Ly.High 20 250 32 250 32 320
a) All cells (5x10s cells/ml) were induced with SEA at 20ng/ml.
b) Lymphocyte to macrophage ratio was 10:1 when macrophages 
were added in those columns headed "With Mo".
c) The low density fraction contained only 5% of the total 
lymphocyte population for both donors.
TABLE 2.5
THE EFFECT OF VARYING MACROPHAGE/LYMPHOCYTE RATIOS ON IFN-GAMMA
PRODUCTION BY LOW AND HIGH DENSITY LYMPHOCYTES.
IFN-gamma titre (U/ml) 
Percentage of macrophages added.
Without Mo 3% Mo 10% Mo 30% Mo
Donor 1 
Ly.Low 130 320 400 320
Ly.High 5 250 630 160
Donor 2 
Ly.Low 63 160 80 100
Ly.High 13 200 200 150
a) All cells (5x10s cells/ml ) were induced with SEA at 20ng/ml
b ) The low density fraction contained only 5% of the total
lymphocyte population for both donors.
TABLE 2.6
TIME COURSE OF SEA-INDUCED IFN-GAMMA PRODUCTION BY PBML 
AND LOW DENSITY LYPHOCYTES.
IFN-gamma titre (U/ml) 
Time after induction.
Oh. 18h. 24h. 2 davs 3 davs 4 davs 5 davs
LGLs 6 25 40 100 400 800 550
PBML <2 3 3 8 50 80 63
a) Macrophage-depleted LGLs were isolated from PBML and contained 
only 8% of the total lymphocyte population.
b) All cells were induced with 20ng/ml of SEA at 5x10s cells/ml.
E+ and E- cells. The E+ cells bore the sheep erythrocyte 
receptor, the high affinity form being found on T-cells, 
whilst the E- fraction was further enriched for non-T 
cells (see characterisation of cell fractions section). 
The IFN-gamma production of these two populations on a per 
cell basis was lower than that of unfractionated 
low-density cells (Tables 7 & 8). The non-rosetting 
fraction generally produced more IFN-gamma than the 
rosetting fraction. In order to check whether this 
reduction of IFN-gamma production by the subfractions was 
due to cell damage during the fractionation procedures, 
reconstitution experiments were performed. It was found 
that reconstitution of the low-density population by 
mixing E+ and E- cells largely restored IFN-gamma 
production to its unfractionated level. This was found to 
be the case in four out of five donors.
In additional experiments, macrophages were added back 
to the E+ and E- fractions in order to examine the role of 
these fractions in macrophage independency of low density 
cells (Table 8). Addition of macrophages to E+ and E- 
cells boosted IFN-gamma levels considerably, 10-fold or 
greater for E+ cells and 5-fold or greater for E- cells. 
This was in contrast to the unfractionated low density 
population whose level of production was far less 
macrophage dependent, with at most a 4-fold increase. In 
the one experiment in which E+ and E- were mixed and 
macrophages added, IFN-gamma production was partially 
restored to its unfractionated level and macrophage 
independence regained. Thus cooperation between the E+ and
TABLE 2.7
IFN-gamma titre (U/ml)
Donors
IFN-GAMMA PRODUCTION BY SUB-FRACTIONS OF LOW DENSITY LYMPHOCYTES.
1 2 3 4 5
PBML 400 800 320 200 320
Ly 120 260 75 8 80
Low 320 500 205 5000 400
Low E- 100 250 105 40 120
Low E+ 55 160 125 18 5
Rec E-/E+ 225 320 325 40 220
a) All cells (5x10s cells/ml) were induced with SEA at 20ng/ml.
b) PBML = Peripheral Blood Mononuclear Leukocytes.
Ly = Macrophage-depleted lymphocytes.
Low = Low density lymphocytes.
Low E- = Non E-rosetting low density lymphocytes.
Low E+ = E-rosetting low density lymphocytes.
Rec E-/E+ = Reconstituted low density lymphocytes (E- 
E+ cells are recombined in the proportions in which 
they were obtained after sheep erythrocyte rosetting).
and
TABLE 2.8
MACROPHAGE ASSISTANCE OF LOW DENSITY LYMPHOCYTE SUB-FRACTIONS 
IN IFN-GAMMA PRODUCTION.
IFN-gamma titre (U/ml)
Donors
1 2  3
Alone With Mo_____Alone With Mo_____Alone With Mo
PBML 320 - 32 - 55 -
Ly 80 800 20 160 6 2000
Low 400 350 100 400 1100 3200
Low E- 120 600 32 170 60 1600
Low E + 5 400 3 100 50 450
Rec E-/E+ 220 110 ND ND
a) All cells (5x10s cells/ml) were induced with SEA at 20ng/ml.
b) PBML = Peripheral Blood Mononuclear Leukocytes.
Ly = Macrophage-depleted lymphocytes.
Low = Low density lymphocytes.
Low E- = Non E-rosetting low density lymphocytes.
Low E+ = E-rosetting low density lymphocytes.
Rec E-/E+ = Reconstituted low density lymphocytes (E- and
E+ cells are recombined in the proportions in which they
were obtained after sheep erythrocyte rosetting). ND = Not Done.
c) Macrophages isolated from the same donor were added in those
columns headed "With Mo" at a macrophage:lymphocyte ratio of 1:10
d) Donor 1 is the same as donor 5 on table 2.7.
E- fractions appears to be a requirement for optimal 
IFN-gamma production in the absence of macrophages acting 
as accessory cells.
Characterisation of cell fractions.
In order to characterise the various cell fractions, the 
expression of three leukocyte surface markers (Leu 11, 
0KT3, and 0KM1) by the cells was examined by
immunofluorescence. Leu 11 is a marker found on LGL. 0KT3 
is found on T-cells, and 0KM1 is found on macrophages and 
some null (i.e. non-T) cells. Unfractionated lymphocytes 
were 11% Leu 11+ and 84% 0KT3+ (Table 9) . A typical
low-density preparation was 23% Leu 11+ and 38% 0KT3+, 
showing enrichment for the LGL marker. If only the top two 
steps of the gradient were used for the low density 
fraction, preparations containing up to 70% Leu 11+ cells 
could be obtained, but the third step was usually included 
to provide sufficient cells for all the fractionation 
procedures. After rosetting, the E- fraction was further 
enriched for Leu 11+ cells and the E+ fraction strongly 
enriched for T-cells. Using different coloured conjugates 
specific for Leu 11 and 0KM1 (fluorescein-labelled
anti-murine IgM against the Leu 11 moab and 
rhodamine-labelled anti-murine IgG against the 0KM1 moab), 
the expression of both markers on the same cell was 
examined. 0FCM1 was found to be generally coexpressed with 
Leu 11. A typical low-density fraction contained 42% Leu 
11+/OKM1+ cells, but after rosetting the E+ fraction 
contained 10% Leu 11+/0KM1+ cells and the E- fraction
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TABLE 2.9
CELL SURFACE MARKERS AND CYTOTOXICITY OF THE LYMPHOCYTE FRACTIONS
% cells bearing markers
Total Ly.
Ly . Low
Low E- fraction 
Low E+ fraction
Leu 11 + 
11%
23%
50%
7%
0KT3 + 
84%
38%
36%
79%
a) All above fractions isolated from a single donor in which the 
low density cells made up 45% of the total lymphocyte population.
Ly.Low
Low E- fraction 
Low E+ fraction
Leu 11+/M1+
42%
60%
10 %
M1+ only
0%
5 %
1 %
b) All above fractions were isolated from a single donor with the 
low density fraction containing 16% of the total lymphocytes.
CYTOTOXICITY 
Ly.Low 
Ly.High
70% Leu 11+ , 31% T3+ 
2% Leu 11+ , 42% T3+
82% cytotoxicity 
16% cytotoxicity
c) Ly.Low contained 13.5% of the total lymphocyte population. 
An effector to target ratio of 30:1 was used for cytotoxicity 
measurements, using 51 Cr labelled K562 target cells.
contained 60% Leu 11+/0KM1+ with 5% 0KM1+ only cells. 
Thus, the low-density fracion is enriched for the LGL 
marker Leu 11 and somewhat depleted of T-cells. Subsequent 
resetting leads to a Leu 11-enriched E- fraction and an 
0KT3-enriched E+ fraction.
Non-specific esterase staining to detect cells of the 
monocyte/macrophage lineage and the addition of indian ink 
to detect phagocytic cells both confirmed macrophage 
depletion. Lymphocytes and low-density fractions were both 
shown to contain less than 0.2% macrophages.
Enrichment for natural killing in the low-density cells, 
LGL possessing NK activity, was confirmed by means of an 
18-hour 5iCr-release assay, using K562 target cells at an 
effector:target ratio of 30:1. Low-density cells were 
found to elicit 82% cytotoxicity and high density cells 
only 16% cytotoxicity, showing clear enrichment for 
NK-activity in the low-density cells.
The low-density fraction was also enriched for B cells, 
containing up to 20% SIg+ cells as detected by 
FITC-labelled anti-human IgG. Nylon wool filtration 
reduced this to <2%.
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DISCUSSION : Chapter 2
There have been numerous demonstrations that induction 
of IFN-gamma by antigen or mitogen in unfractionated 
lymphocytes is macrophage-dependent. However, the results 
described in this chapter show that lymphocyte 
preparations enriched for low density cells do not require 
macrophages for IFN-gamma production, unlike high density 
cells which make up the majority of lymphocytes and are 
strongly macrophage-dependent. Djeu has also shown that 
low density lymphocytes can produce IFN in response to a 
variety of inducers, including SEA, PHA, and Con A, in a 
macrophage-independent fashion (Djeu,1983). It is 
possible, therefore, that low density preparations are 
enriched for cells able to produce IFN-gamma independent 
of the accessory cell function supplied by macrophages. 
These are unlikely to be T-cells, which usually require 
the presence of accessory cells for activation, but may be 
natural killer or null cells (also known as large granular 
lymphocytes = LGL) which are reported to produce a variety 
of lymphokines (Kasahara et al. ,1983b; Scala et al..1984: 
Pistoia et al.,1985) including IFN (Djeu,1983).
The low density preparations examined in this chapter 
were clearly shown to be depleted of macrophages (<0.2% 
esterase positive) and enriched for NEC activity (82% 
cytotoxicity against an NK target cell, K562) and the NK 
cell marker, Leu 11 (up to 70% Leu 11+). The high density 
population, however, were depleted for NK activity and 
contained only 2% Leu 11+ cells. Measurements of IFN-gamma 
production by cells from increasing density percoll steps
revealed that only low density lymphocytes produced high 
levels of IFN-gamma in the absence of macrophages (Table 
2.1). The high density lymphocytes were in comparison 
highly macrophage dependent (Table 2.2) and contained 
mainly T-cells.
B cells are of a similar density to LGL, but B cell 
depletion did not alter the observation that the low 
density cells are the significant IFN-gamma producers 
without macrophages compared to the high density cells 
(Table 2.3). Therefore the macrophage-independent 
IFN-gamma production of low density lymphocytes is more 
likely due to LGL and not to B cells. The relative 
macrophage-independence of low density cells was 
unaffected by changes in mitogen concentration (Table 2.4) 
or increasing macrophage/lymphocyte ratios (Table 2.5).
However, it is also possible that the low density 
preparations are enriched for non-macrophage accessory 
cells which interact with any remaining T-cells also 
present in the low density preparation. The possibility 
was investigated by sub-fractionating the low density 
cells by high affinity sheep red blood cell rosetting, 
thus separating T-cells, which express a high affinity E 
receptor, from null cells, most of which express a low 
affinity form (Kay et al.,1977) of the E receptor. The E+ 
subfraction produced in this way consisted largely of 
0KT3+ cells (79%) and produced little IFN-gamma unless 
macrophages were added (Table 2.8). The E- subfraction, 
which contains most of the Leu 11+,0KM1+ cells but also 
significant numbers of 0KT3+ cells, produced less
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IFN-gamma than the unfractionated low density population, 
but rather more than the E+ cells (Tables 2.7 & 2.8). When 
the low density population was reconstituted by mixing E+ 
and E- cells, IFN-gamma production was almost restored to 
the level produced by unfractionated low density cells. 
The reduction of IFN-gamma production by low density cells 
was thus not due to damage caused by the fractionation 
procedure itself. Therefore it would appear that some form 
of cooperation in IFN-gamma production takes place in the 
absence of macrophages between two low density lymphocyte 
populations separable by rosetting. However, the 
identities of the cell types involved is not clear.
There is ample evidence from studies with T-cell clones 
to show that T-cells can produce IFN-gamma (Matsuyama et 
al.,1982; Pasternack et al.,1984; Morris et al.,1982), but 
there is also evidence to indicate that Leu 11+.0KM1+ 
cells may also be capable of IFN-gamma production
(Kasahara et al.,1983b). In this chapter both E+ and E- 
cells required macrophages for optimal IFN-gamma 
production, although E- cells were still capable of 
significant production in their absence (Table 2.8). A 
possible explanation for these observations is that Leu 
11+ cells, which make up the majority of the E- fraction, 
may themselves produce IFN-gamma without the necessity for 
macrophages, but in addition can act as accessory cells 
for the production of IFN-gamma by low density T-cells, 
which make up the majority of the E+ fraction. This 
explains the required cooperation for maximal IFN-gamma 
production between E+ and E- cells.
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Other reports of lymphokine production by low density 
cells are of considerable interest. Kasahara et al. have 
shown that macrophage and T-cell depleted LGL produce 
greater levels of IL-2 and IFN-gamma in response to 
mitogens than PBML, and that the IL-2 production was not 
enhanced by addition of macrophages or purified IL-1, 
unlike T-cell populations (Kasahara et al.,1983). However, 
the same workers found that depletion of M1+ and T3+ cells 
did reduce IFN-gamma production by LGL significantly, 
suggesting that there was still some T-cell production in 
their low density fraction despite macrophage depletion by 
adherence and nylon columns prior to percoll gradient 
fractionation. The results described in this chapter 
suggest that E- cells could act as accesssory cells for 
low density T-cells in the absence of macrophages, thus 
explaining the apparent production of IFN-gamma by low 
density T3+ cells found by Kasahara in macrophage depleted 
populations.
LGL are a very heterogeneous population and the 
interactions between various subsets therefore complex. 
Kasahara attributes IL-2 production by LGL to an atypical 
T-cell subset (0KT3-,Leul-,0KT11+) rather than the myeloid 
subset (OKM1+), since depletion of 0KT11+ cells using moab 
plus complement greatly reduces IL-2 production. The 
myeloid subset or an 0KT8+ subset appear to regulate this 
production (Kasahara et al.,1983). Scala §t al. have also 
found that an 0KT8+ subset helps regulate IL-1 production 
by LGL, 0KT8+ depletion boosting IL-1 production, which is 
attributed to a B73.1+ (= Leu 11),0KM1+,DR+ subset of LGL
48
(Scala gt al,., 1984). This IL-1 producing subset would be 
equivalent to the E- subset examined in this chapter, 
possibly IL-1 production by E- cells being required by E+ 
cells (chiefly T3+) for optimal IFN-gamma production by 
the unfractionated low density population. IL-1 production 
is shown in chapter 3 to be an important accessory 
function of macrophages for IFN-gamma production.
Subsets of LGL have also been shown to exhibit accessory 
cell functions, T11+,DR+,0KM1+ LGL acting as accessory 
cells for T-cell proliferation in response to soluble 
polyclonal stimulants (Staphylococcus protein A and 
Streptolysin 0) and to surface antigens in mixed leukocyte 
reactions, whilst 0KM1-.DR- LGL do not (Scala et 
al.,1985). This is in contrast to the findings of Brooks 
and Moore (1986) who found that purified populations of 
LGL (sorted with a fluorescence activated cell sorter) 
were unable to present Streptolysin 0 but could stimulate 
mixed lymphocyte reactions. Perhaps LGL can only act as 
accessory cells when antigen uptake and processing is not 
required, but class II MHC expression and IL-1 production 
are, as in the case of mitogen stimulation rather than 
antigen stimulation. The T11+,DR+,M1+ LGL also exhibited 
most of the NK activity, and are therefore equivalent to 
Leu 11 cells characterised in this chapter, since the most 
potent NK activity of NK cells is associated with Leu 11 
expression (Abo et al.,1984; Itoh et al.,1985; Seki et 
al.,1985). Interactions between subsets of LGL have also 
been shown to be important for optimal induction of 
autologous mixed lymphocyte reactions (Scala et ajl. ,1985).
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Thus there is accumulating evidence for a cell type which, 
although it shares at least one marker (0KM1) with 
macrophages, is distinct from them (i.e. non-adherent, 
non-phagocytic, esterase negative, Leu 11+) but able to 
carry out accessory functions, such as IL-1 production. In 
the case of IFN-gamma production, the results described in 
this chapter, and those of other workers, suggest that the 
Leu 11+.0KM1+ cells of the E- fraction (which can also 
contain T11+ cells since the E receptor/Tll of NK cells is 
of low affinity compared to that of T-cells) may therefore 
act as accessory cells for the T3+ cells of the E+ 
fraction. The IFN-gamma production of the E- fraction, 
however, is most likely to be due to Leu 11+ cells since 
these make up the majority of the fraction. Some IFN-gamma 
production by T11-.T3+ cells cannot be excluded, however. 
Whether Leu 11+ cells can replace macrophages in other 
immune responses is as yet unclear, but such an accessory 
function might be important in the early stages of an 
immune response.
LGL enriched cell preparations have been shown to react 
to a wide range of immune stimuli (mitogens, viruses, 
bacteria, mycoplasma-contaminated tumour cells) and are 
thus uniquely equipped to respond to almost all immune 
stimulating agents by rapid production of IFN (Djeu,1983). 
The type of IFN produced, however, depends on the 
stimulus, mitogen stimulation leading mainly to IFN-gamma 
production (SEA stimulated LGL produced IFN which was >99% 
neutralised by anti-IFN-gamma antisera, e.g. 320U/ml to 
<2U/ml) but viral and bacterial stimulation cause
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IFN-alpha production, whilst, T-cells produce only
IFN-gamma (Djeu,1983).
It is shown in this chapter that LGL produce readily 
detectable levels of IFN-gamma within 24 hours (Table 
2.6), unlike PBML (40 vs. 3(J/ml respectively). Such early 
production by LGL could have regulatory effects since 
levels of IFN-gamma as low as lOU/ml induce IL-1 secretion 
by human monocytes (Arenzana-Seisdedos et al.,1985) and 
augment antigen presentation by human astrocytes (Fiers et 
al.,1985). However, since LGL form such a small percentage 
of the total lymphocytes, a few days post-induction their 
contribution to total lymphokine production during an 
immune response would be negligible. It has therefore been 
suggested that their importance as lymphokine producers 
may lie in acting as a rapid macrophage-independent first 
line of defence in response to a wide variety of immune 
stimuli. Their early release of low but detectable levels 
of IFN-gamma could help to activate T-cells, macrophages, 
and other NK cells, thus helping to start a cascade of 
immunological responses to infection (Djeu,1983). The 
possibility that they can act as accessory cells for 
T-cells might also be important in this respect as a 
faster initial alternative to macrophage activity. The 
granularity of LGL suggests a secretory function which may 
be involved in rapid lymphokine release compared to 
T-cells. The spontaneous NK cytotoxicity of LGL, being 
much more rapid than development of cytotoxic T-cell 
activity, would also be compatible with a role in the 
first line of defence against infection (Herberman &
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Ortaldo,1981) . In rats LGL are localised in the spleen, 
rather than with T-cells in the lymph nodes, which may 
act as a preferential site of LGL function, clearing 
blood-borne elements susceptible to LGL killing (Rolstad 
et al.,1986).
However, the contribution of LGL to IFN-gamma production 
by unfractionated PBML is negligible by 3 days 
post-induction. Since nearly all the experiments in 
subsequent chapters use unfractionated PBML, or the total 
lymphocyte population, the contribution of low density 
cells to IFN-gamma yields can be ignored.
In view of the possible interactions between LGL and 
T-cells the former’s origin and lineage become important 
considerations. LGL seem to have characteristics of both 
T-cells and cells of the myeloid lineage. Expression of 
OKM1 and the ability to produce IL-1 (Scala et al.,1984) 
suggest an association with macrophages. However, 0FCM1 
expression and IL-1 production (Durum et al.,1985) are not 
restricted to the myeloid lineage.
Despite the clear differences to mature T-cells, there 
is a body of evidence to suggest a relationship between NK 
and T-cells (Grossman & Herberman,1986). Some NK cells 
express T8 (Kasahara et al.,1983b) and low affinity SRBC 
receptors (Kay et .al.,1977), for example. NK cells as well 
as T-cells respond to IL-2, with resulting stimulation of 
cytotoxic activity and proliferation (Lanier et al.■1985: 
Ortaldo et al.,1983; Shaw et aj,. ,1985; Trinchieri et 
al. . 1984; Miyasaka et al,.,1984). The mechanism for 
promoting proliferation in LGL and T-cells seems identical
since anti-Tac (an anti-IL-2 receptor moab) inhibits 
proliferation of both (Abo et al.,1983; Ortaido et 
al.,1984) but anti-Tac cannot inhibit IL-2 augmentation of 
NK activity (Ortaido at al.,1984; Mukaida at ai.,1986). 
Possibly IL-2 enhances NK activity by binding to a low 
affinity receptor that is not recognised by anti-Tac, 
though whether enhanced NK activity is the result of 
subsequent IFN-gamma production (Ortaido at al.,1984: Itoh 
et al.,1985) or is independent of it (Mukaida et al.,1986) 
is not yet certain. It is also interesting to note that 
some T-cells share the LGL morphology and bind 
specifically to NK target cells, though without killing 
them (Velardi at al.,1985), whilst other T-cells exhibit 
potent NK-like cytotoxicity but not the LGL morphology 
(Schneider at al. .1984 ) .
Observations such as these have led several authors to 
suggest that NK cells are a type of pre-thymic, pre-T cell 
(Mackay at al,.,1985; Kaplan,1986). Grossman and Herberman 
(1986) suggest that the point of departure between T and 
NK lineages occurs when the T-cell receptor gene is 
rearranged and expressed, the phenotypic plasticity of the 
two lineages, exhibited in culture, decreasing as 
maturation proceeds.
If LGL are related to the T-cell lineage, as opposed to 
being a monocytic or independent lineage, then their 
apparent ability to produce IFN-gamma and other T-cell 
derived lymphokines is less surprising.
In conclusion, three points emerge from the results in 
this chapter. Firstly, the rigorous removal of macrophages
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demonstrates that low density lymphocytes, unlike high 
density lymphocytes, can make IFN-gamma in the absence of 
macrophages. The level of this production is relatively 
independent of macrophages compared to that by high 
density cells which make up the majority of the total 
lymphocyte population. Secondly, in the absence of 
macrophages, more than one cell type is necessary for 
optimal IFN-gamma production by low density cells. 
Finally, whilst many authors ascribe IFN-gamma production 
by low density cells to Leu 11 enriched LGL, the results 
in this study suggest that other mechanisms may exist, low 
density T-cells possibly producing IFN-gamma if OKMl+,Leu 
11+ cells act as accessory cells.
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REGULATION BY INTERLEUKINS (IL-1 AND IL-2) AND 
PROSTAGLANDIN E2 OF IFN-GAMMA PRODUCTION.
Introduction.
A variety of molecules produced by cells of the immune 
system, collectively described as lymphokines or monokines 
depending on their source, are believed to be involved in 
regulating the activities of immune cells, including that 
of production of IFN-gamma (Marx,1983). This may itself 
have important regulatory functions in the immune 
response. The major accessory role of macrophages in 
T-cell activation are believed to be IL-1 production and 
crosslinking of the T3-Ti complex (Williams et al..1984: 
Williams £t al. , 1985; Palacios,1985; Kaye gt al. ,1984), 
leading to a calcium flux which results in T-cell 
activation. The importance of IL-1 as a regulatory 
molecule is suggested by the fact that IL-l-like molecules 
can be produced by and responded to by many different cell 
types (Durum at al.,1985). Prostaglandins, particularly E: 
and E2 , are another major group of cell-regulatory 
molecules produced by many cell types, including
macrophages (Roth et al.,1985; Khansari et al.,1985). In 
the latter case, however, PGE2 release appears to act as a 
suppressive mechanism inhibiting IL-2 production (Chouaib 
et al.,1984) and class II MHC antigen induction (Zlotnik 
et al. ,1985 ) .
IL-2 production by activated T-cells stimulates division 
of cells bearing IL-2 receptors. By this interaction IL-2
CHAPTER 3.
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is believed to regulate T-cell proliferation, IFN-gamma 
production (Croll et ai.,1985; Vilcek et al.,1985; 
Kasahara et .al., 1983; Reem and Yeh,1984), expression of 
its own receptor (Katzen et al.,1985), and the specificity 
of the immune response (antigen specific T-cell clonal 
expansion being guaranteed by the normal limitation of 
IL-2 receptor expression to antigen-activated T-cells). In 
the mouse, for example, IL-2 can replace Lyt 1+ helper 
T-cells in mitogen-induced IFM production by Lyt 2+ 
T-cells (Torres g t al.,1982) and is also needed by 
immature mouse T-cells if IFN-gamma production is to occur 
in response to mitogen (Klein and Bevan,1983).
However, early work on lymphokine interaction made use 
of relatively impure lymphokine preparations which 
probably contained other lymphokines too, making results 
from such experiments equivocal. More recently the 
availability of purified and recombinant interleukins, 
plus antibodies against them and their receptors, has 
introduced much greater certainty in the interpretation of 
experiments involving lymphokine interactions. In this 
chapter the roles of both IL-1 and IL-2 (i.e. natural 
ligands as opposed to artificial ligands, such as 
antibodies against cell surface molecules which are 
discussed in chapter four) in the stimulation of IFN-gamma 
production were investigated in a number of situations 
where IFN-gamma production by mitogen induction was 
modified.
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RESULTS
a ) The___Effects of IL-1 on IFN-gamma Production bv
Macrophage-Depleted PBML.
Depletion of macrophages from human PBML has been found 
to reduce considerably IFN-gamma production by mitogen 
stimulated lymphocytes (see Chapter 2). In order to 
determine the possible role of IL-1 in macrophage
assistance of IFN-gamma production, PBML were depleted of 
macrophages by replating and silica treatment and the 
effects of adding back purified IL-1 determined.
Replating PBML three times at hourly intervals on 
plastic petri dishes removed the majority of adherent 
cells, i.e. macrophages. Silica was then added at 200pg/ml 
and the cells incubated overnight to eliminate the few 
remaining phagocytic cells. The lymphocytes were then 
isolated over Ficoll at 35ÛG to remove the silica and cell 
debris (as described in the methods section). It was 
important to remove the majority of macrophages by
adherence first as silica treatment may cause the release 
of macrophage-derived factors into the surrounding medium 
when the cells are destroyed. This method produced >99% 
pure lymphocyte preparations as judged by non-specific 
esterase staining for macrophages.
As can be seen in Table 1, macrophage depletion usually 
reduced IFN-gamma yields by 10-fold or more, confirming 
the importance of macrophage-lymphocyte cooperation for 
IFN-gamma production. The addition of exogenous IL-1
(6U/ml) at the time of induction was found greatly to 
increase IFN-gamma production by macrophage-depleted
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Table 3.1
THE EFFECTS OF IL-1 ON IFN-GAMMA PRODUCTION BY PBML AND 
MACROPHAGE-DEPLETED LYMPHOCYTES.
IFN-Gamroa Yield (U/mi) 
Donors
Celia___________ 1 2 3 4
PBML 400 4000 1600 4000
PBML + IL-1 220 4000 ND 3200
L y . 35 320 40 120
Ly. + IL-1 200 1100 200 2000
a) All cells were induced with SEA
b) Purified IL-1 was used at 6U/ml.
(20ng/ml ) .
lymphocytes (Ly.)> by 5-fold or more, in response to SEA. 
The addition of exogenous IL-1 to PBML (i.e. not 
macrophage-depleted), however, had little if any effect on 
the cells response to SEA with no increase in IFN-gamma 
yields. Thus exogenous IL-1 does not boost IFN-gamma 
yields generally except when the lymphocytes have been 
depleted of macrophages. This suggests that IL-1 
production is one of the accessory functions of 
macrophages for IFN-gamma production. In the case of PBML 
adding exogenous IL-1 has no effect presumably because 
optimal levels of IL-1 are produced by the macrophages 
present.
Using six different donors and a range of IL-1 
concentrations (Table 2) it was found that the optimal 
level of IL-1 for maximum stimulation of IFN-gamma 
production varied from donor to donor. As little as 
0.6U/ml could boost IFN-gamma yields, whilst the highest 
levels of IL-1 used (20U/ml) did not always lead to the 
greatest IFN-gamma yields. In the case of PHA (donor 6, 
table 2) as opposed to SEA induction 2U/ml of IL-1 were 
sufficient for the optimal effect. Although the addition 
of IL-1 did boost yields it was not always to the level 
produced by undepleted PBML.
PBML uninduced by mitogen produced little IFN-gamma and 
the addition of IL-1 without mitogen generally (4 out of 5 
cases) caused only low level production (Table 2). This 
suggests that IL-1 alone is not a sufficient signal for 
significant IFN-gamma production compared to that provided 
by mitogen. However, in the case of a few donors (e.g.
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THE EFFECTS OF IL-1 ON IFN-GAMMA PRODUCTION BY 
MACROPHAGE-DEPLETED LYMPHOCYTES.
IFN-Gamma Yield (U/ml)
Table 3.2
Donors
Cells 1 2 3 4 5 6PBML 4800 5700 1200 60 200 280
Ly. 32 120 160 3 35 32
Ly.+ IL-1 (0.6U/ml) 120 250 ND ND ND ND
Ly.+ IL-1 (2U/ml) 320 250 6000 80 55 250
Ly.+ IL-1 (6U/ml) 320 160 4000 25 135 250
Ly.+ IL-1 (20U/ml) 2000 500 500 25 100 250
Uninduced PBML + IL-1
(6U/ml)
1000 ND 60 250 <3 5
Uninduced PBML 250 3 <3 ND <3 6
a) Donors 1 to 5 were induced with SEA (20ng/ml) and donor 6
with PHA (10fig/ml).
b ) ND = Not Done.
c) Ly.= Lymphocytes, i.e. macrophage-depleted PBML.
donors 1 and 4 in table 2) IL-1 alone did induce some 
IFN-gamma production. perhaps because these donors PBML 
were already partially activated by some endogenous 
infection. This is an example of one of the problems with 
work on the human system, i.e. variation in the response 
of different donors PBML to the same stimulus due to 
differences in the state of their immune systems.
This boosting effect of IL-1 on lymphocyte responses was 
found to be the case for a variety of different mitogens 
(Tables 2 & 3). The effects of macrophage depletion and 
IL-1 on tritiated-thymidine incorporation, as a measure of 
mitogenesis, were also examined. Removal of macrophages 
inhibited incorporation in the case of SEA and 0KT3 
(reproducible for three different donors for each), but 
had the reverse effect when Con A or PHA were used as 
T-cell activators (though only a single donor was 
examined). Reduction of IFN-gamma titre was also less 
severe for these mitogens, suggesting that mitogens may 
differ in their mechanism of T-cell activation. Addition 
of exogenous IL-1 boosted tritiated-thymidine 
incorporation only in the case of SEA but raised IFN-gamma 
production for all four mitogens. The IFN induced by each 
mitogen was shown to be IFN-gamma by its 99% inhibition by 
anti-IFN-gamma antisera.
Thus, using a range of mitogens and donors, exogenous 
purified IL-1 was capable of at least partially replacing 
the activity of macrophages in activating T-cells in 
response to mitogens, and the effect was neither donor nor 
mitogen specific.
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THE EFFECTS OF IL-1 ON IFN-GAMMA PRODUCTION AND 3H-THYMIDINE 
INCORPORATION BY MACROPHAGE-DEPLETED LYMPHOCYTES STIMULATED 
BY DIFFERENT MITOGENS.
Table 3.3
Mitogen
SEA <;20ng/ml) PHA (10pg/ml)
Cells IFN yield 3 H-Thy.inc IFN yield 3H-Thy.inc
PBML 2000 46.397 160 142,025
Ly. 80 25.806 55 193,965
Ly. + IL-1 3200 37,417 250 187,165
0KT3 (10ng/ml) Con A (10pg/ml)
IFN yield 3H-Thy.inc IFN yield 3H-Thy.inc
PBML 55 41,826 125 91,769
Ly. 6 3,110 55 139,749
Ly. + IL-1 120 4,118 100 169,737
a) The same donor was used for PHA and Con A, and different 
donors for SEA and OKT3.
b) IFN-gamma titre (U/ml) was measured on day 3, and 3H-Thy. 
(tritiated-thymidine) incorporation over day 3-4 as the mean 
of four wells (Standard Deviation less than 15%).
c) IL-1 was used at 6U/ml.
d) Similar results for IFN-gamma titre and 3H-Thy.inc. were 
obtained for three different donors for both SEA and 0KT3 
induction (representative data shown). Only a single donor 
was examined for PHA and Con A (data shown).
b ) ---Effect?---of___anti-IL-1 Antibody on IFN-gamma
Production.
A commercially available polyvalent antibody for IL-1 
was used to determine the effect of reduction of free 
endogenous IL-1 during T-cell activation. Using a range of 
concentrations it was found that when added at the time of 
induction anti-IL-1 could greatly reduce the subsequent 
level of IFN-gamma production (Table 4), an effect 
reproducible for eleven different donors. This effect was 
clearly dose dependent for SEA with a reduction of 
IFN-gamma titre of over 90% at the highest antibody 
concentration. Induction by PHA could be similarly 
reduced, but the effect was found to be far more variable 
between donors than in the case of SEA.
The effects of adding anti-IL-1 at various times 
post-induction (Table 5) for one donor were also examined. 
The greatest reduction of subsequent IFN-gamma titre was 
observed when the antibody was added three hours 
post-induction rather than at induction itself. Addition 
at subsequent times had a reduced effect, suggesting that 
endogenous IL-1 was most important for subsequent 
IFN-gamma production in the first 24 hours of induction. 
When added 48 hours post-induction anti-IL-1 had a much 
reduced, for SEA, or no effect, for PHA, on the IFN-gamma 
titre.
Anti-IL-1’s effects on SEA induction were examined for 
several donors (Table 6) and reductions of over 80% of 
IFN-gamma production were obtained in all cases at the
6 0
Table 3.4
IFN-Gamma Yield (U/ml)
SEA (20ng/ml) PHA (lOpg/ml)
THE EFFECTS OF ANTI-IL-1 ON IFN-GAMMA PRODUCTION BY PBML.
Mitogen alone 800 120
With anti-IL-1 (10%) 32 28
With anti-IL-1 (3%) 120 16
With anti-IL-1 (1%) 1000 25
With anti-IL-1 (0.5%) 800 20
a) Single Donor examined (due to shortage of
b) Anti-IL-1 added at induction.
anti
Table 3.5
THE EFFECT OF ANTI-IL-1 ADDED POST INDUCTION ON IFN-GAMMA 
PRODUCTION BY PBML.
IFN-Gamma Yield (U/ml) 
3 days post-induction.
SEA (20ng/ml) PHA
Mitogen alone 1200 400
With anti-IL-1 at induction 100 200
With anti-IL-1 3h . p.i. 55 100
With anti-IL-1 16h . p.i. 160 250
With anti-IL-1 24h . p.i. 200 200
With anti-IL-1 48h . p.i. 550 400
a) Anti-IL-1 used at 5%.
b) p.i. = time of addition post induction.
c) Different donor used to that in Table 3.4.
Table 3.6
INDUCTION BY SEA.
THE EFFECT OF IL-1 ON ANTI-IL-1 MEDIATED INHIBITION OF IFN-GAMMA
IFN-Gamma Yield (U/ml)
Donors 3H-Thy
1 2 3 3
Mitogen alone 3200 2300 120 65,862
With anti-IL-1 ( 5%) 270 400 18 32,908
With anti-IL-1 (1%) 2000 1600 100 ND
With anti-IL-1 (5%) +IL-1 400 800 32 34,157
With anti-IL-1 (1%) +IL-1 2200 3200 160 ND
With IL-1 4000 2500 160 51,472
a) SEA used at 20ng/ml.
b) IL-1 used at 5U/ml.
c) 3H-Thy.(Tritiated Thymidine) incorporation measured over day
3-4 as the mean of four wells (Standard Deviation less than 20%).
higher antibody concentration. Addition of purified IL-1 
at least partially reduced the effect of the antibody 
suggesting that the antibody’s inhibitory effects are 
indeed IL-1 mediated. Addition of purified IL-1 without 
the antibody had little effect on SEA induction, as found 
©arlier (Table 1), presumably because endogenous IL-1 
levels were sufficient for normal levels of induction. In 
the case of the one donor examined anti-IL-1 was also 
found to reduce the level of tritiated-thymidine 
incorporation by 50%. This is an effect similar to that 
found after macrophage depletion (Table 3). Addition of 
exogenous IL-1 as well raised the IFN-gamma titre only 
slightly for this donor and also had only a minimal effect 
on the depression of tritiated-thymidine incorporation.
Con A induction of IFN-gamma is also significantly 
depressed by anti-IL-1 (Table 7) in a dose dependent 
fashion, although only two donors were examined. Purified 
IL-1 again partially reversed the effect of the antibody. 
When PHA was used as the inducer, however, the effects of 
the antibody varied between donors (Tables 4, 5 & 8) and 
were not usually as pronounced as in the case of SEA. Once 
again though the addition of purified IL-1 at least 
partially reversed the antibody’s effects whilst having 
little effect on the IFN-gamma titre otherwise (Table 8).
These experiments with anti-IL-1 suggest that endogenous 
IL-1 levels during induction have an important effect on 
subsequent IFN-gamma production. This was found to be 
reproducible for several mitogens and was not donor 
specific.
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Table 3.7
THE EFFECT OF IL-1 ON ANTI-IL-1 MEDIATED INHIBITION OF IFN-GAMMA
INDUCTION BY CON A.
IFN-Gamma Yield (U/ml)
Donors
1 2
Mitogen alone. 1000 320
With anti-IL-1 (5%) 32 80
With anti-IL-1 (1%) 220 250
With anti-IL-1 (5%) + IL-1 55 250
With anti-IL-1 (1%) + IL-1 18 200
With IL-1 32 180
a) Con A used at 20pg/ml.
b) IL-1 used at 5U/ml.
Table 3.8
INDUCTION BY PHA.
IFN-Gamma Titre (U/ml)
THE EFFECT OF IL-1 ON ANTI-IL-1 MEDIATED INHIBITION OF IFN-GAMMA
Donors.
1 2 3
Mitogen alone 1000 16 400
With anti-IL-1 ( 5%) 360 12 200
With anti-IL-1 (1%) 450 18 180
With anti-IL-1 (5%) + IL-1 450 32 320
With anti-IL-1 (1%) + IL-1 1000 80 320
With IL-1 1000 180 320
a) PHA used at 10pg/ml.
b) IL-1 used at 5U/ml.
c ) The Effects of--Antg-Tac__(an__IL-2__Receptor specific
antibody) on IFN-Gamma Production.
In an analogous set of experiments to those described 
above the role of IL-2 in the stimulation of IFN-gamma 
production was investigated by the use of a monoclonal 
antibody (anti-Tac). This antibody binds to the human IL-2 
receptor (Leonard et a!.,1982) and inhibits various 
aspects of human T-cell activation, including T-cell 
proliferation and the generation of cytotoxic T-cells in 
mixed lymphocyte cultures (Depper gi al.,1983). PBML from 
different donors were treated with PHA, Con A, and 0KT3 at 
different concentrations, alone or in the presence of 
anti-Tac (1/1000 dilution of the ascitic fluid).
When PHA was used as the mitogen anti-Tac had a marked 
depressive effect on the IFN-gamma yield (Table 9), 
measured on both day 2 and day 3 post-induction in order 
to catch the peak IFN-gamma yields. The depressive effect 
of anti-Tac decreased with increasing mitogen 
concentration. However, anti-Tac had little effect on 
tritiated-thymidine incorporation, a measure of 
mitogenesis, at all PHA concentrations.
IFN-gamma levels induced by Con A were similarly reduced 
in the presence of anti-Tac (Table 10). Unlike PHA, 
however, there was also marked inhibition of 
tritiated-thymidine incorporation in all the donors 
examined. Once again the depressive effects decreased with 
increasing mitogen concentration.
0KT3-induced tritiated-thymidine incorporation and
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Table 3.9
THE EFFECTS OF ANTI-TAC ON IFN-■GAMMA INDUCTION BY PHA.
3H-Thy. inc. Day 2 IFN Yield Day 3 IFN Yield(cpm) (U/ml ) (U/ml)
Mitogen Mitogen With Mitogen With Mitogen WithCone. only anti-Tac only anti-Tac only anti-Tac
Donor 1
0.3pg/ml 20,976 18,665 1,000 250 4,000 400
1.Opg/ml 20,034 23,644 2.000 250 400 320
3 . Opg/ml 34,121 30,691 500 250 50 63
Donor 2
0.3pg/ml 46,337 41,491 200 40 200 13
1.Opg/ml 43,227 39,764 160 16 100 6
3.Opg/ml 57,446 56,539 63 40 40 13
Donor 3
1.Opg/ml ND ND 200 40
3.Opg/ml ND ND 27 4
Donor 4
0.3pg/ml ND ND 250 10
1.Opg/ml ND ND 800 <3
3.Opg/ml ND ND 8 4
a) Anti-Tac was added at 1/1000 dilution of ascitic fluid.
b) 3H-Thy (Tritiated-Thymidine) incorporation was measured over
day 3-4 as the mean of 4 wells (Standard Deviation less than 20%)
c) ND Not Done.
Table 3.10
THE EFFECTS OF ANTI-TAC ON IFN-GAMMA INDUCTION BY CON A.
Mitogencone.
Donor 1
3 H-Thy. ( cpm ) inc. Day 2 IFN Yield (U/ml) Day 3 IFN Yield (U/ml)
Mitogen With Mitogen With Mitogen Withonly anti-Tac only anti-Tac only anti-Tac
lpg/ml 2,900 462 <3 <3 <3 <3
3pg/ml 7,459 550 <3 <3 4 <3
10pg/ml 12,516 9,693 80 10 32 4
Donor 2
lpg/ml 6,216 2,015 <3 <3 <3 <3
3pg/ml 7,964 4,050 10 <3 4 <3
10pg/ml 27,369 15,640 32 20 20 6
Donor 3
lpg/ml 8,660 3,243 <3 <3 <3 <3
3pg/ml 22,070 13,312 25 <3 20 <3
10pg/ml 74,662 32,200 32 16 25 20
a) Anti-Tac was added at 1/1,000 dilution of ascitic fluid for
donors 1 and 2, and 1/10,000 for donor 3.
b) 3H-Thy (Tritiated-Thymidine) incorporation was measured over
day 3-4 as the mean of 4 wells (Standard Deviation less than 20%)
IFN-gamma production were also reduced by anti-Tac (Table 
11) .
Similar results were obtained with Con A and 0KT3 (Table
12) at a lower concentration of anti-Tac (1/10,000). Due
to limited supplies of anti-Tac it was not possible to 
determine its effects at higher concentrations on 
mitogenesis and IFN-gamma production. This would have been 
of particular interest in the case of PHA. anti-Tac having 
little effect on mitogenesis at 1/1,000 dilution but still 
inhibiting IFN-gamma production, even though both 
processes are believed to be IL-2 mediated. Thus the
effects of anti-Tac were found to be reproducible for each
mitogen over a range of donors, at least four in each
case.
The depressive effects of anti-Tac on IFN-gamma 
induction by three different mitogens were shown to be 
IL-2 mediated by the addition of purified human IL-2 
together with anti-Tac at the time of induction (Table
13) . The inhibition of IFN-gamma production by anti-Tac
was shown to be reversible if exogenous IL-2 was also 
added. The extent of this reversibility varied with the 
mitogen and its concentration. In the case of PHA
inhibition was nearly completely reversed. Indeed at the 
lowest PHA concentration IL-2 boosted IFN-gamma production 
above that of mitogen induction alone. However, in the 
case of Con A and 0KT3, IL-2 only partially restored 
IFN-gamma levels.
A second monoclonal antibody against the IL-2 receptor 
(from Becton-Dickinson) was also tested. This too
Table 3.11
THE EFFECTS OF ANTI- TAC ON IFN-GAMMA INDUCTION BY 0KT3 .
3H-Thy. (cpm) ine. Day 2 IFN yield (U/ml) Day 3 IFN yield (U/ml)
0KT3 cone. (ng/ml) OKT3only Withanti-Tac OKT3only Withanti-Tac 0KT3only Withanti-Tac
Donor 1
10 10,969 3,568 10.000 320 13 <2
30 11,819 3,272 1,000 10 32 <2
100 9,60 2 2,950 13 50 50 25
Donor 2
10 ND ND 1,200 4 ND ND
a) Anti-Tac was added at 1/1,000 dilution of ascitic fluid.
b) 3H-Thy (Tritiated-Thymidine) incorporation was measured over 
day 3-4 as the mean of 4 wells (Standard Deviation less than 20%)
c ) ND = Not Done.
Table 3.12
IFN-GAMMA PRODUCTION WITH DIFFERENT ANTI-TAC CONCENTRATIONS.
Day 2 IFN-gamma yield (U/ml)
Mitogen cone. Withoutanti-Tac With anti-Tac (1/10,000) With anti-Tac (1/1,000)
Con A (pg/ml)
3 10 <3 <3
10 32 6 20
0KT3 (ng/ml)
10 10,000 500 320
30 1000 15 10
100 13 4 10
a) Donor 2 from Table 3.10 was used for Con A and the same
donor as used in Table 3.11 for 0KT3.
IFN-GAMMA PRODUCTION.
IFN-Gamma Yield (U/ml)
Table 3.13
THE EFFECTS OF IL-2 ON ANTI-TAC MEDIATED INHIBITION OF
Mitogen cone. Donor Withoutanti-Tac Withanti-Tac With anti-Tac and IL-2
PHA (pg/ml)
0.3 1 16 <3 160
1.0 1 160 <3 160
3.0
Con A (pg/ml
1
)
500 320 500
1 3 25 <3 12
10 4 250 25 100
OKT3 (ng/ml)
10 3 800 50 100
10 4 10 <3 40
a) Anti-Tac was added at 1/1,000 dilution of ascitic fluid.
b) Purified IL-2 was used at 100 (Genzyme) U/ml.
inhibited IFN-gamma induction, by PHA and SEA, with 
greater effect at lower mitogen concentrations (Table 14). 
Thus the inhibitory effect is not antibody specific (both 
may bind to the same epitope), but probably due to 
interference with IL-2/IL-2 receptor interactions.
The reversal effect of addition of IL-2 is specific to 
that interleukin since IL-1, used at a concentration that 
boosts IFN-gamma production by macrophage-depleted 
lymphocytes, has little effect on the inhibitory effect of 
either IL-2 receptor antibody (Table 15).
As a control for possible nonspecific effects of ascites 
preparation on IFN-gamma production, mouse IgG and a 
monoclonal antibody W634 (Barnstaple si al.,1978) against 
a species antigen (coded for on chromosome 11 and found on 
all human cells) were tested for their effects on 
IFN-gamma induction (Table 16). Concentrations similar to 
that used for anti-Tac experiments (1/1,000 anti-Tac 
contained approximately 6-8ug/ml) had no significant 
effect on IFN-gamma production. The effects of monoclonal 
antibodies for cell surface molecules associated with the 
immune system are discussed in chapter four.
d) The__Effects of Prostaglandin (a Macrophage Product)
on IFN-gamma Production.
In view of the reported depressive effects of PGE2 on
IL-2 production (Chouaib et al.,1984) its effects on
IFN-gamma production were examined. When added at
induction at a range of concentrations (physiological 
levels are estimated to peak at 30ng/ml in the
Table 3.14
PRODUCTION.
THE EFFECTS OF ANTI-IL-2 RECEPTOR ANTIBODY ON IFN-GAMMA
Day 3 IFN-gamma yield (U/ml) 
Mitogen anti-IL-2 receptor concentration
concentration None 1/1,000 1/10,000
PHA (pg/ml)
1 160 <3 <3
3 40 <3 <3
10 200 200 160
SEA (ng/ml)
20 100 40 25
a) PBML from a single donor were used.
PRODUCTION.
Table 3.15
THE EFFECTS OF IL-1 ON ANTI-TAC-MEDIATED INHIBITION OF IFN-GAMMA
IFN-gamma yield (U/ml)
Mitogen Without With With anti-Tac
anti-Tac anti-Tac and IL-1
PHA (lpg/ml) 18 <2 <2
PHA (3pg/ml) 14 <2 <2
SEA (20ng/ml) 35 12 8
With
anti-IL-2-R With anti-IL-2-R and IL-1
PHA ( 3|ig/ml) 14 8 <3
SEA (20ng/ml) 35 14 25
a) PBML from a single donor were used.
b) Anti-Tac was used at 1/1,000 dilution.
c) Anti-IL-2-R was used at 1/10,000 dilution.
d) IL-1 was used at 6U/ml.
Table 3.16
BY PBML.
THE EFFECTS OF IgG AND W634 BINDING ON IFN-GAMMA PRODUCTION
IFN-gamma titre (U/ml)
Antibody Donor 1 Donor2
Mitogen only 800 1600
W634 (3pg/ml) 1300 2000
(lpg/ml) 3200 1000
Mu IgG (5pg/ml) ND 1000
Clpg/ml) ND 800
a) SEA (20ng/ml) used as mitogen.
b) W634 was used in ascites form and is specific for the spec 
antigen S.A.l found on all human cells.
inflammatory state; Snyder et al.,1982) and with a range 
of different mitogens, PGE2 was found to cause significant 
inhibition of IFN-gamma production (Table 17) for three of 
the mitogens. SEA induction, however, was not 
significantly inhibited. Across a range of different 
donors PGE2 consistently inhibited IFN-gamma levels 
induced by PHA, but inhibited SEA induction in only three 
out of six donors (Table 18). The reduced effect of PGE2 
on the more potent mitogen SEA. compared to the other 
inducers used, suggests that sub-maximal mitogen 
stimulation is required if PGE2 is to cause significant 
inhibition. It was also found that jag levels of PGE2 were 
required for any effect on SEA induction and for 
consistent effects on induction by other mitogens, since 
PGE2 effects varied from donor to donor.
Since PGE2 is known to inhibit IL-2 production, and that 
this lymphokine has an important role in optimal IFN-gamma 
production, the effects of exogenous IL-2 on PGE2 mediated 
inhibition were examined. Exogenous IL-2 was found to 
reverse the inhibitory effects of PGE2 on a range of 
donors using PHA as the inducer (Table 19). In only two 
out of six cases, however, were IFN-gamma levels fully 
restored.
The effects of both IL-1 and IL-2 on PGE2 inhibition 
were tested using a range of mitogens (Table 20). Purified 
IL-1 was used at a concentration that boosted IFN-gamma 
production by macrophage-depleted lymphocytes. When added 
at induction IL-1 had no effect on the inhibition but IL-2 
at least partially reversed it. In the case of PHA
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Table 3.17
THE EFFECTS OF PGE2 ON IFN-GAMMA PRODUCTION IN RESPONSE TO
DIFFERENT MITOGENS.
IFN-gamma yield (U/ml)
pge2 concentration (ng/ml)
Mitogen None 3 30 300 3000
PHA (3pg/ml) 930 80 67 54 13
Con A (20)ag/ml) 27 8 2 <2 <2
0KT3 (10ng/ml) 14 <2 <2 <2 <2
SEA ( 2Clng/ml ) 400 960 750 1000 ND
a) The same donor was used for Con A and 0KT3 with different 
donors for PHA and SEA.
b) Conditions were set up in triplicate and the mean titre 
calculated.
c) ND = Not Done.
THE EFFECTS OF PGE2 INHIBITION ON PHA AND SEA INDUCED IFN-GAMMA
PRODUCTION BY PBML.
Table 3.18
IFN-gamma titre (U/ml) 
Donors
Mitogen 1 2 3 4 5 S
PHA (10pg/ml) 250 12 40 16 25 1600
PHA + PGE2 25 <2 <2 12 <2 <2
SEA (20ng/ml) 250 160 160 450 320 2000
SEA + PGE, 250 16 100 80 80 4000
a) PGE2 was used at lpg/ml.
PRODUCTION.
Table 3.19
THE EFFECT OF IL-2 ON PGE2 MEDIATED INHIBITION OF IFN-GAMMA
IFN-gamma titre (U/ml) 
Donors
1 2 3 4 5 6
PHA (3pg/ml) 250 320 80 8 14 25
PHA + pge2 16 160 <2 <2 a <2
PHA + PGE2 + IL-2 160 800 16 5 32 32
a) PGE2 was used at 3pg/ml.
b) Recombinant IL-2 was used at 2U/ml.
THE EFFECTS OF IL-1 AND IL-2 ON PGE2 MEDIATED INHIBITION OF 
IFN-GAMMA PRODUCTION BY PBML.
Table 3.20
IFN-gamma yield (U/ml) 
and tritiated-thymidine incorporation (cpm)
Culture conditions
Mitosen _ Mitogen only With PGE; PGE, + IL-1 PGEo + IL-2
PHA 250 25 20 80
(3pg/ml) 116,712 150,779 ND 337,614
Con A 10 <2 6 250
(5pg/ml) 88,364 86.593 ND 188,726
OKT3 25 3 <2 160
(lng/ml) 72,570 47,789 ND 259,944
SEA 200 200 400 500
(lng/ml) 143,446 182,325 ND 256,811
a ) p ge2 was used at 3jug/ml
b) IL-1 was used at 10U/ml
c) Recombinant IL-2 was used at 2U/ml.
d) IFN titre was measured on day 3 and tritiated-thymidine
incorporation from day 3 to 4.
e) All results came from a single donor.
stimulation the IFN-gamma levels were partially restored 
by the addition of exogenous IL-2, but for Con A and 0KT3 
stimulation they were elevated far above the yield 
produced by mitogen stimulation alone. This is consistent 
with the stimulatory properties of exogenous IL-2 when 
stimulation is sub-maximal (see next section).
Despite its inhibitory effects on IFN-gamma levels, PGE2 
did not inhibit mitogenesis. as measured by 
tritiated-thymidine incorporation (Table 20). The presence 
of exogenous IL-2 boosted tritiated-thymidine 
incorporation 2-3 fold for all mitogens, except SEA.
e ) The Effects of IL-1 and/or IL-2 on IFN-gamma induction 
by mitogens and on IFN-gamma production without mitogen 
stimulation.
When high titres of IFN-gamma were induced by mitogens, 
in the absence of inhibitory factors, the addition of 
exogenous IL-2 had little or no effect on the titre 
produced (Table 21). This was seen in the case of both PHA 
(donor 1) and OKT3 (donor 2). However, when IFN-gamma 
production by mitogen stimulated PBML was "low" 
(<100U/ml), as with donor 3 using Con A and PHA, exogenous 
IL-2 considerably boosted IFN-gamma production.
Without mitogen IL-2 induced IFN-gamma production only 
when added at high (20U/ml) concentrations (Tables 22 & 
23). Yet when added at the same high concentration in the 
presence of mitogen IL-2 had least amplificatory effect 
(Table 22). However, it should be noted that only a single 
donor was examined in this case.
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BY PBML.
Table 3.21
THE EFFECTS OF IL-2 ON MITOGEN STIMULATED IFN-GAMMA PRODUCTION
IFN-gamma yield (U/ml) 
---Donor___Mitogen only IL-2 only_ Mitogen + IL-2
PHA (lpg/ml) 1 1000 32 1600
OKT3 (lng/ml) 2 250 32 400
Con A (5pg/ml) 3 6 ND 160
PHA (3ug/ml) 3 16 ND 1000
a) Recombinant IL-2 was used at 2U/ml.
Table 3.22
THE EFFECTS OF IL-2 ON IFN-GAMMA PRODUCTION BY PBML WITH 
AND WITHOUT MITOGEN.
IFN-gamma yield (U/ml) 
Exogenous IL-2 concentration
None 0.2 U/ml 2.0 U/ml 20 U/ml
No mitogen 25 100 32 4000
PHA (lpg/ml) 1000 3200 1600 1000
a) PBML from a single donor were used.
Table 3.23
THE EFFECTS OF IL-2 ON IFN-GAMMA PRODUCTION BY PBML WITH 
AND WITHOUT IL-1 IN THE ABSENCE OF MITOGEN.
IFN-gamma yield (U/ml)
Exogenous IL-2 concentration.
____None_____Q-2 U/ml_____2.0 U/ml 20 U/ml
No IL-1 <2 3 5 20
With IL-1 (6U/ml) <2 18 <2 18
a) PBML from a single donor were used.
IL-1 in the absence of mitogen rarely induced any 
IFN-gamma production by PBML. as described earlier in the 
chapter. It also had little effect on IL-2 induced 
IFN-gamma production, in the absence of mitogen (Table 
23). Thus the two interleukins do not appear to act 
synergistically, in the absence mitogen, and both require 
mitogen as an additional signal for significant IFN-gamma 
induction, compared to the levels induced by mitogen 
alone. The two situations in which exogenous interleukins 
have a stimulatory effect are for macrophage-depleted 
lymphocytes, in the case of IL-1, and low level mitogen 
stimulation, in the case of IL-2.
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DISCUSSION : Chapter 3.
Because of the breadth of data covered in this chapter 
the discussion has been broken down into the following 
sections: 1) the role of macrophages and IL-1; 2) the role 
of IL-2; 3) the action of PGE2 .
1) THE ROLE OF MACROPHAGES AND IL-1 IN IFN-GAMMA 
INDUCTION.
Many workers have investigated the role of macrophages 
in T-cell activation and the importance of IL-1 in 
macrophage/T-cell interactions. Such studies, however, 
have concentrated on such markers of T-cell activation as 
IL-2 production and IL-2 receptor expression with little 
attention being paid to IFN-gamma production.
The primary signal for T-cell activation is thought to 
be the binding of antigen or mitogen to the T-cell 
receptor, or the closely associated T3 molecular complex. 
Activation by antigen (monoclonal) does not appear to 
differ from activation by mitogen (polyclonal) in any 
qualitative fashion, only quantitatively. If macrophages 
are not also present, however, both early (IL-2
production, IL-2 receptor expression, and RNA synthesis) 
and late (DNA synthesis) T-cell responses are prevented 
(Williams fit al.,1984). Several groups have shown that 
purified IL-1, usually obtained from mitogen-stimulated 
macrophage supernatants, can partially restore T-cell 
responses to mitogens (Williams fit fil.,1984) or to anti-T3 
monoclonal antibodies (Schwab fit fil.,1985; Williams fit 
fil.,1985; Palacios,1985a) in the absence of macrophages,
but. full activation seems to require the accessory cell 
membrane, pesumably to present antigen in the context of 
class II MHC (Unanue si si-.1984). Both IL-1 and IL-2 have 
been shown to be involved in IL-2 receptor expression 
(Schwab et al.,1985; Williams et al.,1985). but some extra 
macrophage signal is still needed for IL-2 production with 
IL-1 seeming to amplify rather than induce IL-2 production 
(Palacios,1985a). In a recent study using an IL-1 
sensitive cell line (EL4 thymoma cells) it was shown that 
IL-1 is involved in the induction of both IL-2 secretion 
and IL-2 receptor expression, apparently by a third 
intracellular pathway that can synergise with either 
increased intracellular calcium ions levels or protein 
kinase C activation for IL-2 production, and with 
activation of protein kinase C only for expression of IL-2 
receptors (Lowenthal et al. .1986 ) .
The exact role of IL-1 in IFN-gamma production is also 
not clear, but the results obtained in this study strongly 
suggest that it is an important regulatory factor. 
Macrophage-depletion from PBML clearly reduces IFN-gamma 
induction at least 10-fold (Table 1), just as other 
workers have found for IL-2 induction. Bearing in mind the 
importance of IL-2 production and binding to its receptor 
for maximal IFN-gamma production (also shown in this 
chapter) it is not surprising that if induction of IL-2 
and its receptor are reduced by macrophage-depletion then 
IFN-gamma titres would also be greatly reduced as a 
consequence. Similar to the situation found by others for 
IL-2 production in macrophage-depleted populations, in
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this study it was found that the addition of purified 
exogenous IL-1 could at least partially restore IFN-gamma 
production (Table 1). The lymphocyte preparations 
contained less than 0.5% macrophages, as shown by 
non-specific esterase staining, and yet the addition of 
exogenous IL-1 clearly boosted IFN-gamma production for a 
variety of mitogens (Table 3) and donors (Table 1 and 2). 
This boosting effect, however, was not related to the IL-1 
concentration in any clear cut manner, the dosage effects 
varying from donor to donor (Table 2). The maximum limits 
of impurity claimed by Genzyme for the IL-1 used were 1.0% 
IL-2 and lU/ml of IFN, with an IL-1 activity of >100U/ml 
(one unit is defined as that amount of IL-1 required to 
double the proliferative response of mouse thymocytes 
stimulated with lpg/ml of PHA). It is reasonable therefore 
to assume that any effects were IL-1 mediated rather than 
due to impurities, especially since IL-1 had no effect 
when IL-2 did. Therefore when IL-1 did show effects it 
would not be due to IL-2.
When exogenous IL-1 was added with mitogen to PBML it 
had no effect on IFN-gamma levels. This lack of 
stimulation is presumably because the macrophages already 
present in PBML produce sufficient endogenous IL-1 for 
optimal subsequent IFN-gamma production, any exogenous 
IL-1 added therefore having no additional effect. Thus 
exogenous IL-1 is not a general stimulator of IFN-gamma 
production but acts only when the cell population is 
macrophage-depleted.
Addition of IL-1 to PBML in the absence of mitogen
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induced significant IFN-gamma levels in only a few donors 
(Table 2) and at most only very low levels in the 
remainder (Table 2 and 23). Why some donors responded to 
IL-1 alone is not clear. Possibly some lymphocytes in 
these preparations were already preactivated by some 
natural infection of the donor, making the cells more 
responsive to IL-1. In general, however, IL-1 was not a 
sufficient signal alone for lymphocyte activation, as 
others have shown (e.g. Palacios,1985a).
The lymphocyte populations in these experiments (i.e. 
macrophage-depleted PBML) still produced low but 
significant levels of IFN-gamma (usually 100U/ml at most) 
even though the titres were much reduced compared to the 
undepleted population. This suggests that either not all 
lymphocytes require accessory cells, as appears to be the 
case for the low density lymphocytes discussed in chapter 
2, or that very low levels of residual macrophages remain 
after depletion (<0.5%) and that these were sufficient to 
support low level IFN-gamma production, or that 
non-macrophage accessory cells are present.
If IFN-gamma production by macrophage-depleted cells is 
chiefly attributable to low density lymphocytes, then the 
addition of exogenous IL-1 at least partly replaces the 
macrophage requirement of the higher density T-cells for 
activation. In this case IFN-gamma levels are boosted to 
an intermediate level and not fully restored to levels 
produced if macrophages are present. This agrees with the 
findings of Williams that adding IL-1 restores indicators 
of T-cell activation, notably IL-2 and IL-2 receptor
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expression, to intermediate levels in accessory cell 
depleted T-cell populations, which otherwise show no signs 
of activation in response to PHA (Williams gt al.,1984). A 
similar study by Williams (Williams el al.,1985) with a 
monoclonal antibody for the T-cell receptor (therefore 
arguably more akin to antigen stimulation than with PHA) 
came to similar conclusions, providing the antibody was 
sepharose-bound and not just in soluble form. This 
sepharose binding is thought to facilitate crosslinking of 
the T3-Ti complexes on the T-cell surface, thus mimicking 
the action of the Fc receptor on macrophages, leading to 
T3-Ti modulation as one signal for IL-2 production (Schwab 
el al. , 1985 ) .
Even if the depleted preparations used in this study 
still contained sufficient residual macrophages for 
low-level T-cell activation, it is still clear that IL-1 
can greatly boost IFN-gamma production in this situation. 
This suggests that endogenous IL-1 production is an 
important role of macrophages in response to T-cell 
mitogens for maximal IFN-gamma production. It could be 
argued of course that the exogenous IL-1 simply 
substitutes for some other macrophage function, but the 
depressive effects of the anti-IL-1 antibody on IFN-gamma 
production described in this chapter suggests that this is 
not the case and that endogenous IL-1 production is indeed 
important.
It is possible that endogenous IL-1 does not have to be 
actively secreted for macrophages to support T-cell 
proliferation (Haq at &1..1984), but is active in a
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membrane bound form known to be present on murine 
macrophages (Kurt-Jones et al.,1985a&b) and on B-cells 
(Kurt-Jones et al.,1985c). These can act as
antigen-presenting cells under different circumstances 
from macrophages.
IL-l’s effects on macrophage-depletion were found to 
vary in extent between the different mitogens used (Table 
3). Depletion clearly reduced the IFN-gamma titre and 
tritiated-thymidine incorporation using SEA or 0KT3 as 
stimulators. The effect on mitogenesis was especially 
noticeable for OKT3 stimulation, reflecting the importance 
perhaps of macrophage Fc receptors for T3-Ti crosslinking 
as a signal for IL-2 production (Schwab §t al..19851. 
Exogenous IL-1 had little effect on 0KT3 stimulated 
lymphocyte mitogenesis, but partially restored the level 
of mitogenesis when SEA was the mitogen. This may reflect 
a difference in activation between SEA and OKT3, the 
latter being very dependent on macrophage Fc receptors for 
crosslinking. PHA and Con A in contrast were independent 
of macrophages for T-cell activation in terms of 
proliferation, although their induction of IFN-gamma 
levels was reduced by macrophage depletion. Exogenous IL-1 
served only to restore IFN-gamma levels with little effect 
on proliferation. These results are in agreement with the 
findings of Lederman that macrophage-depletion reduced 
SpA-induced (Staphylococcus aureus protein A)
tritiated-thymidine incorporation by 80%, and depressed 
the calcium ion flux, compared to PBML, but had no effect 
on proliferation or calcium flux if PHA was the mitogen
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(Lederman si al.,1984), even though SEA is a stronger 
inducer of IFN-gamma and IL-2 than PHA or Con A (Carlsson 
and Sjogren,1985). PHA has also been found to cause 
blastogenesis of T-cells in the absence of macrophages 
(Maizel si al.,1981), although further progression through 
the Gi phase of the cell cycle requires macrophages or a 
source of IL-1. It would appear then that PHA and Con A 
have effects independent of macrophages, including the 
ability to induce a shift from the resting Go stage of 
the cell proliferation cycle to an activated Gi stage, 
whilst SEA and 0KT3 require the presence of macrophages 
for proliferation.
The differences in responses between mitogens noted in 
this and other studies may reflect their differing binding 
specificities. 0KT3 triggers cell activation by binding to 
the T3 complex of the T-cell receptor with 40-50,000 
homogeneous receptor sites per cell (Van Wauwe si 
al.,1980), while the mitogenic lectins bind to 
carbohydrate moieties D-mannose and D-glucose (Ito si 
.al.,1984) and therefore bind to a large and partially 
overlapping range of lymphocyte glycoproteins 
(Diller-Centerlind si ai-,1980) with up to 10 million 
"receptor" sites per cell. However, only 10% or less of 
these sites are likely to be responsible for initiating 
proliferation, with other lectin induced changes mediated 
by other sites. Thus PHA causes disproportionately greater 
uridine uptake and inositol incorporation than 0KT3 (Walls 
et si.,1984) and may activate the Til pathway (O’Flynn si 
al.,1985a). Con A is known to bind to T3 but PHA may not
(Kanellopoulos et al.,1985), or may bind to a 20 kDa 
member of the T3 complex (Valentine et al.,1985). But 
despite these differences in activation pathways the 
results in this chapter suggest that all four mitogens 
examined require IL-1 for optimal IFN-gamma production, 
which presumably occurs further on in the cell 
proliferation cycle than Gi , beyond a stage requiring 
macrophages.
The importance of endogenous IL-1 production is 
supported by the effects of anti-IL-1 polyclonal antibody 
on IFN-gamma induction by SEA (Table 6), Con A (Table 7), 
and PHA (Table 8) and that they could be reversed by the 
addition of exogenous IL-1, confirming that the antibody's 
effects were mediated by blocking IL-1 action. In the case 
of SEA, anti-IL-1 depressed proliferation and its effects 
were found to be dose dependent, suggesting that IFN-gamma 
production is proportional to the level of IL-1. 
Similarly, the proliferative response of mouse thymocytes 
in the presence of excess IL-2, but without mitogen, has 
also been found to be proportional to the level of IL-1 
present (Mannel et .al.,1985). Anti-IL-1 had its greatest 
depressive effects if added within 24 hours of induction 
(Table 5) suggesting that high endogenous IL-1 levels are 
necessary only in the early stages of IFN-gamma 
production. Indeed, the proliferative responses of T-cells 
to mitogens are known to depend on macrophages only in the 
early stages of activation, whilst B-cell activation is 
continuously dependent on accessory cells (Thiele and 
Lipsky,1982). Other inhibitory effects of antibodies
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against IL-1 include blocking of purified T-cell responses 
to autologous monocytes pulsed with tetanus toxoid (Chu et 
al.,1984) or inhibition of mouse thymocyte responses to 
IL-1 (Mannel al.,1985). Thus the results described in 
this section concur with findings of other workers and 
also strongly suggest that endogenous IL-1 production is 
one of the major roles of macrophages in the production of 
IFN-gamma.
2) THE ROLE OF IL-2 IN IFN-GAMMA INDUCTION.
The recent availability of both purified and recombinant 
IL-2 and a monoclonal antibody for the IL-2 receptor known 
as anti-Tac (Leonard et al.,1982), which binds to the 
receptor and inhibits various aspects of human T-cell 
activation (Depper gt al.,1983), make it possible to 
determine the various roles of IL-2 with greater 
certainty. Other workers have used purified IL-2 in a 
variety of experiments that suggest that exogenous IL-2 
can regulate IFN-gamma production (Kasahara gt al..1983a: 
Reem and Yeh,1984), but anti-Tac had not previously been 
used to examine the role of endogenous IL-2.
In this study anti-Tac was shown to have a marked 
depressive effect on IFN-gamma production by PBML in 
response to several mitogens (Tables 9 to 11). Its effects 
on proliferation, however, varied between mitogens. There 
was marked depression of tritiated-thymidine incorporation 
for Con A and 0KT3 stimulation but little effect for PHA 
at the same concentration of antibody. This lack of effect 
on proliferation, despite reduced IFN-gamma production, is
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not. unexpected in view of the finding that there is no 
strict correlation between IL-2 stimulation of IFN-gamma 
production and cell proliferation (Kasahara et al.■1983a1. 
Higher concentrations of anti-Tac might have suppressed 
PHA induced proliferation, however.
The reversal of anti-Tac’s inhibitory effects by the 
addition of exogenous IL-2 (Table 13) strongly suggest 
that the antibody’s inhibitory effects are indeed mediated 
by blocking of IL-2/IL-2 receptor interactions, as opposed 
to some other mechanism, such as down regulation of IL-2 
receptor expression. Depper et al. (1983) have shown that 
anti-Tac does not inhibit IL-2 production but does block 
both mitogen and antigen induced T-cell proliferation, 
inhibit cytotoxic T-cell formation, and reduce T-cell 
dependent PWM activated B-cell Ig production. The fact 
that the antibody does not inhibit IL-2 production but 
that its inhibitory effects can be reversed by adding 
highly purified IL-2 are consistent with the view that the 
antibody reacts with the IL-2 receptor. A second 
anti-IL-2-receptor antibody was also found to inibit 
IFN-gamma production (Table 14). Depper also found that 
anti-Tac was least able to inhibit responses associated 
with the greatest proliferation. In this study PHA-induced 
proliferation was generally 2-5 times greater than that 
induced by Con A and 0KT3, but was inhibited 
proportionately to a much lesser extent, in agreement with 
Depper. This effect and the failure of anti-Tac to inhibit 
IFN-gamma production completely could be due to several 
factors.
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Firstly, IL-2 has a much greater affinity for its 
receptor than does anti-Tac (KdrlO'12mol/l for IL-2 and 
10”9mol/I for anti-Tac)(Leonard si al.,1982) and the 1,000 
fold difference means that IL-2 binding is strongly 
favoured over anti-Tac. Thus anti-Tac probably does not 
block binding of all endogenously produced IL-2. This is 
particularly the case for PHA which, judging from its 
stronger induction of proliferation, induces greater 
levels of IL-2 than Con A or 0KT3.
Secondly, factors other than IL-2 may also be 
responsible for stimulation of IFN-gamma production, 
although IL-2 binding to its receptor is a major factor 
judging from the results obtained.
Thirdly, non T-cells (e.g. NK cells) may also produce 
IFN-gamma in response to mitogens, possibly in an IL-2 
independent manner.
The effects of anti-Tac were further shown to be IL-2 
specific by the failure of IL-1 to reverse inhibition 
(Table 15), and non-specific effects of the antibody seem 
unlikely in view of the failure of mouse IgG or W634 to 
depress IFN-gamma levels when used at similar 
concentrations to anti-Tac (Table 16).
When IL-2 was added to mitogen-induced PBML in the 
absence of any inhibitory factors, such as anti-Tac or 
PGEj , the IFN-gamma titre was boosted significantly only 
if there had been only "low" level induction (i.e. 
<100U/ml of IFN) by the mitogen (Table 21). Thus exogenous 
IL-2 acts synergistically with "low" level mitogen 
stimulation, as with Con A (also see Kasahara si
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.al.,1983a), but not if the mitogen had delivered a strong 
signal for IFN-gamma production (Tables 21 and 22). Welte 
has shown that 0KT3 at concentrations too low to be 
mitogenic (25pg/ml) together with IL-2 (20U/ml) lead to 
Tac expression and proliferation when separately they have 
no effect (Welte §t al-,1984). It is suggested by Welte 
that at such low concentrations 0KT3 cannot cause Tac 
expression but can still somehow pre-activate T-cells to 
become IL-2 responsive, so that exogenous IL-2 can lead to 
Tac expression and proliferation.
In the absence of mitogen IL-2 stimulated only low 
levels of IFN-gamma (Tables 21 and 23) unless used at high 
concentrations (20U/ml) or the PBML already produced low 
levels of IFN-gamma in the absence of stimulation (Table 
22). The addition of IL-1 made no appreciable difference 
to IL-2 induced IFN-gamma production, suggesting that an 
additional signal is required to the two interleukins for 
cell activation. IL-2 may, however, be mitogenic for a 
population of T-cells in the presence of macrophages, or 
IL-1, which are not Tac +ve (Roosnek gt ai.,1986).
Vilcek finds that exogenous IL-2 can stimulate a good 
IFN-gamma yield, but it has to be added at concentrations 
(1000U/ml) far higher than normal physiological levels of 
5-30U/ml (Vilcek gì ai-,1985). He also found, as in this 
study (Croll gt ai-,1985), that anti-Tac treatment 
inhibited IFN-gamma production induced by mitogen, but not 
by IL-2 stimulation (unsurprising in view of IL-2’s 
greater affinity for its own receptor). He also found, as 
shown in Table 21, that doses of Con A which induce
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little IFN-gamma on their own increased IFN-gamma 
induction by exogenous IL-2, even when the latter was 
added at the physiological levels used in this study. The 
high levels of IL-2 needed to activate PBML in the absence 
of mitogen may be necessary because of the very low number 
of pre-activated (i.e. Tac +ve) cells present in otherwise 
unstimulated PBML. Alternatively, large IL-2 
concentrations may activate Tac -ve cells or cells 
expressing low-levels of Tac. Taylor has found that IL-2 
alone is mitogenic only for Tac +ve lymphocytes (Taylor et 
ai.,1986a), since IL-2 alone appears to induce 
proliferation by expanding only that small fraction of 
cells in a resting population (1 to 5%) already expressing 
the IL-2 receptor (Tac +ve). Thus after 24 hours of IL-2 
stimulation less than 8% of PBML are Tac +ve compared to 
25-50% with PHA stimulation. IL-2 does not appear to 
induce IL-2 receptor expression on cells previously 
lacking it, unlike mitogen, and thus acts as a secondary 
rather than primary signal for IFN-gamma production and 
general T-cell activation. Virtually all T-cells that 
produce IFN-gamma after PHA stimulation are reported to 
express IL-2 receptors (Palacios,1984), whilst both Tac 
+ve and -ve cells can produce IL-2. Removal of IL-2 from 
cultures of continuously proliferating T-cells causes them 
to stop cycling and enter the dormant Go phase, mitogen 
and macrophages being needed to reactivate them (Bettens 
et al.,1984). Having stressed the importance of IL-2 
binding to its receptor as a requirement for IFN-gamma 
production it is not, however, by itself sufficient to
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cause it. Growing T lymphoblasts (i.e. previously 
activated T-cells) in IL-2 containing medium already 
express IL-2 receptors, but they do not constitutively 
produce IFN-gamma or its mRNA unless mitogen is also added 
(Wilkinson and Morris,1984; Siggens si al. .1984 ) . 
suggesting that mitogen provides signals additional to 
induction of IL-2 and its receptor.
3) THE ACTION OF PGE-, .
Having investigated the role of macrophages and IL-1 on 
IFN-gamma production, the effects of PGE2 were examined. 
PGE2 is also produced by macrophages (Roth si al.■1985). 
although apparently by a different subset to the major 
IL-1 producers (Khansari et al.,1985). In vivo 
prostaglandins act as local rather than systemic hormones, 
with those of the E series potentiating inflammation and 
those of the F series counteracting it. Anti-inflammatory 
drugs such as aspirin are thought to act by interfering 
with prostaglandin synthesis (Ninneman,1984 ) .
When added at induction PGE2 significantly inhibited 
IFN-gamma induction by PHA, 0KT3, and Con A, but had 
little effect when SEA was the inducer (Table 17). This 
inhibitory effect was evident over a range of 
concentrations (3 to 300ng/ml) down to levels found 
physiologically. Basal level of PGE are estimated to be no 
greater than O.lng/ml in serum, but traumatic injuries 
(e.g. burns) result in large prostaglandin release with 
l-3ng/ml in serum (Ninneman,1984) and even higher local 
concentrations of 30ng/ml at inflammatory sites (Snyder si
al. ,1982) . Thus responses of lymphocytes to prostaglandin 
concentrations of 3 to 300ng/ml (lOnM to lpM) may reflect 
in vivo effects, despite being apparently above 
physiological levels, since high local concentrations may 
exist at sites of inflammation and during close 
macrophage-lymphocyte contact.
The effects of PGEg were found to vary to some extent 
between donors (Table 18) but pg/ml concentrations gave 
consistent inhibition of ten-fold or greater (Tables 18 to 
20) for all mitogens except SEA. Even when SEA and PHA 
induced similar IFN-gamma titres in the same donors (Table 
18, donors 1 and 6; Table 17 and 20) PGE2 significantly 
reduced IFN-gamma titres in the case of PHA but had little 
or no effect on SEA induction. Disparate effects between 
mitogens were not due to donor variation but may have been 
the result of different activation pathways or SEA 
inducing higher IL-2 levels than the other mitogens.
Other workers have also found PGE2 effects to be 
suppressive, probably by inhibiting IL-2 production 
(Makoulet gt al.,1985; Wolf e£ ai.,1985). Whether PGE2 
acts by inducing suppressor cells (Chouaib gt al.,1984; 
Leclerc gt al.,1984), perhaps by enhancing 0KT8 +ve cell 
proliferation (Gualde and Goodwin, 1982), or by directly 
inhibiting IL-2 production and IL-2 dependent 
proliferation (Tilden and Balch,1982) is not clear. 
However, it has been claimed that T-cells incubated with 
PGE2 produce two peptides (PITS alpha and beta) which are 
potent inhibitors of T and B cell responses (Roger gfc 
al.,1984). Also a subset of T-cells exist (10-30% of all
T-cells) which bind PGEj and exert strong suppressive 
activity on T and B cell proliferation (Fisher et 
al.,1985).
In view of the reported suppressive effects on IL-2 
production and the latter’s role in IFN-gamma production, 
exogenous IL-2 was added to PGE2 suppressed cells. It 
clearly reversed the inhibitory effects of PGE2 for a 
range of donors, although IFN-gamma levels were not fully 
restored in all cases (Table 19). The concentration of 
IL-2 used (2U/ml) did not usually boost IFN-gamma 
production, unless the mitogenic stimulation was "low" 
level (Table 21), suggesting that its effects on PGE2 
inhibition were not simply due to non-specific boosting 
but to replacement of depressed endogenous IL-2 
production.
However, it must be noted that PGE2 did not exhibit any 
depressive effects on cell proliferation in this study, 
even though IFN-gamma levels were depressed (Table 20). 
This reflects the lack of a strict correlation between 
IL-2 stimulated IFN-gamma production and proliferation 
(Kasahara et al.,1983a), also found with PHA and anti-Tac. 
It is possible that higher levels of IL-2 are needed for 
IFN-gamma stimulation than for proliferation. Exogenous 
IL-2 not only reversed PGE2 inhibition of IFN-gamma levels 
but also boosted proliferation above that induced by 
mitogen alone.
Other inhibitory actions of prostaglandins may play a 
role in depressing IFN-gamma production. PGE2 affects 
macrophages too, inhibiting full induction of class II MHC
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antigens (Zlotnik gt al.,1985) with the implication of 
reduced antigen presentation (Beller,1984 ) . However, 
Zlotnik found that despite reduced la levels antigen 
presentation was not impaired, probably because most 
T-cells only need fairly low la levels on the surface of 
presenting cells. Thus IL-2 producing T-cells are probably 
more sensitive to PGE2 than antigen presentation.
PGE2 also depresses NK cell activity (Zielinski g£ 
al.,1984), although IFN-gamma secretion appears to 
antagonise this effect (Tracey gt gl.,1982; Dore-Duffy et 
al.,1983). There is also a body of evidence that 
prostaglandins are antagonists of IL-1 production and 
effects on B-cells (Goldings.1986) and murine thymocytes 
(Hayari gt al.,1985). PGE2 treatment has been found to 
reduce the natural cytotoxicity of large granular 
lymphocytes by reducing their IL-1 production (Herman and 
Rabson,1984) and the IL-1 production of LPS-stimulated 
peritoneal macrophages (Kunkel g£ gl.,1986). In the latter 
case inhibitors of the cyclooxygenase pathway that leads 
to PGE2 production, such as indomethacin, reduced PGE2 
production up to 40 fold while boosting IL-1 levels up to 
6 fold. IL-1 was also found to boost PGE2 levels, 
suggesting that IL-1 can regulate its own production via a 
partially self-induced inhibitor.
However, in this study exogenous IL-1, when added at 
stimulatory levels for lymphocytes, had no effect on PGE2 
mediated inhibition of IFN-gamma production (Table 20). 
Thus the possible effects of PGE2 on IL-1 discussed above 
do not appear to be a major inhibitory mechanism in the
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case of IFN-gamma levels. FGE2 suppression of T-cell IL-2 
production appears to be the main inhibitory pathway in 
this case. Any effects on human peripheral macrophages (as 
opposed to murine peritoneal cells examined by Kunkel) 
appear negligible in comparison, since only exogenous IL-2 
was necessary to reverse the inhibition.
If PGE2 has a true endogenous regulatory role in the 
immune system, it may be the down-regulation of IL-2 
levels, and hence IFN-gamma, after the transient IL-2 
response to an immune stimulation. At the peak of an 
immune response FGE2 effects may be negligible due to high 
IL-2 levels and possible IFN-gamma mediated inhibition of 
prostaglandin synthesis by macrophages (Dore-Duffy et 
al.,1983). Exogenous PGE2 effects on IFN-gamma levels do. 
however, suggest that this possible regulatory pathway 
requires further investigation to determine if it does 
occur in vivo as oppose to in vitro.
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CHAPTER 4.
REGULATION OF IFN-GAMMA PRODUCTION BY CELL SURFACE
MOLECULES BINDING SPECIFIC LIGANDS.
Introduction
An ever increasing group of cell surface molecules have 
been implicated in regulation of the immune response. Some 
are receptors for molecules involved in cell-cell
communication, such as the IL-2 receptor discussed in the 
previous chapter, or receptors for IL-1 (Dower si 
ai-,1985) and IFN-gamma (Orchansky si ai.,1986). T-cells 
possess other cell-surface molecules which are important 
in cell-cell recognition and signal transduction. These 
are involved, for example, in the interaction between 
antigen presenting cells and T-cells, leading to
antigen-specific T-cell activation via the T-cell antigen 
receptor. T-cells appear to recognise antigen only on the 
surface of cells bearing the appropriate self major 
histocompatability complex (MHC) gene product, which they 
were "restricted" to recognise in the thymus. Regulation 
of the level of MHC expression on antigen presenting cells 
may be involved in regulating the immune response (Unanue 
Si ai.,1984).
In recent years a series of molecules have been defined 
on the T-cell surface, using monoclonal antibodies
(moabs), and described in terms of clusters of 
differentiation, or CDs (Bluestone & Hodes,1983;
Townsend,1985). The most interesting of these are T3, T4, 
T8, and Til. These molecules work by binding to other 
cell-surface structures or ligands which may or may not
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yet be identified. In this chapter the various monoclonal 
antibodies which bind to these cell-surface structures are 
used as model ligands. Although obviously they are not the 
natural ligands, unlike purified interleukins which 
deliver physiological signals, they are presumed to mimic 
a physiological ligand and do have their advantage of 
specificity and simplicity. The use of moabs as agonists 
to induce activation, growth, or differentiation of 
lymphocytes has recently been reviewed by Clark and 
Ledbetter (1986).
The human T4 (CD4) and T8 (CD8 ) molecules and their 
murine equivalents may play a role in T-cell recognition 
by enhancing the overall avidity of cell-cell interactions 
through specific binding to non-polymorphic cell surface 
ligands, possibly the non-polymorphic regions of class II 
and class I MHC molecules respectively (Reinherz et 
al.,1981; Reinherz et al.,1983). Moabs against MHC 
molecules and the T-cell subset markers specific for them 
have been used to investigate their functions in a variety 
of studies.
Another T-cell marker Til (CD2) known as the sheep red 
blood cell (or E) receptor is found on all T-cells, like 
the T-cell antigen receptor and associated T3 complex 
(T3-Ti). Like T3-Ti, the E receptor also appears to be 
involved in T-cell activation and has been described as an 
alternative antigen-independent activation/suppression 
pathway (Meuer gt .al.,1984). It has been shown that some 
moabs binding to Til can suppress IFN-gamma production 
(Wilkinson & Morris,1984a), IL-2 production (Tadmori gt
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aT.,1985), and IL-2 receptor expression (Reed ei 
al.,1985a&b), whilst moabs binding to other epitopes can 
lead to T-cell activation (Meuer et al.,1984: Fox et 
al.,1985; Wilkinson & Morris.1984b). Thus some moabs may 
deliver signals different from those delivered by the 
physiological ligand to the same receptor. The natural 
ligand of Til and the in vivo role of the Til pathway are 
not yet certain, but recently a new lymphokine ("IL-4A" = 
T-cell activation factor) has been described, derived from 
antigen specific activation of T-helper cells, which seems 
to bind to Til and cause T-cell activation (Milanese et 
aj,.,1986a). Furthermore, the presence of the Til molecule 
as the first T-cell marker to be expressed by thymocytes 
has led Reinherz to suggest the Til pathway is important 
for imparting self-tolerance and MHC restriction in the 
thymus (Reinherz.1985).
Not only may the various T-cell and macrophage cell 
surface molecules be involved in cell-cell interactions, 
but it has also been suggested that they can act as 
transmembrane signal receptors, or transducers. On T-cells 
Til may act as a "negative signal receptor" (Palacios & 
Martinez-Maza,1982), although the description of "IL-4A" 
suggests otherwise, and T4 may have a similar role, in 
addition to its involvement in accessory cell interaction 
(Bank & Chess,1985). Similarly, human HLA-DR antigens and 
their murine equivalent (H2 I-A) on macrophages and B 
cells may act as signal transducers, as well as 
restriction elements (Durum & Gershon,1982; 
Palacios,1985b).
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In this chapter the ability of these cell surface 
molecules to regulate IFN-gamma production was 
investigated, using a variety of monoclonal antibodies as 
model ligands since to use the natural ligands would not 
usually be possible. This is in contrast to the previous 
chapter where purified or recombinant versions of the 
soluble mediators, which are the natural ligands, are 
used.
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RESULTS
Effects__of__IL-1__and__IL-2 on inhibition of IFN-gamma
production by Moab 9 .6.
The monoclonal antibody 9.6, which binds to the T-cell 
marker Til, was found to inhibit IFN-gamma production if 
added at the time of induction at a sufficient 
concentration (lpg/ml). IL-1, despite its effects on low
IFN-gamma yields by lymphocytes, did not reverse this 
inhibition, over a range of concentrations, for both PHA 
and SEA induction (Table 1). This was found to be the case 
for a total of seven donors (Table 1 is representative) 
and at the highest concentrations (20U/ml) IL-1 even 
seemed to increase the level of inhibition caused by 9.6. 
Thus the inhibitory effects of 9.6 are not mediated by 
preventing IL-1 production.
Recombinant IL-2, however, was able to reverse 9.6 
mediated inhibition (Table 2). Both IFN-gamma yields and 
proliferation, as measured by tritiated-thymidine
incorporation, were depressed significantly by 9.6.
Addition of IL-1, at a concentration that reversed the 
effects of macrophage depletion, had little effect on this 
depression, whilst recombinant IL-2 clearly reversed both 
depressive effects for three different mitogens. The 
addition of recombinant IL-2 at induction at 2 U/ml of 
biological activity often restored tritiated-thymidine 
incorporation to a level above that stimulated by mitogen 
alone. This is most clearly seen when 0KT3 is the T-cell 
activator. 9.6 causing a 25-fold drop in mitogenesis but 
IL-2 more than reversing this. The depressive effects on
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TABLE 4 . 1
THE EFFECTS OF IL-1 ON THE INHIBITION OF IFN-GAMMA PRODUCTION 
BY AN E-RECEPTOR SPECIFIC MONOCLONAL ANTIBODY (9.6).
IFN-gamma Yield (U/ml)
PHA (10pg/ml) SEA (20ng/ml)
Mitogen only 1000 250
Mitogen + 9.6 20 40
Mitogen + 9.6 + IL-1 (0.6U/ml) 20 32
Mitogen + 9.6 + IL-1 (2 U/ml) 40 25
Mitogen + 9.6 + IL-1 (6 U/ml) 8 10
Mitogen + 9.6 + IL-1 (20 U/ml) 6 8
a) 9.6 was used at lpg/ml.
b) PBML from a single donor were used.
Table 4.2
THE EFFECTS OF IL-1 AND IL-2 ON INHIBITION OF IFN-GAMMA 
PRODUCTION AND PROLIFERATION BY 9.6.
Mitogen
PHA (lOpg/ml) OKT3 (10ng/ml) SEA (20ng/ml)
Donor 1 IFN 3H-Thv IFN 3 H-Thy IFN 3H-Thy
Mitogen ojaly 35 83,413 25 48,722 100 129,011
Mitogen + 9.6 <2 51,068 <2 1,820 32 51,764
Mitogen +9.6+IL-l <2 35,373 <2 1,654 50 62,691
Mitogen +9.6+IL-2 12 128,126 16 85,843 200 119,369
Donor 2 IFN IFN IFN
Mitogen only 320 800 6000
Mitogen + 9.6 60 3 1200
Mitogen +9.6+IL-l 160 <3 2500
Mitogen +9.6 + IL-2 320 100 4000
a) IFN-gamma titre was measured in U/ml 3 days post-induction. 
3H-Thymidine incorporation was measured for donor 1 over a period 
of 24 hours, 3-4 days post-induction, as the mean of four wells. 
Standard deviation was 10% or less.
b) 9.6 was used at lpg/ml.
c) Purified IL-1 was used at 5U/ml and recombinant IL-2 at 2U/ml.
mitogenesis are less severe when SEA or PHA are used as 
mitogens. This effect of IL-2 on 9.6 inhibition appeared 
to be neither mitogen nor donor specific and suggests that 
depressive effects of 9.6 on IFN-gamma production are 
mediated by inhibition of IL-2, but not IL-1. reducing its 
production or somehow interfering with its effects.
Effects of Moabs binding to T4 and T8 surface markers__on
IFN-gamma production.
0KT4 and 0KT8 monoclonal antibodies were added to PBML 
at a range of concentrations 30 minutes prior to induction 
and the effects on subsequent IFN-gamma titres measured 
(Table 3). At concentrations of up to lOOng/ml neither 
moab had any significant effect on IFN-gamma induction by 
SEA, but at 500ng/ml IFN-gamma production was reduced, 
3-fold in the case of 0KT8 and 10-fold for 0KT4, or the 
two moabs combined. Immunofluorescence using a 
fluorescence activated cell sorter (FACS) analyser showed 
that IFN-gamma induction was inhibited at concentrations 
(500ng/ml or greater) of moab equal to, in the case of 
0KT8, or less than, in the case of 0KT4, those which 
caused significant binding to the cell surface (Figs 4.1 & 
4.2). The moabs were titrated out and the level of 
fluorescence at each concentration (from lng/ml to 5pg/ml) 
compared to that caused by non-specific binding of the 
FITC-conjugate alone. In the case of 0KT4 there is no 
significant binding of the moab at less than 500ng/ml and 
definite binding only at l-5pg/ml (Fig 4.1). In the case 
of 0KT8 significant binding of the moab occurred only at
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TABLE 4 . 3
THE EFFECTS OF VARYING CONCENTRATIONS OF OKT4 AND OKT8 ON 
IFN-GAMMA PRODUCTION BY PBML.
IFN-gamma Titre (U/ml) 
Moab concentration ( ng/ml)
10 50 100 500
0KT4 100 50 80 10
0KT8 130 80 130 40
OKT4 + OKT8 160 80 80 16
Mitogen only 80 _ _ _
a) Moab added 30 minutes prior to induction.
b) SEA (20ng/ml) was used to induce the PBML from a single donor.
c) Using immunofluorescence both moabs were found to bind at 
concentrations of 30ng/ml or greater. No binding was detectable 
at <30ng/ml.
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concentrations of 500ng/ml or greater (Fig 4.2), i.e. the 
same range of concentrations as those which cause 
inhibition of IFN-gamma induction. Thus inhibition occurs 
at concentrations of both moabs equal to or less than 
those required for significant binding as revealed by- 
fluorescence, and is not due to some non-specific effect 
caused by a great excess of antibody.
These inhibitory effects of 0KT4 and 0KT8 were 
demonstrated across a range of donors (Table 4). 0KT4 was 
found to be a more potent inhibitor than 0KT8 at the same 
concentration, particularly when effects on proliferation 
are compared. 0KT3 was also found to be inhibitory at 
these high concentrations, despite its stimulatory effects 
at lower levels.
However, this inhibition of T-cell activation seems to 
be dependent upon the time of addition of the moab 
relative to induction, based on results from two donors. 
When 0KT4 and 0KT8 are added one hour post-induction, as 
opposed to one hour prior to induction, there is a 
difference in the levels of inhibition (Table 5). In the 
case of 0KT8 mediated inhibition IFN-gamma levels were 
unaffected or at most reduced by 50% if the SEA had been 
added first, compared to >10-fold inhibition when PBML 
were pretreated with 0KT8. Inhibition by 0KT4 was still 
significant (7-fold or greater) even if added one hour 
post-induction, however. 0KT4 thus seems to be a rather 
more potent inhibitor than 0KT8. Different inhibitory 
mechanisms may be involved or the difference in effects 
may reflect different involvement of the two T-cell
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TABLE 4.4
THE EFFECTS OF OKT4 AND OKT8 ON IFN-GAMMA PRODUCTION BY PBML.
IFN-gamma Titre (U/ml) 
Donors
1 2 3 4 5 6 6 (prolif.)
Mitogen alone 130 160 1000 500 400 320 103,115
With OKT4 6 80 40 50 80 4 7,360
With OKT8 40 80 160 160 120 8 52,216
With OKT4 + OKT8 25 250 25 5 ND ND ND
With OKT3 ND ND ND ND 32 3 1,616
a) Moab (500ng/ml) was added 30 minutes prior to induction
with SEA (20ng/ml)
TABLE 4.5
THE EFFECTS OF OKT4 AND OKT8 BINDING TO PBML BEFORE AND AFTER INDUCTION.
IFN Titre (U/ml)
Donors
1______________ 2.
SEA only 2100 8000
SEA then OKT4 320 320
SEA then 0KT8 4000 4000
OKT4 then SEA 80 1000
0KT8 then SEA 250 250
a) The SEA was added one hour before or one hour after the moab.
b) Moab was used at 500ng/ml and SEA at 20ng/ml.
subsets in IFN-gamma production. However, these
conclusions are tentative since only two donors were 
examined in this situation.
Effects_of__moab binding to MHC class I and II molecules on 
IFN-gamma production.
The addition of moabs against class I MHC cell surface 
molecules at the time of induction caused a severe 
reduction of the IFN-gamma titre for two donors (Table 6). 
Both BBMI (specific for the beta-2-microglobulin chain of 
MHC class I cell surface complexes) and W6/32 (specific 
for a determinant common to most heavy chains of HLA-A, B, 
or C class I antigens; Barnstaple et al.,1978) caused 
significant inhibition of IFN-gamma production across a 
range of concentrations. W6/34 antibody is thought to bind 
to a widely distributed tissue common or species antigen 
(SA1), coded for on chromosome 11, with no connection to 
MHC antigens, coded for on chromosome 6. Neither W6/32 or 
murine IgG had any depressive effect on IFN-gamma 
production when used at similar concentrations to W6/32 or 
BBMI. Thus the depressive effects of W6/32 and BBMI are 
unlikely to be the non-specific result of binding to just 
any cell surface molecule, since W6/34 has no effect, or 
due to the presence of IgG somehow inhibiting T-cell 
activation. Their inhibitory effects are thus probably due 
to their interaction with class I HLA complexes, 
consisting of the 43kd heavy chain plus the 12kd 
beta-2-microglobulin chain.
Antibodies against class II HLA-DR antigens, found on
TABLE 4.6
THE EFFECTS OF ANTIBODIES AGAINST CLASS I HLA MOLECULES ON 
IFN-GAMMA PRODUCTION BY PBML.
IFN-gamma Titre (U/ml)
Antibody Donor 1 Donor
Mitogen alone 800 1600
BBMI (lpg/ml) <2 80
(0.5pg/ml) <2 50
(0.3pg/ml) 32 1000
W6/32 (lpg/ml) 40 160
(0.5pg/ml) 16 100
(0.3pg/ml) 4 320
W6/34 (3pg/ml) 1300 2000
(lpg/ml) 3200 1000
Mu IgG (5pg/ml) ND 1000
(lpg/ml) ND 800
a) SEA (20ng/ml) was used as the inducer for PBML throughout.
b) BBMI was used in the form of an ascites supernatant and 
binds to beta-microglobulin.
c) W6/32 (ascites supernatant-IgG2 ) binds to HLA class I 
heavy chain.
d) W6/34 (ascites supernatant-IgG2 ) binds to a species antigen 
(SA1) found on all human cells.
macrophages, B lymphocytes, and some other cells, also 
inhibited IFN-gamma production by PBML from six different 
donors (Table 7). The effect was dose specific, although 
the actual protein concentration of the anti-DR 
preparations was not measured. The level of inhibition was 
reduced if the anti-DR moab was added 24 hours post 
induction rather than at the same time as the mitogen. 
Thus interactions involving HLA-DR antigens required for 
optimal IFN-gamma production would appear to occur in the 
first 24 hours of induction. These inhibitory effects were 
shown to be neither donor nor mitogen specific. However, 
the level of inhibition was found to be greater for SEA 
than PHA induction (90% versus 50% inhibition).
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TABLE 4.7
THE EFFECTS OF HLA CLASS II (DR) SPECIFIC ANTIBODIES ON IFN-GAMMAPRODUCTION BY PBML.
1
IFN-gamma Titre (U/ml) 
Donors 
2 3 4
SEA alone 2000 1200 600 320
SEA + anti-DR (1/1000) 120 400 ND ND
SEA + anti-DR (1/100) 55 50 800 100
SEA + anti-DR (1/10) 55 32 100 40
SEA + anti-DR (1/100) 24h p.i ND ND 800 120
SEA + anti-DR (1/10) 24h p.i. ND ND 600 160
a) Anti-DR supplied by the Dr .W.Bodmer (ICRF)
Donors
__1_____________ 2__
SEA (20ng/ml) 320 400
SEA + anti-DR (1/100) 32 32
SEA + anti-DR (1/10) 24h p.i. 120 250
PHA (lOpg/ml) 40 45
PHA + anti-DR (1/100) 20 20
PHA + anti-DR (1/100) 24h p.i 32 40
a) Different anti-DR (DAKO) used from above.
DISCUSSION : Chapter 4.
The results in this chapter clearly demonstrate that a 
variety of cell surface molecules, other than receptors 
for interleukins 1 and 2, can regulate IFN-gamma 
production. To a great extent. however, involvement of 
these cell surface molecules in regulating IFN-gamma 
levels may reflect their overall importance in T-cell 
activation (Bluestone & Hodes.1983; Townsend,1985 ) .
The growing evidence for the Til pathway as an 
alternative antigen-independent activation/suppression 
pathway to the T3-Ti pathway made the possible role of 
interleukins in regulation of its effects on IFN-gamma 
production an obvious candidate for investigation. A 
variety of monoclonal antibodies to the Til molecule (the 
E receptor) have been shown to suppress IL-2 production 
(Tadmori et al.,1985; Moretta si si.,1985) and IL-2 mRNA 
accumulation (Tadmori et ai.,1986). 0KT11A also inhibits 
expression of IL-2 receptors (Palacios &
Martinez-Maza,1982; Reed si ai.,1985a&b) and T-cell 
mitogenesis (Van Wauwe si si-.1981). There are an 
estimated 2x10* binding sites/cell for 0KT11A (Van Wauwe 
Si si-,1981), which is similar to the number of binding 
sites reported for 0KT3. The Til moab 9.6 has also been 
shown to inhibit both RNA and DNA synthesis plus IFN-gamma 
production, as induced by several different mitogens, 
although tumour promoters can reverse these effects 
(Wilkinson & Morris,1984a).
However, binding of sheep erythrocytes to the E receptor 
can augment IFN-gamma production (Wilkinson &
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Morris.1984b) , whilst antibodies against epitopes other 
than those bound by SRBC. 9.6. or 0KT11A can induce T-cell 
proliferation in the absence of antigen and/or presenting 
cells (Meuer et al.,1984; Yang et al,1986). At least three 
distinct epitopes exist, recognised by different moabs, 
and have been designated Tllj , Tll2 , and Tll3 . One of 
these epitopes. Tll3 . is found only after activation or 
binding of moab to the Tll2 epitope, both being unrelated 
to the SRBC binding site, Tllt (Fox et al..1985). 
Activation via these epitopes can trigger cytotoxic cells, 
independently of antigen exposure (Siliciano et al. .1985 ) . 
and IL-2 receptor expression on both T3+ and T3- 
thymocytes, although without inducing IL-2 production (Fox 
et ai.,1985). The effects of the Til pathway appear,
therefore, to depend on the epitope(s) bound to. More
recently a new lymphokine ("IL-4A") has been described 
which is produced by antigen specific activation of 
T-helper cells and leads to non-specific activation of 
resting T-cells by binding to the Til molecule (Milanese 
et al,., 1986a). ''IL-4A'' is apparently distinct from IL-1 or 
IL-2 in size and action. It stimulates IL-2 receptor 
expression by binding to Til and does not require the 
presence of macrophages for its action, similar to the
action of anti-Tll2 + 3 , "IL-4A" also stimulates the
cytotoxic activity of cytotoxic T-cell clones, inducing 
them to kill targets lacking the apropriate MHC molecules, 
and T3-.T11+ NK cell clones (Milanese si al. .1986b) .
In this study the Til moab 9.6 was used. It depressed 
IFN-gamma induction by several mitogens as has been shown
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before. Addition of IL-1 at levels stimulatory for 
lymphocytes had no effect on this depression, but addition 
of IL-2 reversed both the depression of IFN-gamma levels 
and of tritiated-thymidine incorporation. This concurs 
with the findings of Reed et ai. (1985a&b> and Tadmori et 
al. (1985 & 1986) that several different moabs blocked 
mitogen-induced IL-2 production and IL-2 mRNA 
accumulation, IL-2 receptor expression, and 
tritiated-thymidine incorporation, but the addition of 
IL-2 reversed these suppressive effects. Thus 9.6 
depressed IFN-gamma levels are probably restored by 
exogenous IL-2 boosting the depressed levels of IL-2 and 
IL-2 receptor expression.
Tadmori si al.(1985) found that 9.6 could inhibit 
proliferation even when added 48 hours after stimulation 
and therefore is unlikely to act by blocking 
mitogen/antigen binding to the cells. However, Wilkinson 
et ¿1.(1984a) found that 9.6 needed to be added within 15 
hours of stimulation for significant inhibition of 
IFN-gamma production. Since IL-1 production occurs 
rapidly, within 3 hours of activation (Durum et al..1985). 
it seems unlikely that Til depression, which can occur 
much later, acts via IL-1 levels. Hence, addition of 
exogenous IL-1 would not be expected to reverse any Til 
mediated inhibitory effects. Since IL-2 binding to its 
receptor is required for optimal IFN-gamma production, as 
shown in chapter 3, and the Til pathway is known to reduce 
levels of both IL-2 production and expression of its 
receptor, exogenous IL-2 is most likely to restore
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IFN-gamma production by boosting depressed IL-2 levels and 
by increasing IL-2 receptor expression (Reem & Yeh,1984).
The way in which different Til epitopes can transmit a 
positive or negative signal is not understood, although it 
is interesting to note that there are even two different 
mechanisms of Til mediated activation, distinguishable by 
causing a calcium flux or not (Holter et al., 1986b). 
Modulation of the T3-Ti complex by a non-mitogenic anti-T3 
moab can block activation via the Til pathway, but Til 
modulation by a non-mitogenic anti-Tll moab does not 
inhibit T-cell activation by 0KT3 (Fox et al. .1986 ) . 
Anti-T3 moab can costimulate macrophage-depleted T-cells 
if an anti-Tll moab against the appropriate epitope is 
also present, suggesting that the two pathways can be 
jointly involved in T-cell activation (Yang et al.,1986). 
The pathways are clearly interactive and Reinherz (1985) 
has suggested that regulation of Til induced thymocyte 
expansion by the T3-Ti antigen/MHC receptor pathway, Til 
appearing earlier than T3-Ti in thymocyte development, can 
explain MHC restriction in the thymus. Thymocytes whose 
T3-Ti has a high affinity for self MHC molecules (i.e. 
autoreactive) found on dendritic cells in the thymus would 
be inactivated via the Til pathway so that they cannot 
respond to IL-2. T3-Ti activation needs IL-1, which is not 
present in the thymus, but Til activation is independent 
of IL-1. Thymocytes lacking autoreactive T-cell receptors 
would not have their Til pathway inhibited and could 
therefore repond to IL-2 and expand in number.
As yet, however, the natural ligand(s) for Til has not
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yet been positively identified. The hormone early 
pregnancy factor (EPF) can inhibit certain immune 
reactions, possibly via Til since it blocks SRBC resetting 
(Whyte & Heap,1983). Possibly EPF, by acting via Til, 
helps regulate the maternal immune system during pregnancy 
to aid survival of the fetal allograft". If EPF actually 
does regulate immune function in vivo. and this is far 
from certain, it may well act by regulating IL-2 and 
IFN-gamma levels to some extent. A 42,000 m.wt. 
glycoprotein has also been isolated which may be the 
target structure (TUTS) for Til, since it blocks rosette 
formation and competes with anti-Tll moabs in binding the 
E receptor (Hunig, 1985) . Possibly Til and TUTS are 
complementary cell interaction molecules involved in 
regulating T-cell proliferation. The most likely in vivo 
Til ligand, however, is the newly described lymphokine 
''IL-4A" which acts as a non-specific T-cell activator 
(Milanese gt ai.,1986a). Its actual role in vivo has yet 
to be shown. however, since it is not known how the 
apparent non-specific amplificatory effects of IL-4A would 
be regulated and how antigen specificity would be 
maintained.
Considering the importance of "restriction" in the 
immune response (the ability of T-cells to recognise 
antigen only in the context of the MHC molecules to which 
they are exposed in the thymus), the role of the cell 
surface molecules involved in mitogen activated IFN-gamma 
production was examined. Numerous studies show that T-cell 
subsets can be distinguished on the basis of their
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expressed cell-surface phenotype, and that there Is a 
strong association between cell-surface phenotype and the 
class of MHC product recognised (Bluestone & Hodes.1983). 
Thus T-cell populations in man which are class II reactive 
appear to express the T4 (62,000 m.wt. ) glycoprotein and 
are usually T helper cells (Dalgleish,1986) . Class I 
reactive T-cells, however, predominantly express the 
33.000 m.wt. T8 cell surface marker and are usually 
cytotoxic or suppressor T-cells. T4 and T8 may act as 
stabilising elements, enhancing the overall avidity of 
cell-cell interactions through specific binding to 
non-polymorphic regions of class II and class I molecules 
respectively (Reinherz et aj,.,1984; Maddon at al..1985) 
when the T-cell’s receptor has low affinity for its ligand 
(polymorphic MHC region plus antigen).
Monoclonal antibodies against T4 and T8 have been used 
to examine their function, e.g. anti-T8 inhibits cytolytic 
function of T-cells (Reinherz et al.,1981) and moabs 
against the murine equivalent of T4 (L3T4) or T8 (Lyt 2) 
inhibit antigen induced lymphokine production by class I 
or class II MHC reactive clones (Lancki at aj,.,1984). In 
this study moabs against 0KT4 and 0KT8 both inhibited 
mitogen induced IFN-gamma production, when added at 
500ng/ml. 0KT4 was found to be a more potent inhibitor 
than 0KT8. This may be because T8 positive cells are a 
smaller subset (35%) of the total T-cell population. 
Alternatively, the difference in level of inhibition could 
be due to differing roles in lymphokine production, or 
differing levels of production by the two subsets. The
100
moabs differed also in their effects relative to the time
of induction. 0KT8 caused inhibition only when added prior 
to or very shortly after induction. If added even one hour 
after induction the inhibitory effects were greatly 
reduced (>10-fold). 0KT4 mediated inhibition, however, was 
only slightly reduced by addition one hour post-induction. 
Why there should be this difference in effect according to 
the time of addition is unclear. Possibly 0KT8 acts by 
blocking cell-cell interactions necessary for induction, 
whilst 0KT4 mediated inhibition is due instead to T4 
acting as a negative signal transducer (Bank & 
Chess,1985). Alternatively, the difference may reflect 
different roles of the subsets in IFN-gamma production as 
has been suggested for the murine system (Torres et 
al.,1982). 0KT8 has been shown by other workers to inhibit 
IL-2 production and IL-2 receptor expression by 0KT8+ 
cells, but not 0KT4+, if added less than 2 hours after 
stimulation. Thereafter it failed to suppress IL-2 
receptor expression, although IL-2 production is still 
reduced up to 20 hours post induction (Welte et al.,1983). 
In the same study it was shown that 0KT8 did not interfere 
with binding of the 0KT3 used as inducer and therefore 
acts either as a negative signal or blocks cell 
interactions needed for activation.
Perturbation of T4 also seems to deliver a negative 
signal, inhibiting helper cell functions, proliferation, 
and lymphokine release. Bank and Chess (1985) have found 
that the moab 0KT4c can inhibit proliferation irrespective 
of whether la +ve macrophages or la -ve U937 cells are
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used as the accessory cells. This makes it less likely 
that T4 is purely a receptor for non-polymorphic regions 
of class II (la) molecules, but instead can act as a 
transducer of negative signals. OKT4 inhibition would 
therefore be due to T4 perturbation rather than blocking 
T4-MHC interactions. Perhaps T4-Ia interaction in the 
absence of antigen leads to a negative signal, but the 
presence of antigen changes this to a positive signal.
Recently it has been shown that anti-T4 and T8 moabs 
specifically inhibit all types of cytotoxicity of T4+ and 
T8+ CTL respectively, regardless of whether the target 
cells expressed class I or class II antigens (Fleischer et 
al.,1986). Thus T4 and T8 binding may have a regulatory, 
inhibitory effect so that high affinity binding of CTL to 
a relevant target cell is required to stimulate a strong 
positive signal from the T-cell antigen receptor. This 
would overcome the weak negative signal transmitted by 
perturbation of T4 or T8, which would otherwise prevent 
lysis of low affinity irrelevant targets. Inhibition of 
IFN-gamma production by 0KT4 and 0KT8 could therefore be 
due to such negative signals caused by perturbation of T4 
and T8 molecules. The observation that 0KT4 still causes 
significant inhibition one hour post induction (up to 24 
hours post-induction according to Banks & Chess,1985) make 
it less likely that it acts by interfering with mitogen 
binding or macrophage/T-cell interactions needed for 
activation. This may not be the case for 0KT8, however.
Further interest in the T4 molecule has been stimulated 
by the discovery that it acts as the receptor for LAV (or
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HTLV III) virus, since preincubation of T4+ cells with 
0KT4 blocks cell infection by this virus (Klatzman ei 
aj,., 1984). Recent sequencing of the genes encoding T4 
(Maddon et al., 1985) and T8 (Littman et al.,1985; Sukhatme 
et al.,1985) proteins reveal significant homology with 
members of the immunoglobulin superfamily, which includes 
MHC antigens and the T-cell receptor (Williams,1984). Both 
have V-like domains homologous to equivalent regions of 
both immunoglobulin and the T-cell antigen receptor 
chains, but T4 also has a J-like region making it, at 435 
amino acids, twice the si2e of T8 (Maddon êt al.,1985). 
Possibly T4 reflects a more primitive gene that evolved 
before the emergence of rearrangement mechanisms, found in 
immunoglobulins and the T-cell antigen receptor, similar 
to receptors operative in more primitive cellular immune 
responses. Thus a growing body of work, plus the findings 
described in this chapter, suggest that T4 in particular 
may have regulatory functions beyond that of restriction 
alone.
Antibodies against MHC molecules, both class I and II, 
were also shown in this chapter to inhibit IFN-gamma 
production, possibly by interfering with restriction 
requirements. Class I MHC molecules are expressed on all 
cells, which is hardly surprising since any cell can be 
parasitised and thus should be a potential lytic target 
for the class I restricted cytotoxic T-cells (T8). Class 
II MHC molecules, however, are found only on 
antigen-responsive and accessory cells (e.g. B cells and 
macrophages), since these are the only targets for helper
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T-cells (T4). If there was only a single class of 
restricting element then cells not related to the immune 
system would compete for helper T-cell recognition of 
antigen presenting cells, decreasing the level of 
activation considerably.
In this study moabs against both the class I heavy chain 
(W6/32 against HLA-A. -B, and -C gene products) and the 
associated beta-2-microglobulin chain inhibited IFN-gamma 
induction 10-fold or more when added at induction. These 
effects were shown to be specific since similar 
concentrations of murine IgG or a moab against a species 
antigen, found on all cells, had no effect on induction. 
Taylor §t ad have also shown that HLA class I molecules 
have a functional role in human T-cell activation, moabs 
against HLA-A, -B, and -C gene products (including W6/32) 
inhibiting both 0KT3- and ionomycin- (a calcium ionophore) 
induced proliferation of both T4+ and T8+ enriched 
populations by reducing IL-2 secretion and IL-2 receptor 
expression (Taylor gt al. ,1986b). Since it was also shown 
that anti-class I moabs still caused inhibition when added 
some 40 hours post-induction, and since they also 
inhibited ionophore induced proliferation, it seems 
unlikely that these moabs interfere with antigen 
recognition but that HLA class I molecules are somehow 
directly involved in early events of lymphocyte activation 
and proliferation (e.g. protein kinase C activation; see 
chapter 5).
Similarly, moabs against HLA class II DR molecules, 
found on macrophages and B cells, could inhibit the level
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of IFN-gamma production by 10-fold or more. The effect was 
dose dependent and also greatly reduced if the anti-DR 
moab was added 24 hours post-induction rather than at 
induction itself. This reduced effect post-induction is 
probably due to the importance of restriction during 
T-cell activation, rather than in subsequent stages of 
activity. Thus anti-DR moab’s inhibitory effects on 
IFN-gamma levels are most likely to be due to their 
interference with initial macrophage/T-cel1 interaction. 
However, restriction may not be as important when 
polyclonal activating mitogens are used, as opposed to 
specific antigen recognition by T-cells. In mice anti-I-A 
(equivalent to human DR) moabs have been shown to inhibit 
lectin induced IL-2 production, the addition of IL-1 
reversing this inhibition, but not if the induction was 
antigen specific (Larsson & Coutinho,1984). This suggests 
that class II antigens play two roles in lymphokine 
induction, being involved both as restricting elements in 
antigen recognition, a requirement overcome by lectins, 
and in directly mediating activation signals to 
macrophages at the level of IL-1 production. Other workers 
have found that I-A molecules may have a role in signal 
transduction, since anti-DR moabs can stimulate human 
macrophages to secrete IL-1 (Palacios,1985b) and IL-1 can 
replace the requirement for I-A positive cells in the 
proliferation of antigen primed mouse T-cells (Durum & 
Gershon,1982). Perhaps I-A recognition is required by 
T-cells not to trigger the T-cell but for the T-cell to 
trigger the macrophage to secrete IL-1.
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In vivo treatment of mice with anti-I-A antibodies
down-modulates la expression by their cells and has been 
shown to obliterate the antigen presenting ability of 
their spleen cells (Aberer et al.,1986). The depressive 
effects of anti-HLA moabs on human PBML function has also 
been demonstrated by Akiyama gt al. (1985) who found that 
the depressive effects on proliferation varied between the 
types of mitogen used. Anti-class II moabs blocked 
proliferation in response to 0KT3 and PWM, but not PHA and 
Con A. whilst anti-class I blocked responses to all four 
mitogens. Findings such as these, and the effects on 
IFN-gamma production described in this chapter, suggest 
that both class I and II antigens have an important role 
in the sequence of events following interaction of 
mitogens with cells. Antibodies against them may disturb 
macrophage/T-cell interactions, or perhaps mitogen 
binding. the effects varying between different mitogens 
possibly because different binding sites are involved or 
because mitogens may differ in their requirements for the 
presence of cells expressing MHC for lymphocyte 
activation. Differences such as these may explain the 
difference in level of inhibition of IFN-gamma production 
by anti-DR between SEA and PHA induction, the relative 
level of inhibition being less when PHA was the inducer.
Whatever the exact role of class II restriction there is 
evidence for a relationship between la or DR expression 
and IFN-gamma levels. Because macrophage la expression is 
facultative, unlike class I expression, the regulation of 
the level of la in antigen presenting cells may be crucial
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for controlling the level of the immune response (Unanue 
et .al.,1984). Prostaglandin Ej can suppress murine, but 
not human, macrophage la expression (Kunkelet et 
al.,1986). whilst IFN-gamma can induce I-A expression, 
both on cells which normally express it and also cells 
that do not, and thus augment antigen presentation and 
hence the immune response (Ameglio et al .,1983; Kelley et 
al..1984: Fierz et al.,1985; Becker.1985; Ueppert & 
Lipsky,1985; Virelizier et al. ,1984 : Janeway et al. , 1984 ) . 
Recombinant IFN-gamma has been shown to act at the level 
of transcription, inducing HLA-BR gene expression and 
boosting the level of class I HLA mRNA (Koefler et 
a_l.,1984; Collins et al.,1984). Similarly IFN-gamma can 
induce class I HLA and beta-2-microglobulin expression on 
cells which are usually class I negative, such as human 
amnion cells (Hunt & Wood,1986) and neuroblastoma cell 
lines (Lampson & Fisher,1984). IFN-gamma has also been 
shown to have in vivo effects, since its injection into 
mice leads to increased levels of antibodies in response 
to antigen (Nakamura et al.,1983) and increased (at least 
4-fold) levels of class I and II expression in a variety 
of tissues (Skoskiewicz et ai.,1985; Momburg et 
al.,1986a&b). IFN thus appears to be both a modulator, 
able to increase the level of an MHC gene product already 
expressed, and a real inducer, able to induce de novo 
activation of both classes of MHC genes (Rosa & 
Fellous,1984). The importance of la antigen expression in 
T-cell activation and consequent IFN-gamma production, 
combined with the latter’s effects on boosting la antigen
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expression, and hence increased T-cell activation and IL-1 
production by macrophages, would indicate the existence of 
an amplification loop in the immune response.
In conclusion, the results described in this chapter 
show that the binding of ligands to a variety of cell 
surface molecules can regulate mitogen activated IFN-gamma 
production. The Til pathway was shown to be capable of 
depressing IFN-gamma production, probably via depressive 
effects on IL-2 production. What significance the Til 
pathway has for immune regulation _in vivo has yet to be 
demonstrated, however. Cell surface molecules involved in 
MHC restriction on both macrophages and T-cells were also 
shown to have effects on IFN-gamma induction. Inhibitory 
effects of moabs against class I and II molecules, as well 
as T4 and T8, were probably due to the involvement of 
these molecules in the macrophage/T-cell interaction 
during the initial stages of T-cell activation. However, 
these effects varied, depending on the cell surface 
molecule involved and also the mitogen used. Furthermore 
T4 may have a regulatory role beyond its involvement in 
restriction since 0KT4 has inhibitory effects long after 
induction. Possibly 0KT4 can act as a negative signal 
transducer in a similar way to the Til molecule. Its 
membership of the immunoglobulin "superfamily", with 
structural similarities to the T-cell antigen receptor, 
adds circumstantial evidence for this possibility. It must 
be reiterated, however, that all of the regulatory effects 
described in this chapter are probably the consequence of 
overall inhibitory effects on T-cell activation being
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carried through to the level of IFN-gamma production. It 
should also be borne in mind that some of the conclusions 
drawn come from results obtained from an artificial model 
system, i.e. monoclonal antibodies binding to cell surface 
molecules. The depressive effects of moabs against these 
cell surface molecules suggest, if nothing else, that 
separation techniques involving them may cause some degree 
of inactivation.
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CHAPTER 5.
THE INDUCTION OF IFN-GAMMA AND IL-2 PRODUCTION AND THEIR 
mRNAs BY PHORBOL ESTERS AND A CALCIUM IONOPHORE.
Studies by several groups have shown that an increase in 
the concentration of cytoplasmic free calcium ions is 
associated with the transmembrane signal delivered by the 
T-cell antigen receptor in response to the binding of 
mitogenic lectins (Tsien et al,.,1982), antibodies against 
the T3 complex (Oettgen et al.,1985), or the appropriate 
antigen (Nisbet-Brown et al.,1985; Shapiro et al.,1985). A 
direct role for an increase in calcium concentration in 
cellular activation is supported by the activation of 
T-cells by calcium ionophores such as A23187 and the 
inhibition of T-cell activation by blocking calcium flux 
with EGTA (Weiss et al. ■1984 ) .
A second "signal" implicated in transmembrane signalling 
is the activation of the enzyme protein kinase C (Wolf et 
al.,1985) usually by the binding of calcium (May et 
al.,1985), but also by the binding of phorbol esters to 
the enzyme (Castagna et al.,1982; Kikkawa et al..1983: 
Niedel et al.,1983). This may explain the synergism of 
phorbol esters with mitogens for T-cell activation (Ashman 
et al.,1984) and their ability to partially replace 
macrophage functions in lymphocyte activation (Koretzky et 
al..1982).
When cells are stimulated by external ligands (mitogens 
or antigens) binding to the T-cell receptor, both 
"signals", i.e. increase in calcium ion concentration and
no
activation of protein kinase C. are normally triggered 
(see discussion and recent review by Isakov et al.,1986). 
However, experimentally these two synergistically acting 
signals can be mimicked by using non-physiological 
chemicals which trigger one signal or the other (Figure 
5.1). Thus in combination calcium ionophores and phorbol 
esters can mimic antigenic/mitogenic stimulation, 
bypassing the requirement for an antigenic/lectin signal 
at the onset of lymphocyte activation (Truneh et 
al. . 1985a&.b; Isakov & Altman, 1985 I . In this chapter, their 
ability to induce IFN-gamma production in the absence of 
mitogen was investigated. The involvement of calcium ion 
flux and protein kinase C as signals for IFN-gamma and 
IL-2 gene activation was also examined. Using cDNA probes 
made it possible to look at gene activation independently 
of downstream effects which could modulate supernatant 
levels, such as those examined in previous chapters, and 
in the absence of protein synthesis. Furthermore cDNA 
probes are both very specific and very sensitive, i.e. the 
mRNA can be detected long before the protein it codes for. 
The results suggest that the two genes are coordinately 
induced by calcium ion flux and tumour promoters, that 
macrophages may play a role in regulating messenger RNA 
levels, and that protein synthesis is unnecessary.
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Figure 5.1 A SIMPLIFIED M O D E L  OF T-CELL
ACTIVATION.
l. Calcium Antigen or 2. Tumour Promoter
lonophore Mitogen Phorbol Esters
protein kinases 
Protein-------- »-Protein-P
NUCLEUS 
DNA Replication 
Cellular Responses
Interaction between the T-cell receptor and a ligand activates 
phospholipase C, which hydrolyses Ptd Ins P2 into IP3 and DG. These 
act synergistically to elicit physiological responses. The intracellular
signals mediated by IP3 and DG can be independently mimicked by 
Ca2+ ionophores and phorbol ester tumour promoters, respectively.
RESULTS
Synergy between A23187 and phorbol ester.
Separately the calcium ionophore A23187 and phorbol 
esters meaerein, teleocidin. and TPA induced low levels of 
IFN-gamma production at the concentrations used. Higher 
levels of A23187 (lOpM) usually led to cell death. 
Together. however. the ionophore and phorbol ester acted 
synergistically to induce high levels of IFN-gamma, and 
also IL-2 (Table 1). This IFN activity was shown to be due 
to IFN-gamma by its 99% inactivation by anti-IFN-gamma 
anti-serum, which reduced the A23187/Mezerein induced IFN 
activity from 1260U/ml to <2U/ml. Higher concentrations of 
TPA and teleocidin (30ng/ml or greater) were needed for 
the same level of induction caused by 10ng/ml of mezerein. 
with A23187. In view of the reported ability of phorbol 
esters to replace the accessory function of macrophages, 
the ability of IL-1 to synergise with A23187 was examined. 
Unlike phorbol esters, however, IL-1 failed to act as a 
co-inducer with ionophore, even when used at levels which 
reverse the effects of macrophage depletion (Table 2).
The levels of IFN-gamma induced by A23187 and mezerein 3 
days post-induction were frequently significantly much 
greater than induced by the powerful mitogen SEA (Tables 1 
and 3). Depletion of macrophages greatly reduced SEA 
induction but generally had little effect on 
A23187/mezerein induction of IFN-gamma production (Table 
3). In only one out of five donors was the level of 
IFN-gamma reduced by a comparable amount (>10 fold) for 
both methods of induction. In the remaining donors it can
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Table 5.1
SYNERGY OF CALCIUM IONOPHORE AND PHORBOL ESTERS FOR BOTH 
IFN-GAMMA AND IL-2 INDUCTION.
IFN-gamma titre (U/ml) 
Donors
1 . 2 3 4 5
SEA (20ng/ml) 1000 400 320 320 500
A23187 <2 40 10 <2 <2
Mezerein <2 32 25 ND ND
Teleocidin <2 3 <2 ND ND
TPA <2 3 <2 ND ND
A23187 + Mez. 180 6000 5000 1600 4000
A23187 + Tel. <2 50 120 500 25
A23187 + TPA 320 120 8 200 1200
IL-2 titre (U/ml)
A23187 <2 <2
Mezerein <2 <2
A23187 + Mez. 16 20
a) PBML used at 5x10s cells/ml.
b) IFN-gamma titres were measured on day 3 and the IL-2 titres 
on day 1 post-induction.
c) A23187 was used at lpM. All phorbol esters were used 
at lOng/ml.
Table 5.2
THE EFFECTS OF A23187 AND IL-1 ON IFN-GAMMA PRODUCTION
IFN-gamma titre (U/ml)
Donor 1 Donor 2
SEA ( 20ng/ml ) 320 500
A23187 (lpM) <2 <2
+ IL-1 (1 U/ml) <2 <2
+ IL-1 (3 U/ml) <2 <2
+ IL-1 (10 U/ml) <2 <2
+ Mez . (10ng/ml) 1600 4000
a ) PBML used at 5x10s ce 1Is/ml.
b ) IFN-gamma titre measured on day 3.
,
Table 5.3
THE EFFECTS OF MACROPHAGE DEPLETION ON IFN-GAMMA PRODUCTION
INDUCED BY MEZEREIN AND A23187.
IFN-gamma titre (U/ml) 
Donors
PBML 1 2 3 4 5
SEA (20ng/ml) 160 2000 250 800 160
A23187 + Mezerein 2000 12000 6000 1000 250
LvnvD hocvt.es
SEA 40 8 20 160 40
A23187 <2 12 <2 <2 <2
Mezerein <2 <2 <2 <2 <2
A23187 + Mez. 2500 3200 400 1200 3200
a) PBML and Ly used at 5x10s cells/ml.
b) A23187 was used at lpM and mezerein at 10ng/ml.
Table 5.3
THE EFFECTS OF MACROPHAGE DEPLETION ON IFN-GAMMA PRODUCTION
INDUCED BY MEZEREIN AND A23187.
IFN-gamma titre (U/ml) 
Donors
PBML 1 2 3 4 5
SEA (20ng/ml) 160 2000 250 800 160
A23187 + Mezerein 2000 12000 6000 1000 250
SEA 40 8 20 160 40
A23187 <2 12 <2 <2 <2
Mezerein <2 <2 <2 <2 <2
A23187 + Mez. 2500 3200 400 1200 3200
a) PBML and Ly used at 5x10s cells/ml.
b) A23187 was used at lpM and mezerein at 10ng/ml.
be seen that any reduction in IFN-gamma levels is far less 
when A23187 and mezerein are the inducers as opposed to 
the mitogen SEA. Thus mitogen induction is clearly 
macrophage-dependent but A23187/mezerein induction is 
probably not, implying that different activation pathways 
may be in operation for the two types of induction.
A23187 could not only act as a powerful co-activator but 
also reversed the depressive effects of the Til pathway on 
induction of IFN-gamma by SEA (Table 4). The monoclonal 
antibody 9.6, which binds to the Til cell-surface 
molecule, depressed IFN-gamma production by at least 
five-fold. A23187 induced little IFN-gamma on its own and 
did not act in synergy with SEA, as it does with mezerein, 
but was capable of at least partially reversing the 
inhibitory effects of 9.6. This was found to be the case 
in 70% of donors tested (10 out of 14) and is further
evidence for a rise in cytoplasmic calcium ion
concentration acting as a positive signal in T-cell
activation. The effects of mezerein on depression of
IFN-gamma production by 9.6 were not examined as the 
phorbol ester has known synergistic effects with SEA.
Medium containing the two inducers at the concentrations 
used for induction had no effect on the WISH cell IFN 
assay. Thus the high titres observed were not an artefact 
due to non-specific effects of the ionophore or tumour 
promoter on Wish cells.
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Table 5.4
THE EFFECTS OF A23187 ON THE INHIBITION OF IFN-GAMMA PRODUCTION
BY MONOCLONAL ANTIBODY 9.6
IFN-gamma -titre (U/'ml) 
Donors
1 2 3 4 5
SEA (20ng/ml) 250 1000 160 2000 320
A23187 (lpM) <2 <2 <2 55 10
SEA + 9.6 ( ljAg/ml ) 18 200 16 50 10
SEA + 9.6 + A23187 55 1000 100 300 8
SEA + A23187 320 320 ND ND ND
a) PBML used at 5x10s cells/ml.
b) In 10 out of 14 cases A23187 at least partly reversed the 
inhibitory effects of 9.6 (representative data shown).
The--induction__of__IL-2 and IFN-gamma mRNA production bv
A23187 and mezerein.
Using cDNA probes for IL-2 and IFN-gamma mRNA the 
induction of both messages in cells treated with A23187 
and mezerein under different conditions was studied. It 
was found that A23187 with meserein induced high levels of 
both messages compared with little effect seperately 
(Table 5). Fresh PBML from pooled donors (up to four 
donors per experiment in order to get enough material) at 
3x10s cells/ml were cultured for one hour in either 
untreated medium or medium containing cycloheximide 
(200pg/ml). Cells were then induced with A23187 and/or 
mezerein and harvested 4 hours post-induction, a period 
which allowed steady-state levels of mRNA to increase to 
values which could be quantitated accurately while 
avoiding long term incubation in the presence of 
cycloheximide (CHX), a metabolic inhibitor. Their RNA was 
isolated and levels of IFN-gamma or IL-2 specific mRNA 
determined by dot-blotting (Thomas,1980) using labelled 
cDNA probes homologous to IFN-gamma (Siggens et al..1984) 
or IL-2 (Taniguchi £t al.,1983), Since A23187 with 
mezerein plus CHX generally gave the greatest level of 
induction this level was assigned the arbitrary value of 
1.0 and other levels given relative to this. Inclusion of 
standard samples containing 0.1, 0.01, and 0.001 ng of
IFN-gamma DNA proved that the level of hybridisation was 
indeed proportional to the level of specific message 
expressed.
In two experiments A23187 and mezerein seperately
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induced only low steady state levels of both IFN-gamma and 
IL-2 mRNA (Table 5, donors 1 and 2). In combination, 
however, A23187 and mezerein acted synergistically 
inducing levels of mRNA 5 to 10 times greater than either 
did alone. The synergy of the ionophore and phorbol ester 
for IFN-gamma gene expression may thus at least partly 
explain their powereful induction of IFN-gamma production.
The role of protein synthesis in activation of either 
gene was examined by addition of an inhibitor of protein 
synthesis, cycloheximide, one hour before induction. 
Protein synthesis was reduced by 99% as determined by 
35S-methionine incorporation (147,000 cpm in untreated 
cells was reduced to 1,950 in CHX treated cells). The 
levels in cells treated with inhibitor were usually either 
unaffected or even somewhat augmented (see in particular 
IL-2 mRNA levels induced by A23187 plus mezerein). 
Therefore both genes can be expressed in the absence of 
synthesis of proteins, such as interleukins 1 and 2. In 
the absence of T-cell induction, the presence of CHX was 
shown not to induce any IFN-gamma gene expression.
When mRNA production by PBML was compared to that by 
macrophage-depleted lymphocytes (Table 6) the level of 
expression of both genes was found to be higher in 
lymphocytes than PBML. However, the relative level of 
expression varied between experiments, with PBML 
expressing 9% of the level found in lymphocytes in one 
experiment but 58% in another, at 4 hours post-induction. 
In a third experiment results very similar to experiment 1 
were obtained judging from the opaqueness of dots on
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Table 5.5
INDUCTION OF IL-2 AND IFN-GAMMA mRNA.
Experiment
1 2  3
IFN I L - 2 . . IFN IL-2 IFN I L - 2
A 2 3 1 8 7  (lpM) 0.13 0 . 0 2 0 0 . 0 3 N D N D
A 2 3 1 8 7  + C H X 0.22 0 . 1 3 0 .06 0 . 0 7 N D N D
M e z e r e i n  ( 1 0 n g / m l ) 0.15 0 . 1 0 0 0 . 0 7 ND N D
Mez. + C H X 0.27 N D 0.04 0 .11 ND N D
A 2 3 1 8 7  + Mez. 0.90 0 . 5 1 0 . 3 9 0 . 6 8 0 . 9 5 0 . 9 5
A 2 3 1 8 7  + M e z .+ C H X 1.00 1 . 0 0 1.00 1.00 1.00 1 .00
c p m  e q u a l  t o  1.00 (1,057) ( 2 1 7  ) (547) ( 241 ) ( 324) ( 11 )
a) RNA was harvested 4 hours post induction, with 1 hour 
pre-treatment with cycloheximide (CHX) at 200pg/ml where 
indicated.
b) Hybridised cpm for RNA samples (20pg) from PBML treated 
with A23187, mezerein, and CHX were arbitrarily assigned
a value of 1.0 and levels of mRNA in other samples were then 
calculated relative to this sample. Each value is the mean of 
duplicate 20pg samples. The cpm equivalent to 1.00 for 
each experiment is given at the bottom of the table.
c) A standard of O.lng IFN-gamma mRNA = 1.06, 2.05, and 1.59 
for experiments 1 to 3 respectively.
Table 5.6
INDUCTION OF IL-2 AND IFN-GAMMA mRNA BY A23187 PLUS MEZEREIN 
IN PBML VERSUS LYMPHOCYTES.
Experiments
1
IFN IL-2
2
IFN IL-2
PBML at 4 h. 0.09 0 0.58 0.60
PBML at 24 h. 0 0.02 0 0
Ly. at 4 h. 1.00 1.00 1.00 1.00
Ly. at 24 h. 0.90 0.46 0.44 0.22
cpm equal to 1.00 ( 533) (475) ( 560 ) (124)
a) All preparations were induced with A23187 (lpM) 
plus mezerein (10ng/ml).
b) Hybridised cpm for RNA samples (20pg dots) from 4 h. 
lymphocyte (Ly.) samples were assigned a value of 1.00 
and levels of RNA in other samples calculated relative 
to this. The cpm equivalent to 1.00 for each experiment 
is given at the bottom of the table.
c) A standard of 0.lng IFN-gamma mRNA = 1.04 and 1.6 for
experiments 1 and 2.
autoradiographs after hybridisation of the probes, but due 
to the small amounts of RNA isolated it was not possible 
to count the level of hybridisation on the filter by 
liquid scintillation counting. When levels of mRNA were 
examined 24 hours post-induction the contrast between 
levels in PBML and lymphocytes was even clearer. At 24 
hours PBML did not express detectable levels of either 
mRNA, whilst macrophage-depleted lymphocyte mRNA levels, 
although lower than at 4 hours, were still detectable at 
24 hours. Thus macrophage-depleted lymphocyte populations 
express higher levels of both messages than PBML, and 
although the level of expression is reduced at 24 hours 
compared to 4 hours it is not wholly abolished as in PBML. 
Using this induction scheme macrophages are thus not 
required for expression of either gene.
Comparison of the level of message at different times 
post-induction also shows that induction of gene 
expression in PBML is both very rapid and transient using 
this method of activation, peaking in only a few hours and 
being shut down within 24 hours. This is in contrast to 
mitogen induction which gives maximal steady state mRNA 
levels at 1-2 days at 3xl06 cells/ml as used in this 
chapter (Siggens et al.,1984).
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DISCUSSION : Chapter 5.
The ability of A23187 plus mezerein synergistically to 
induce the high levels of IFN-gamma found in this study is 
consistent with the findings of many other workers that 
such a combination can mimic antigenic/mitogenic 
stimulation (Truneh et al.,1985a). A23187 and phorbol 
esters are able to induce IL-2 receptor expression and 
IL-2 production (Isakov & Altman.1985 ) . In the case of 
immature murine thymocytes this can be induced even before 
the cells have developed the ability to respond to 
mitogens (Lugo et al.,1986) and in a mutant T-cell line 
(S5) which lacks the T3 complex and also does not respond 
to mitogen stimulation (Weiss et ai.,1984b). Thus 
ionophore plus phorbol esters can activate T-cells in a 
fashion that bypasses the T-cell receptor. They also act 
synergistically to trigger B-cell proliferation (Clevers 
et ai.,1985). Another calcium ionophore called ionomycin 
has similar properties (Delia et ai.,1984).
This synergy is thought to be due to the involvement of 
two signalling pathways in T-cell activation (Imboden et 
ai.,1985; Isakov et ai,1986). Perturbation of the T-cell 
antigen receptor stimulates a phosphodiesterase 
(phospholipase C) to hydrolyse phosphatidylinositol 
4,5-bisphosphate (PtdInsP2 ) found in the cell membrane. 
The products of this hydrolysis are diacylglycérol (DG) 
and inositol tri-phosphate (IP3 ) which act as second 
messengers triggering two signalling pathways 
(Berridge,1984). IP3 formation leads to a rise of 
cytoplasmic calcium ion concentration, chiefly by release
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of calcium from internal stores (Imboden & Stobo,1985). 
Activation of T-cells via the T3 molecular complex by 
mitogens (Fleischer,1984), 0KT3 (Oettgen et al.,1985), or 
antigens (Nisbet-Brown et al.,1985) typically leads to a 
calcium ion flux across the cell membrane, providing one 
signal for activation. This rise in intracellular calcium 
ion concentration may activate calcium-dependent protein 
kinases, resulting in protein phosphorylation. 
Diacylglycerol is thought to act as the other “signal" by 
activating protein kinase C (PKC), increasing its affinity 
for calcium ions (Imboden & Stobo,1985; Nishizuka,1984). 
This activation model is shown in figure 5.1.
Activation via T3/Ti thus generates both calcium flux 
and activates protein kinase C, but this can be mimicked 
by an artificially induced calcium flux, using a suitable 
ionophore, combined with the addition of a phorbol ester 
which activates protein kinase C (Castagna et al..1982: 
Niedel et al.,1983; Kikkawa et al.,1983; Weiss et 
al.,1984b). PHA and 0KT3 stimulate a transient 
redistribution, and consequent activation, of PKC from the 
cytosol to the cell membrane, reaching a maximum within 20 
minutes of stimulation (Farrar & Ruscetti,1986). 
Activators of PKC lead to internalisation of the T3 
complex (Cantrell et al.,1985) similar to that observed 
during normal T-cell activation. Transient PKC 
redistribution is also found in monocytes during 
activation (Meyers §t al.,1985) and after IL-2 binds to 
its receptor (Farrar & Anderson,1985). It should be noted 
though that IL-2 induced proliferation is independent of a
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calcium ion flux (Mills et al. , 1985b; Gelfand et 
al.,1986), unlike mitogenesis, and ionophores plus phorbol 
esters cannot replace the IL-2 dependent triggering of the 
IL-2 receptor (Albert et ad.,1985). A rise in cytoplasmic 
free calcium ion concentration acts as a signal for IL-2 
production but not for expression of the IL-2 receptor 
(Mills et ad.,1985a) which can occur even when calcium 
flux is blocked (Gelfand et al..1986 ).
There is thus a considerable body of evidence for the 
existence of the two signal model of T-cell activation. In 
this study it was clearly shown that ionophore plus tumour 
promoter could also stimulate high level IFN-gamma 
production in the absence of any other signal, e.g. 
mitogen (Table 1). They also acted synergistically to 
induce IL-2 production when neither could alone (Table 1). 
While stimulation of IL-2 production by this method has 
been demonstrated by other workers. the effects on 
IFN-gamma production had not previously been investigated. 
They were found to be consistent with other effects on 
cell activation. Mezerein was the most potent co-activator 
with A23187 in this study, the combination often inducing 
significantly greater levels of IFN-gamma than the mitogen 
SEA. Higher concentrations of teleocidin or TPA were 
required for similar effects. This may reflect 
differential capacities between the tumour promoters for 
protein kinase C binding and activation. On its own A23187 
induced only low levels of IFN-gamma at most, with optimal 
effects at lpM. At higher concentrations it caused cell 
death, probably due to gross disturbance of mitochondria
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morphology, which act as intracellular stores of calcium 
ions. Although A23187 alone can lead to blastogenesis of 
lymphocytes (Luckasen et al.,1974), with enlarged 
cytoplasm and increased tritiated-thymidine uptake similar 
to the effects of PHA (Maino et al.,1974), it was not a 
sufficient signal on its own for significant induction of 
IFN-gamma.
Similarly, on their own tumour promoters induced at most 
only low levels of IFN-gamma. Teleocidin and TPA, however, 
are reported to induce IL-2 receptor expression (Isakov et 
al.,1985: Ando et al.,1985a&b) and IL-2 independent 
proliferation (Isakov e£ .al.,1985), presumably via PKC 
activation.
In view of the reported ability of TPA at least 
partially to replace macrophage involvement in T-cell 
activation (Ashman,1984; Koretzky et al..1982: Davis & 
Lipsky,1985) it is possible that phorbol esters and IL-1 
share to some unknown extent a similar mechanism of T-cell 
activation. However, IL-1 showed no ability to synergise 
with A23187 in the induction of IFN-gamma (Table 2), 
making it unlikely that IL-1 acts via protein kinase C 
activation in a similar fashion to phorbol esters. The 
exact role(s) of IL-1 in T-cell activation are still far 
from clear. It may induce some signal that interacts 
synergistically with diacylglycerol-activated PKC, as when 
resting macrophage-depleted T-cells are stimulated with 
sepharose bound 0KT3 plus recombinant IL-1 (Manger et 
al.,1985). IL-1 may induce some as yet unknown "third” 
signal in addition to both calcium flux and PKC
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Thisactivation.  possible third intracellular signal or 
pathway has been shown to be distinct from yet act 
synergistically with both calcium flux, inducing IL-2 
secretion, and PKC activation, inducing IL-2 secretion and 
also IL-2 receptor expression (Lowenthal gt al. .1986 ) .
Depletion of macrophages prior to induction had 
different effects on activation by SEA as opposed to 
A23187/mezerein (Table 3), the latter being able to induce 
significant IFN-gamma levels in the absence of 
macrophages. However. there was still a reduction in two 
donors despite the lack of effect in the other three. This 
may have been due to differing stringency of depletion 
between donors. Far fewer macrophages are reportedly 
required for optimal proliferation in response to TPA than 
to SEA (Ashman,1984; Davis & Lipsky,1985). Reduction of 
A23187/mezerein induction occurred only in those donors 
where the response to SEA was most severely reduced (>10 
fold) and not when the depletion may have been less severe 
(SEA response reduced only 4-5 fold). In the latter case 
there may have ben a sufficient residual level of 
macrophages for A23187/mezerein induction to be unaffected 
compared to SEA, whilst there was some effect when 
depletion was most stringent (donors 2 and 3). Thus 
although macrophages are not required for A23187/mezerein 
to induce significant levels of IFN-gamma, presumably 
because requirements for macrophage/T-cell interaction for 
mitogens are bypassed by acting at the level of the two 
basic transmembrane "signals", very low levels of 
macrophages may still be required for optimal response
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(perhaps for IL-1 to provide a possible "third" 
intracellular signal). Macrophages may therefore provide 
signals additional to their involvement in antigen 
presentation to T-cells which A23187/mezerein cannot 
wholly replace.
The involvement of the Til pathway in T-cell activation, 
discussed in chapter 4, has been shown by many workers, 
along with its ability to act as a positive or negative 
signal transducer according to which epitopes are bound by 
monoclonal antibodies. Differential effects on calcium 
flux may well be involved since it has been reported that 
T-cell stimulation via Til usually involves a calcium flux 
(Weiss et al. ,1984a; Ho Iter et sJ. - , 1986 ) whilst 
suppression via Til may block calcium entry (Palacios & 
Martinez-Maza,1982). In view of the depressive effects of 
the Til monoclonal antibody 9.6, the role of calcium was 
investigated using A23187. In a total of 10 out of 14 
experiments, A23187 at least partially reversed the 
inhibitory effects of 9.6 on SEA induction, but did not 
boost the level of IFN-gamma production induced by SEA 
alone. The ionophore would appear then to specifically 
reverse the inhibitory effects of 9.6 and does not simply 
act as a general booster of IFN-gamma production by 
mitogen induction. Presumably the calcium flux induced by 
SEA, in the absence of 9.6, is optimal for T-cell 
activation so that A23187 then has no additional effect. 
Tumour promoters may boost SEA induction, however, because 
PKC activation by SEA alone is not optimal. It has been 
suggested that Til can act as a "negative signal receptor"
by turning off the process by which calcium enters the 
cell upon stimulation, e.g. 0KT11A inhibits proliferation 
of T-cells stimulated by A23187 alone (Palacios & 
Martinez-Maza,1982).
The partial reversal of Til inhibitory effects by A23187 
tend to confirm that they are indeed at least partially 
mediated by inhibition of calcium flux. Also the 
importance of calcium influx at the commencement of T-cell 
activation would explain why 9.6 must be added shortly 
after induction for significant inhibition of IFN-gamma 
production (Wilkinson & Morris,1984a). However, the 
failure of A23187 to completely reverse the inhibition and 
its total lack of effect in some donors suggests that some 
other inhibitory effects are also involved. Antibodies 
against Til are reported to block calcium flux if PHA is 
used, but not Con A or 0KT3 (O’Flynn si al.,1985a), 
despite their inhibition of proliferation in all three 
cases (Palacios & Martinez-Maza,1982), suggesting that 
other, calcium-independent, signals are regulated by the 
Til 50kD surface protein. Further investigation of the Til 
activation/inhibition pathway and its relationship to the 
T3-Ti pathway are clearly necessary. It has yet to be 
established, for example, what the in vivo role of Til is, 
if any, and what its natural ligand is ("IL-4A" perhaps).
IFN-gamma and IL-2 gene induction.
In order to examine gene activation independently of the 
downstream effects of immune modulators cDNA probes were 
used. They also made it possible to examine gene
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activation in the absence of protein synthesis. Using cDNA 
probes for both IL-2 and IFN-gamma mRNA, it was found that 
ionophore and mezerein separately induced only low level 
transcription of both genes compared to their synergistic 
effects. In combination A23187 and mezerein were potent 
inducers of both genes and thus high levels of IFN-gamma 
production are probably due to effects at the level of 
transcription. Also levels of mRNA production for both 
genes were not depressed by the presence of cycloheximide 
(CHX) at a concentration sufficient to reduce protein 
synthesis by >99%. This shows that synthesis of proteins, 
such as IL-1 or IL-2, is not a requirement for expression 
of either gene. Siggens et al. (1985) similarly showed 
that activation of the IFN-gamma gene by SEA could still 
occur without protein synthesis, at up to 76% of normal 
levels, but CHX abolished the synergistic effects of 
mezerein with SEA. This is in contrast to the findings in 
this study, using A23187 with mezerein, in which CHX had 
no depressive effect on induction of either gene. It has 
also been shown that exogenous IL-2 has little or no 
effect on IL-2 or IFN-gamma mRNAs, but does significantly 
increase c-myc, IL-2-receptor, and heat shock protein 
mRNAs (Granelli-Piperno gt ai.,1986). Thus protein factors 
appear to have no role in initial activation of either 
gene by A23187 and mezerein acting in synergy, although 
they may be involved in synergistic effects of tumour 
promoters with mitogens (Siggens et al.,1985). In some 
cases CHX even boosted the level of induction. This may 
have been due to partial "superinduction", a variety of
1 2 4
Imetabolic inhibitors having been shown to boost the level 
of IL-2 mRNA (Efrat £t âl.,1984; Efrat & Kaempfer.1984) 
and IFN-gamma mRNA expression (Siggens & Morris,1985), 
possibly by blocking production of a labile repressor 
protein. A longer period of induction is usually required 
for "superinduction" to become obvious, however. Other 
workers have found similar synergistic effects for IL-2 
mRNA production using TPA and PHA (Hirano et al. ■1984 : 
Efrat et al.,1982) and TPA with A23187 (Yamamoto et 
al,.,1985). These effects appear to be specific since the 
level of "housekeeping" non-lymphokine gene expression, 
such as actin, microglobulin, and c-myb, has been found to 
be unaffected by signals which induce IL-2 and IFN-gamma 
genes (Wiskocil et a!.,1985; Granelli-Piperno et 
al. . 1986).
Examination of mRNA levels in PBML compared to 
macrophage-depleted lymphocytes, at 4 and 24 hours 
post-induction, revealed that macrophage-depletion 
increases the level of gene expression. The level of mRNA 
in PBML peaked early with little still detectable at 24 
hours compared to 4 hours post-induction. In comparison 
the mRNA levels, although reduced by 24 hours, were still 
detectable in macrophage-depleted lymphocytes. These 
results suggest that macrophages are involved in 
regulating expression of both genes since their absence 
both boosts the level of induction and retards the rapid 
shut-down of mRNA expression found in PBML. Some 
macrophage product may act to depress gene induction, only 
slightly at 4 hours, but significantly at 24 hours
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post-induction. It would be useful to examine the effects 
of CHX on PBML at 24 hours to determine if mRNA levels are 
restored to those found in lymphocytes, although this may 
be too long an exposure to a metabolic inhibitor. The 
hypothetical inhibitory macrophage product may be the same 
as the putative labile repressor protein suggested to be 
involved in superinduction.
The rapid accumulation and subsequent shut-down of 
IFN-gamma gene expression observed here is reminiscent of 
that seen in preactivated lymphoblasts as compared to 
fresh lymphocytes. IFN-gamma mRNA peaking at 8 hours in 
the former and up to 4 days post-induction in the latter 
(Siggens gt al.,1984). Also, levels of mRNA induced in 
lymphoblasts have been found to be up to five times 
greater per cell than induced in previously unstimulated 
T-cells (Granelli-Piperno et al.,1986). Thus activation by 
A23187 and mezerein may be as rapid as in metabolically 
active growing T-lymphoblasts because preliminary stages 
involved in activating resting T-cells are bypassed in 
both cases.
The importance of two signals in T-cell activation are 
thus confirmed in this study. Furthermore, various 
observations suggest that activation of IL-2 and IFN-gamma 
genes occurs coordinately when these signals are provided.
1. These signals can induce both genes in the absence of 
translation, suggesting that they act on transcription and 
that the protein product of one gene is not required for 
induction of the other gene.
2. The levels of mRNA for both genes are affected in a
similar fashion by macrophage depletion and the type of 
inducer(s) used. Situations which induce high or low 
levels of RNA for one gene have the same effect on the 
transcription of the other gene.
3. The mRNA levels for both genes follow a similar time 
course.
Very similar findings were made in a study using TPA 
plus mitogen to activate the T-cell line Jurkat in which 
coordinate expression of IL-2 and IFN-gamma genes also 
seems to occur (Wiskocil et al..1985). Grabstein et al. 
(1986) have also shown that IL-2 mRNA and IFN-gamma mRNA 
both show early accumulation after PHA stimulation, 
peaking simultaneously at 60 minutes. However, IFN-gamma 
mRNA exhibits a secondary greater peak at 20 hours 
post-induction subsequent to its earlier peak (Grabstein 
et al.,1986). The first IFN-gamma mRNA peak is probably 
independent of any IL-2 requirement, since it occurs 
coordinately, but the later peak would appear to be IL-2 
dependent. However, no sign of this later peak was found 
using A23187 plus mezerein as inducers of PBML as opposed 
to PHA. This may have been due to some difference between 
mitogen activation and the artificial system of ionophore 
plus tumour promoter, although Efrat et al. (1982) also 
used PHA as the inducer and found that both messages 
levelled off by 16 hours post-induction.
Thus despite the apparent sequential nature of 
lymphokine production, with IL-2 binding to its receptor 
being a requirement for optimal IFN-gamma production, at 
the level of transcription at least the two lymphokines
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appear to be coordinately regulated using the induction 
method described in this chapter. Both genes can be 
transcribed in the absence of protein synthesis and there 
does not seem to be any delay between appearance of each 
message. Efrat et al.(1982) also observed very similar 
kinetics for appearance of both messages, using PHA 
activated lymphocytes at a similar cell density to that 
used in this chapter and by Grabstein at al. (1986), 
beginning at 4 hours and levelling off at 16 hours. It 
should be noted that the kinetics of appearance of 
IFN-gamma mRNA in PBML are partly dependent on cell 
density during incubation with the inducer, as well as the 
nature of the inducer and the state of the cells, higher 
cell densities giving more rapid induction. The peak of 
IFN-gamma mRNA accumulation in response to mitogen 
reportedly occurs earlier (1-2 days versus 3 days) at 
3x10® cells/ml than at 5x10s cells/ml (Siggens a£ 
Sjk. , 1984 ) .
Possibly the two signals induce production of an 
intermediate substance which influences both genes or RNA 
processing and stability. It is interesting to note that 
there is a homologous sequence (83%) in the 5’ flanking 
region of both IL-2 and IFN-gamma genes 300 bp upstream of 
the genes’ promoter in a region of potential regulatory 
importance (Hardy at al.,1985). This common sequence is 
highly conserved. e.g. 85% homology in the IL-2 genes of 
mouse and man while the coding region is only 72% 
homologous (Fuse at al.,1984), and may well be involved in 
coordinate expression. The methylation state of the
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IFN-gamma gene may also play a role in it3 regulation, 
since demethylation of some unknown sequences (not the 
gene itself, which can be active and methylated) restore 
the ability of a murine T-cell line to produce IFN-gamma 
in response to IL-2 (Farrar et al.,1985). Some of the 
deleterious effects of human T-lymphotropic viruses types 
I and III (AIDS) may be due to disruption of the 
regulation of IL-2 and IFN-gamma gene expression. In HTLV 
III (AIDS) infected cells IL-2 gene transcription, induced 
by PHA/TPA, is unaffected but IFN-gamma transcription is 
inhibited. The reverse is the case in HTLV I infected 
cells where the IFN-gamma gene is actively transcribed but 
the IL-2 gene is not (Arya & Gallo,1985). Such effects are 
surprising in view of the coordinate expression described 
in this study.
The depressive effects of 9.6 binding to Til may also 
occur at the level of transcription. since 9.6 added 
within 4 hours of induction is reported to inhibit IL-2 
mRNA accumulation, the level of inhibition being inversely 
proportional to the strength of the mitogenic signal 
(Tadmori et .al.,1986). As in the case of Wisckocil et al. 
(1985), these effects on IL-2 gene expression are 
relatively specific since beta-actin gene expression is 
not affected.
In conclusion, the results described in this chapter 
demonstrate that mitogenic stimulation of IFN-gamma 
production can be mimicked by the combination of two 
signals, calcium flux and protein kinase C activation, 
using A23187 and phorbol esters. Using these activators
129
the requirements for macrophages as accessory cells can be 
at least partially bypassed and the inhibitory effects of 
the Til pathway reversed, using A23187. High levels of 
IFN-gamma production are reflected by rapid induction of 
IFN-gamma and IL-2 gene expression, the two genes seeming 
to be coordinately inducible. This induction does not 
require the production of other lymphokines or proteins. 
Macrophages are also found to be involved in regulating 
the level of gene expression and its rapid shut-down. 
These findings are consistent with those of other workers 
using a variety of activation methods. Induction with 
A23187 plus mezerein therefore provides a useful model for 
examining the mechanisms by which calcium ion mobilisation 
plus protein kinase C activation leads to T-cell 
activation at the level of lymphokine protein and mRNA 
production.
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CHAPTER 6 .
GENERAL DISCUSSION AND CONCLUDING REMARKS.
In this concluding chapter the major points of the 
thesis and how they are interrelated will be discussed, 
along with possible further avenues of investigation 
suggested. The original aim of the thesis was to 
investigate at least some of the factors involved in 
regulating human IFN-gamma production because of the 
possible importance of this lymphokine in the immune 
response. IFN-gamma production also serves as a more 
specific marker of T-cell activation than proliferation. 
These two processes often occur together but are not in 
fact linked. Since no significant qualitative differences 
have been found between antigen and mitogen activation, 
polyclonal mitogen activation is a reasonable model for 
the specific activation caused by antigens. Furthermore 
mitogen-like activation may well occur in vivo■ caused by 
bacteria and bacterial products, and is therefore worthy 
of investigation in its own right. However, it would also 
be possible to investigate antigen activation of PBML by 
using antigens to which the majority of the population 
have been exposed, such as the tuberculin purified protein 
derivative. This, however, would only provide information 
on secondary responses. Primary reponses are too small to 
examine easily in mixed T-cell populations.
PBML form a very heterogeneous population of cells and 
yet IFN-gamma production was originally ascribed only to T 
lymphocytes, with macrophages acting as accessory cells. 
More recently attention has focused on the non-T cell
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natural killer population known as LGL, which are 
themselves a very heterogeneous population. They have been 
described as producing a variety of lymphokines and in 
this study it was shown that they can also produce 
IFN-gamma. Furthermore, unlike T-cells, they do not 
require macrophages for this production, perhaps because 
of their ability to produce lymphokines, such as IL-1, 
which are needed for optimal IFN-gamma production and 
which T-cells cannot produce. Optimal IFN-gamma production 
was shown to require the interaction of at least two LGL 
subsets. It is argued that Leu 11+ NK cells (E-) can not 
only produce IFN-gamma but may also act as accessory cells 
for low density T-cells (E+) in the absence of 
macrophages. This particular interaction of LGL subsets 
has not previously been described, although there is 
growing evidence for other LGL subset interactions. Thus 
not only can non-T cells produce IFN-gamma but they may 
also be able to regulate its production by T-cells. Since 
LGL form only a small fraction of the total PBML, how 
important is their contribution to the overall response? 
Can LGL act as accessory cells for all T-cells?
Since LGL do not express T3 and the associated T-cell 
antigen receptor, how are they activated by mitogens, 
which are thought to cause activation by binding to these 
structures? Presumably mitogens must activate Leu 11+ LGL 
via some other- cell surface receptor, implying that the 
T3-Ti pathway is not the only one that leads to IFN-gamma 
production. Different receptors may be involved for 
different IFN types, since mitogens cause IFN-gamma
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production but. tumour cells cause IFN-alpha production. 
Since LGL may be related to T-cells, is IFN-gamma 
production triggered by essentially the same processes as 
in T-cells? The reported inhibitory effects of anti-Tac on 
LGL suggest that they resemble T-cells at least in this 
respect. A considerable amount of work on the interactions 
of the various LGL subsets hinted at in this study awaits. 
LGL are reported also to produce IL-1 and IL-2, but are 
these producer cells the same as those that produce 
IFN-gamma?
However, the bulk of IFN-gamma production by PBML is 
ascribable to T-cells. Most of the work described in this 
thesis was aimed at investigating the role of various 
regulatory molecules in IFN-gamma production. The recent 
availability of highly purified and recombinant 
interleukins at last makes it possible to investigate the 
proposed role of these lymphokines in T-cell activation in 
the absence of any other contaminating regulatory 
substances. The work described here to a large extent 
confirms the existence of the lymphokine "cascade" with 
regards to IFN-gamma production. IL-1 production was shown 
to be a major component of the accessory role of 
macrophages during mitogen activation since purified IL-1 
could largely replace macrophages. This may not be the 
case for antigens, other non-secretory properties of 
macrophages such as antigen presentation also being 
important. There also appeared to be differences in the 
importance of macrophages and IL-1 between the different 
mitogens which require further investigation. We also need
T-cellto know more about IL-l’s exact roléis ) in 
activation. What are the processes involved in regulating 
IL-1 production? It is still not clear whether IL-1 acts 
by triggering or amplifying IL-2 production or IL-2 
expression or both? The availability of recombinant IL-1 
and probes for mRNA expression of the IL-2, IL-2 receptor, 
and IFN-gamma genes now make it possible to examine if 
IL-1 acts at the level of gene activation and also which 
of these genes are involved. We also need to know a lot 
more about the recently identified IL-1 receptor(s). Is 
its expression regulated in any way, as the IL-2 receptor 
is?
It had not previously been clearly demonstrated that 
IL-2 is involved in triggering IFN-gamma production, as 
proposed by the lymphokine cascade. Using anti-Tac to 
block IL-2 binding to its receptor, this study confirmed 
that IL-2 binding is definitely required for optimal 
IFN-gamma production. The reversal of this effect with 
IL-2 but not IL-1 confirms that anti-Tac’s effects are 
indeed IL-2 mediated. However, the low affinity of 
anti-Tac for the IL-2 receptor compared to IL-2 itself 
meant that not all IL-2 binding could be blocked. Thus the 
effects of anti-Tac decreased with increasing strength of 
mitogen stimulation. It was thus not possible to determine 
if IFN-gamma production was wholly dependent on IL-2 
binding. Are there any situations in which IL-2 or its 
receptor are not produced but IFN-gamma production can 
still occur (perhaps by LGL)? Thus are all the regulatory 
situations for IFN-gamma described in this study due to
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effects on IL-2 production or IL-2 receptor expression 
carrying through to IFN-gamma production? IL-2 induced 
proliferation and IFN-gamma production presumably follow a 
common pathway up to some point. But clear differences 
have been demonstrated between the two processes since 
there is often no correlation between them, as shown in 
this study, and since blockage of either process has been 
shown not to necessarily inhibit the other. Just where do 
these pathways diverge? The results using cDNA probes 
demonstrates that IFN-gamma gene activation is a primary 
event in T-cell activation which does not rely on 
production of other proteins.
IL-2 alone was not found to be sufficient for IFN-gamma 
production. The low levels of IFN produced by high 
concentrations of IL-2 are thought to be due to the 
presence of a small fraction of activated T-cells 
expressing the IL-2 receptor in an otherwise unactivated 
PBML population. The presence of some T-cell activator, 
such as a very low level of mitogen, was required for 
exogenous IL-2 to boost IFN-gamma levels.
The effects of other physiological ligands were also 
investigated. Prostaglandin E2 which is produced in vivo 
by a variety of cell types, including macrophages, was 
found to depress IFN-gamma production. It has been
reported to depress IL-2 production as well and its
effects on IFN-gamma production appeared to be a
consequence of this. Thus PGE2 appears to have
antagonistic effects to IL-1, also a macrophage product. 
Perhaps these depressive effects of PGE2 have some jja vivo
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role, helping to make T-cell activation transitory by 
depressing the immune response.
A variety of cell surface molecules connected with the 
immune system were also found to have effects on IFN-gamma 
induction. Monoclonal antibodies against these cell 
surface molecules were used as model ligands. Molecules 
involved in MHC restriction, T4 and T8 on T-cells and 
class I and II MHC molecules, and hence T-cell activation 
were not unsurprisingly also found to have regulatory 
effects on IFN-gamma production. Blockage of 
T-cell/maerophage MHC interactions with antibodies at the 
initial stages of T-cell activation depressed IFN-gamma 
induction. However, it may not be simply a case of 
antibodies blocking cell interactions. Perhaps they cause 
T4 and DR cell surface molecules to act as negative signal 
transducers.
The T-cell surface molecule Til (CD2) is drawing 
increasing attention. In this study it was confirmed that 
anti-Tll moabs can inhibit IFN-gamma production. The 
reversal of this inhibition by exogenous IL-2 suggests 
that the effect is due to depressed IL-2 levels. The Til 
molecule appears to mediate an alternative 
activation/suppression pathway to T3-Ti. Just what the 
role of this pathway is in vivo is far from clear, but it 
does seem to be partly linked to T3-Ti mediated activation 
in some fashion. The recent description of a proposed 
natural ligand for Til, which helps activate T-cells and 
has been tentatively named "IL-4A", makes the involvement 
of the Til pathway in T-cell ativation of even greater
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interest. Just how do the Til and T3-Ti pathways interact 
in vivo? Would antibodies against "IL-4A" inhibit T-cell 
activation?
Now that the mystery of the identity of the T-cell 
antigen receptor has been essentially solved, attention 
should now switch to the intracellular processes mediated 
by antigen or mitogen binding. It has been shown, both in 
this study and by many others, that calcium ionophores and 
tumour promoting phorbol esters can mimic normal T-cell 
activation by causing a rise in calcium ion levels and 
activating protein kinase C. Very high levels of IFN-gamma 
are induced by these two substances acting 
synergistically. Does this induction require IL-1 and IL-2 
production, or is the lymphokine cascade bypassed and 
IFN-gamma production activated directly? Experiments with 
anti-IL-1 and anti-Tac should give some indication, 
although very high affinity antibodies against IL-2 and 
its receptor will be needed to overcome the very high 
titres of IL-2 that A23187/mezerein probably also induces. 
The ability of A23187/mezerein triggering to largely 
bypass the macrophage requirement for optimal IFN-gamma 
production suggests that they do directly activate 
IFN-gamma production without any source of IL-1 being 
needed.
Unlike tumour promoters, IL-1 did not appear to act 
synergistically with A23187, suggesting that it does not 
act by protein kinase C activation. Also, IL-2 induced 
proliferation is reported to be independent of calcium ion 
flux, another difference from IFN-gamma production. So
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just what intracellular events are triggered by IL-1 and 
IL-2, and how do they differ from those caused by the 
T3-Ti pathway? The ability of A23187 to reverse the 
inhibitory effects of the Til pathway suggests that the 
latter has effects on calcium ion concentration.
The most interesting finding using this induction method 
was that although optimal IFN-gamma production requires 
the presence of IL-2, their genes are expressed 
coordinately rather than sequentially. Similar findings 
have been made by other groups using mitogens as inducers. 
Furthermore production of their mRNAs does not require 
protein synthesis. Thus IL-1 and IL-2 may be needed for 
production of IFN-gamma but not for activation of its 
gene. This suggests that IL-1 and IL-2 act as regulators 
of IFN-gamma beyond the level of transcription, at the 
level of translation, or possibly message processing or 
stability, or even secretion. Thus initial T-cell 
activation may trigger coordinate activation of several 
lymphokine genes, but translation of their messages seems 
to be sequential and rely on the lymphokine cascade. It is 
also possible, however, that IL-1 and IL-2 binding to 
their receptors trigger fresh bursts of gene activation, 
such as the reported double peak of IFN-gamma mRNA.
The coordinate induction may involve the concensus 
sequence reported to be upsteam of both the IL-2 and 
IFN-gamma genes, in which case any regulatory factor(s) 
which bind to this sequence must be identified.
The kinetics of IFN-gamma mRNA expression were more 
rapid than has been reported when mitogens are the
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inducers. This may be due to A23187 and mezerein bypassing 
the initial steps of T-cell activation triggered via the 
T-cell receptor, such as PtdInsP3 hydrolysis. Activation 
of both genes in PBML was shut down within 24 hours, 
neither message being detectable at this time. However, 
this appeared to be regulated by macrophages since their 
depletion both boosted the general level of induction and 
lengthened the period over which both mRNAs were 
detectable. Are macrophages down-regulators of IL-2 and 
IFN-gamma gene activation or message stability? This would 
be in contrast to their importance as accessory cells, 
acting as positive regulators of IFN-gamma protein 
production. Further experiments involving the effects of 
macrophage-depletion on induction of IL-2 and IFN-gamma 
mRNAs are required to check this possibility, since 
regulation of the termination of IFN-gamma production is 
as crucial as its activation. Would the addition of IL-1 
or PGE2 to lymphocyte cultures affect the level of these 
mRNAs? What about the effects of anti-Tll moabs or "IL-4A" 
on lymphokine gene activation?
Whether all of the regulatory situations which occur in 
vitro are also relevant An vivo is far from clear. 
Hopefully work on animal models and diseases of the human 
immune system will provide some of the answers. More clear 
cut information on the An vivo importance, or otherwise, 
of IFN-gamma should be obtained by studies with mice 
presently being made at the University of Warwick using 
recently prepared antibodies against murine recombinant 
IFN-gamma.
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In conclusion, it is clear that regulation of IFN-gamma 
production is a complex process dictated by the 
interaction of a variety of natural regulatory molecules 
and cell types. The great heterogeneity of PBML means that 
these interactions are both complex and far from 
completely understood. The ability of LGL also to produce 
IFN-gamma makes the situation even more complicated. The 
results described in this study have confirmed the 
proposed importance of several positive immune modulators 
in IFN-gamma production, such as IL-1 and IL-2, and 
additionally indicated that several down-modulators may 
also be involved, such as PGE2 . Several cell surface 
molecules can also exert regulatory effects, probably via 
their involvement in MHC restriction during T-cell 
activation. The alternative Til pathway may also be 
involved. It is also now possible to begin investigating 
some of these regulatory effects at the molecular level 
and a start has been made in this study. This avenue of 
research should prove particularly rewarding in the near 
future.
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CHAPTER 7.
MATERIALS
a) Mitogens
1. Purified Staphylococcal enterotoxin A (SEA) was 
supplied by the Food and Drug Administration of the U.S.A. 
(Washington, D.C.).
2. Crude Staphylococcus aureus supernatant was supplied by 
Dr. A. Meager (National Institute of Biological Standards 
and Control, Holly Hill, Hampstead. London).
3. Purified phytohaemagglutinin (PHA) from Wellcome 
Reagents Ltd.
4. Concanavalin A (Con A) from Miles-Yeda Ltd.
b) Tumour Promoters
1. Mezerein from L.C. Services Corporation.
2. 12-0-tetradecanoy1 phorbol acetate (TPA) from Sigma 
Chemical Co. Ltd.
3. Teleocidin was provided by Dr. H. Fujiki (National 
Cancer Research Institute, Tokyo).
c) Polyclonal Antibodies :
1. Rabbit anti-human IL-1 binds to the common smaller 
molecular weight form of IL-1 (natural and recombinant) 
pis 5.0 and 7.0 (17.5kD) and also to the larger molecular 
weight precursor (31-40kD). Supplied by Genzyme Koch-Light 
Ltd.
2. Sheep anti-human IFN-gamma serum was supplied by Dr. A.
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Meager at the National Institute for Biological Standards 
and Control (Holly Hill, Hampstead, London) and prepared 
against >95% pure recombinant IFN-gamma obtained from 
Genentech Inc.
3. FITC (fluorescein isothiocyanate) conjugated goat 
anti-mouse IgG from Sigma Chemical Co. Ltd.
4. FITC conjugated goat anti-mouse IgM from Sigma.
5. RITC (rhodamine isothiocyanate) conjugated goat 
anti-mouse IgM from Sigma.
6. FITC conjugated sheep anti-human IgG from Wellcome 
Reagents Ltd.
d) Monoclonal Antibodies (Murine anti-human) :
1. 0KT3 (IgG2a) from Ortho Diagnostic Systems Ltd.
2. 0KT4 (IgG2b) from Ortho.
3. 0KT8 (IgG2a) from Ortho.
4. 0KM1 (IgG2b) from Ortho.
5. Leu lib (IgM) from Becton-Dickinson Monoclonal Center 
Inc.
6. Anti-human IL-2 receptor from Becton-Dickinson.
7. Anti-Tac (human IL-2 receptor) was kindly provided by 
Dr.T.A .Waldman of the National Cancer Institute (Bethesda, 
MD, USA) in ascites form containing approximately 6-8mg/ml 
of IgG2a antibody.
8. 9.6 (anti-E receptor; IgG2a) from New England Nuclear 
Ltd.
9. Anti-BBMI (against beta-chain of MHC class I MHC 
antigens) was kindly provided by Dr.E.Jones (Biological 
Sciences Dept., Warwick University, Coventry) in ascites
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form (IgG2).
10. W6/32 (anti-class I heavy chains) was kindly provided 
by Dr.E.Jones (see above) in ascites form (IgG2),
11. W6/34 (anti-species antigen 1) was kindly provided by 
Dr.E.Jones (see above) in ascites form (IgG2 ).
12. Anti-DR was kindly provided by Dr.W.Bodmer of the 
Imperial Cancer Research Fund.
13. Anti-DR also from DAKO.
e) Interleukins :
1. Human Ultrapure Interleukin 1 from Genzyme Koch-Light 
Ltd.
2. Human Ultrapure Interleukin 2 from Genzyme Koch-Light 
Ltd.
3. Recombinant Human Interleukin 2 from Biogen.
f ) Media :
Medium RPMI 1640, GMEM (Glasgow’s modification of 
Eagle’s Minimal Essential Medium), foetal calf serum and 
newborn calf serum were all obtained from Gibco Ltd. RPMI 
was buffered with 20mM Hepes (pH 6.9) and GMEM with 
bicarbonate (pH 7.0). All media was supplemented with 
penicillin (60pg/ml) and streptomycin (lOOyig/ml), both 
obtained from Glaxo Laboratories Ltd., plus 2mM glutamine. 
GMEM was also supplemented with non-essential amino acids 
(NEAA).
g) Cells :
1. Buffy coats were obtained from the U.K. West Midlands
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Blood Transfusion Centre (Edgbaston. Birmingham) on the 
same day of use. The buffy coats were prepared in the 
presence of citrate by two centrifugation steps to remove 
the majority of the plasma and the red blood cells.
2. WISH human amnion cells from Flow Laboratories Ltd.
3. Sheep erythrocytes from Tissue Culture Services.
4. K562 human erythroleukemic cells from Ian Kimber at the 
Patterson Laboratories, Christie Hospital, Manchester.
5. CTLL from Dr.R.Wilsoncroft, St. Thomas Hospital.
London.
h) Radiochemicals :
1. 5-3H-Uridine (29Ci/mmol) from Amersham Radiochemicals 
PLC.
2. Methyl-i) *3H-thymidine (5-lOCi/mmol) from Amersham.
3. si Cr from Amersham.
4. 32 phosphate labelled dCTP and dGTP ( 3000Ci/mmol) from 
Amersham.
i) Other Materials :
Actinomycin D (Sigma)
Bovine serum albumen (Sigma)
Butanol (Fisons)
Caesium chloride (BRL)
Chloroform (May & Baker Ltd)
Complement (Rabbit; Pel Freeze)
Cycloheximide (Sigma)
DEPC (Diethyl pyrocarbonate; Sigma)
EDTA (Diaminoethanetetra-acetic acid, sodium salt; Sigma)
1 4 4
Eppendorf tubes, 1.5ml (Sarstedt)
Ethanol
Ficoll-Hypaque (Pharmacia)
Flat bottomed microtitre trays (Flow;
Formamide (Fisons)
Guanidinium isothiocyanate (Fluorochem Ltd.)
Hydrochloric acid 1M (BDH Chemicals Ltd)
Human IFN-gamma standard
International human IFN-gamma standard (Research Resources 
Section, National Institute of Allergy and Infectious 
Diseases, Bethesda, Maryland, USA), 
lonophore A23187 (Sigma)
2-mercaptoethanol (BDH Chemicals Ltd.)
Micropipette tips, 200pl & 1ml (LIP Ltd)
Microtiter trays: round bottomed (Flow Labs Ltd.) and flat 
bottomed (Sterilin)
Nitrocellulose filter membrane (Anderman & Co. Ltd) 
Non-specific esterase staining kit (Sigma)
Nylon wool (Leuko Pak)
Percoli (Pharmacia)
Plastic universals and petri dishes (Sterilin) 
Prostaglandin E2 (Sigma)
PBS (pH 7.4)
Salmon Sperm DNA (Sigma)
Sephadex G75 (Pharmacia Fine Chemicals Ltd.)
Scintillation fluid: EP or NA (Beckman Ltd.)
Sephadex G75 (Pharmacia)
Silica (Sigma)
Sodium hydroxide 1M (BDH Chemicals Ltd)
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Trichloroacetic acid (May & Baker Ltd. )
Tris = TRIZMA base (Trishydroxymethylaminomethane; Sigma) 
Trypsin (Sigma)
Ultracentrifuge tubes (MSE)
X-ray film (Fuji)
j) Buffers and Solutions.
1. Lytic Buffer:
4M guanidinium isothiocyanate 
1M 2-mercaptoethanol
20mM sodium acetate pH 5 = (600pl 3M NaAc pH 6 + 
HOpl 3M NaAc pH 5)
Solution must be warmed at 370C to dissolve the 
isothiocyanate, and then filtered through Millex or 
Nalgene filters. Store in the dark at room temperature.
2. Caesium chloride solution:
5.7M CsCl
Refractive index should be adjusted to 1.405. Filter 
through Millex filter before use.
3. DEPC treated water:
0.1% DEPC (Diethyl pyrocarbonate)
Autoclaved to remove residual DEPC.
4. Tris:
5mM Tris (pH 7.5) in DEPC treated water.
5 . Ti o Ni 5 o El :
lOmM Tris (pH 7.5)
150mM NaCl
ImM EDTA (pH 7.5)
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20X SSPE :6 .
3.0M NaCl
2Û0mM NaH2 PO4 (pH 7.4)
20mM EDTA (pH 7.4)
7. 20X SSC:
3M NaCl
0.3M Na citrate (pH 7)
8. Denhardt's solution:
0.02% Ficoll
0.02% polyvinylpyrrolodine 
0.02% bovine serum albumen
9. 10X RP buffer:
500mM Tris HCl (pH 7.5)
500mM NaCl 
lOOmM MgCl2
70mM beta-mercaptoethanol 
500pg/ml bovine serum albumen
10. Phosphate buffered saline (PBS) pH 7.4
0.8% NaCl 
0.02% KC1
8mM disodium hydrogen phosphate 
1.5mM potassium dihydrogen phosphate
11. RNA loading dye :
5mM EDTA 
40% Ficoll
0.05% bromophenol blue
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k) Names and adresses of suppliers:
Amersham International : White Lion Rd., Amershara. Bucks 
HP7 9LL.
Anderman & Co. Ltd : Central Avenue, East Molesey, Surrey.
Beckman Ltd. : High Wycombe, Bucks.
Becton-Dickinson Monoclonal Center Inc. : Mountain View. 
CA. USA.
BDH Chemicals Ltd.: Poole, Dorset.
Biogen : Geneva. Switzerland.
BRL-Life Technologies Inc. : PO Box 6009, Gaithersburg,
MD. USA.
DAKO : DAKOPATTS Ltd., Copenhagen, Denmark.
Fenwal Laboratories : Illinois, USA.
Fisons pic : Bishops Meadow Rd., Loughborough, Leics 
LEI1 ORG.
Flow Labs Ltd. : Irvine Industrial Estate, PO Box 17 
Second Avenue, Ayrshire. Scotland. KA12 8NB.
Fluorochem Ltd. : Peakdale Rd., Glossop. Derbyshire 
SKI3 9XE.
Fuji Photo Film Co. Ltd : Tokyo, Japan.
Genentech Inc. : San Francisco, CA. USA.
Genzyme Koch-Light Ltd. : Hollands Rd., Haverhill, Suffolk 
CB9 8PU.
Gibco Europe Ltd. : PO Box 35 Trident House, Renfrew Rd., 
Paisley. Scotland, PA3 4EF.
Glaxo Laboratories Ltd. : Greenford, England.
L.C. Services Corporation : Woburn, MA, USA.
Leuko Pak : Fenwal Laboratories, Illinois, USA.
LIP (equipment & Services) Ltd : 111 Dockfield Rd.,
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Shipley, W. Yorkshire.
May & Baker Ltd. : Dagenham
Miles-Yeda Ltd. : Box 37, Stoke Poges, Slough, Berkshire.
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METHODS
a) Call preparation and culture
i) PBML.
Peripheral blood mononuclear leukocytes (PBML) were 
obtained by centrifugation over Ficoll-Hypaque of human 
buffy coat residues from normal blood. The cells were 
cultured in RPMI-1640 medium buffered with HEPES and 
supplemented with 10% foetal calf serum (FCS), penicillin 
(60pg/ml) and streptomycin (100pg/ml). This medium was 
used for all procedures and incubations involving PBML and 
fractions of PBML. unless otherwise stated.
ii) Lymphocytes.
Macrophage-depleted lymphocytes were prepared by 
replating PBML three times at hourly intervals on plastic 
petri dishes to remove adherent cells. Silica was then 
added at 200pg/ml overnight to eliminate the few remaining 
phagocytic cells. The lymphocytes were then isolated over 
Ficoll at 350G to remove the silica and cell debris. This 
method produced lymphocyte preparations containing <1% 
macrophages judged by non-specific esterase staining.
iii) Macrophages.
Macrophages/monocytes were isolated by virtue of their 
density and adherent properties. Since they are of lower 
density than the majority of lymphocytes, macrophages were 
initially enriched for by centrifugation of PBML on a 4 
step Percoll/RPMI gradient consisting of 40, 43, 46, and
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50% Percoll fractions. The Percoll was buffered by mixing 
8 parts of lOx concentrated phosphate buffered saline 
(PBS) with 92 parts Percoll, before adding RPMI 1640/10% 
FCS for the required concentrations. After centrifugation 
the lowest and highest density fractions were discarded 
since they contain mainly platelets and lymphocytes, 
respectively. The middle two fractions which are enriched 
for macrophages were incubated (37<>C) on FCS treated 
plastic petri dishes (prepared by a 4 hour treatment of 
the plates with FCS at 4°C ). Non-adherent cells 
(lymphocytes) were removed at intervals over the next 18 
hours (at least 5 times). Ail macrophage/monocyte 
preparations obtained by this method contained >99% 
macrophages as .judged by the india ink test (1 hour 
incubation in 0.5% ink. followed by visual examination for 
any non-phagocytic cells remaining). Macrophages were 
removed from the FCS treated plates by incubation at 4<>C 
for at least 30 minutes in chelating buffer (0.2% EDTA and 
5% FCS in PBS). This caused resuspension of the adherent 
cells, aided by vigorous pipetting and several washes with 
PBS.
iv) Low density lymphocytes.
Separation of lymphocytes into differing density 
sub-populations was achieved by centrifugation at 550G for 
30 minutes over a six step discontinuous Percoll/RPMI 
gradient whose steps varied from 40% to 52.5% Percoll. 
Cells were harvested from each layer and counted to 
determine the percentage of the total lymphocyte
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population present in each step. Cells from the top one to 
three steps were used as the low density fraction, varying 
from 5 to 30% of the total lymphocyte population, the 
percentage depending on efficiency of separation. The low 
density lymphocytes were chiefly found at the interface 
between the 42.5 and 45% steps. In later experiments a 
single 46% Percoll cushion was used to isolate low density 
cells. Cells isolated from the bottom three steps or below 
the 46% interface were considered high density lymphocytes 
(i.e. chiefly T-cells).
v) High affinity sheep red blood cell rosetting.
The low density population was further fractionated into 
E+ and E- cells by high affinity sheep red blood cell 
(SRBC) or erythrocyte (E) rosetting which separates T from 
non-T cells by virtue of the high affinity sheep 
erythrocyte or E receptor found on all T-cells (Timonen gt 
âl.,1981). Lymphocytes were washed twice in PBS and 
resuspended in RPMI at 2x106 cells/ml. SRBC. after three 
washes in PBS, were resuspended in RPMI at 3x108 cells/ml. 
Equal volumes of lymphocytes and erythrocytes were mixed 
and then an equal volume of FCS added. After gentle 
pelleting (200G) the cells were incubated at 29°C for one 
hour. After gentle resuspension with a wide bore pipette, 
in order not to disturb any "rosettes" formed between 
T-cells and SRBC, the rosetted and non-rosetted cells were 
separated by Ficoll centrifugation (30 minutes at 500G). 
Only the denser rosetted E+ cells fell through the Ficoll 
to form a pellet, whilst the E- cells formed a layer above
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the Ficoll. After checking visually that rosettes had 
actually formed. SRBC were removed from the rosetted 
lymphocytes by incubation in lysis buffer (0.14M ammonium 
chloride. 20mM tris, pH 7.5) for 10 minutes at 37«C, 
followed by three washes in PBS.
vi) Nylon wool column filtration.
Both adherent macrophages and B cells could be removed 
from PBML by nylon wool chromatography (Julius et 
<1.1., 1973). For 10® cells a 10ml syringe was packed with 
0.6g of nylon wool (sterilised as an assembled unit). The 
column was equilibrated with RPMI 1640/2% FCS medium for 
45 minutes at 37®C, rinsed with 10ml of medium, and then 
5ml of 1x10® cells was loaded on. After 45 minutes at 
37®C, the nylon wool non-adherent cells were eluted with 
warmed medium at a rate of one drop per second until no 
further cells were collected.
vii) Induction__.of__LFN-gamma__production__and_metabolic
Cells were cultured at 370C in fresh medium (RPMI 
1640/10% FCS) at a cell density of 5x10® cells/ml. 
Round-bottomed 200pl well microtiter trays (Flow Labs 
Ltd.) were used. Inducers were added at the concentrations 
stated in the results sections, usually those found to 
give optimum stimulation, i.e. SEA at 20ng/ml, PHA at 
lOpg/ml, Con A at 20pg/ml, and 0KT3 at lOng/ml. 
Supernatants were harvested 3 days post-induction, unless 
otherwise stated, since IFN-gamma production usually
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peaked at this time. The level of general cell activation, 
as measured by 3H-thymidine incorporation, was determined 
3-4 days post-induction.
b ) Characterisation_____of_____ cell_____ fractions____using
immunofluorescence.
Indirect immunofluorescence was used to characterise 
fractions by virtue of the cell surface markers that they 
expressed. This involved an initial incubation with the 
required mouse monoclonal antibodies and a second 
incubation with fluorescein (FITC) labelled goat
anti-mouse Ig. An IgG specific FITC conjugate was used 
with all the monoclonal antibodies except Leu 11. This 
required an IgM specific FITC or rhodamine (RITC) 
conjugate. A lOOpl volume of cells at 10? cells/ml were 
incubated for 30 minutes at 4°C with 5pl of the mouse 
monoclonal antibody. Every 10 minutes the mixture was 
gently shaken. The cells were then washed 3 times in cold 
PBS and the entire procedure repeated with 50pl of 
FITC-labelled anti-mouse Ig. This dilution of conjugate 
usually ensured that non-specific binding was kept to a 
minimum, i.e. <5% of the cells appeared fluorescent in the 
reagent control. The cells were then resuspended in 80ul 
of glycerol:PBS for storage at -20°C or examination on a 
UV fluorescence microscope. The percentage of positive 
cells was determined by judging which cells were more 
fluorescent than control cells (treated only with FITC 
labelled anti-mouse Ig) and examining at least 200 cells 
per sample. However, if the cells were to be analysed by
154
FACS (fluorescence activated cell sorter) then they were 
fixed in a 3% paraformaldehyde solution instead.
A direct procedure was used to determine the percentage 
of human B-cells. Cells were incubated with FITC labelled 
rabbit anti—human IgG by the same procedure as above. A 
B-cell line was shown to be 100% positive by this method.
c ) Assay Methods, 
i) IFN assay.
Interferon was assayed by the INAS-50 method (Atkins et 
al.,1974) using Semliki Forest virus to challenge human 
amnion (WISH) cells. Viral replication was measured by 
tritiated uridine incorporation, the extent of which 
depended on the degree to which an IFN sample had induced 
an antiviral state.
WISH cells were grown in GMEM medium plus 10% newborn 
calf serum (NBS) at 370C in 5% C02 humidified incubator. 
For an assay they were plated out in flat bottomed 
microtitre trays at approximately 4x10“» cells/well 18 
hours before use in order to allow the cells to adhere to 
the well bottom surface. Cells were initially plated out 
in GMEM/10% NBS, but this was replaced with 180ul/well of 
GMEM/2% NBS (minimum maintenance level to reduce cellular 
RNA synthesis) before making dilutions of the IFN samples. 
To dilute out the samples 2Cijil volumes of the neat IFN 
samples were placed in duplicate wells and serial ten-fold 
dilutions, also in duplicate, were made across the plate. 
The WISH cells were then incubated for a further 12-18 
hours in order to allow the antiviral state to be induced
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proportional to the level of IFN in the sample.
A laboratory IFN-gamma standard was included to 
calibrate the assays, and this was itself calibrated 
against an international standard of human reference 
IFN-gamma (National Institute of Health. Bethesda, MD). 
Laboratory units of IFN were found to be equivalent to 
reference units.
The IFN dilutions were then aspirated off and the cells 
challenged with Semliki Forest virus (SFV) stock (L10 
strain of the order of 109 pfu/ml) in the presence of 
3pg/ml of actinomycin D (AMD) in fresh medium (2% NBS), 
adding lOOpl per well. The purpose of the AMD was to 
inhibit cellular DNA-dependent RNA synthesis, yet allow 
virus-specific RNA synthesis. After 3 hours lOpCi/ml of 
3H-uridine in the the presence of AMD in fresh medium (2% 
NBS) was added, lOOpl/well to give a total volume of 200fil 
in each well. The cells were incubated for at least a 
further 3 hours. The medium was then aspirated and the 
cell monolayers washed once with PBS, then twice with cold 
5% trichloroacetic acid to precipitate the incorporated 
3H-uridine, and once with absolute ethanol. The cell 
sheets were then dried and 48pl of molar NaOH added to 
each well. The plates were left overnight at 37®C for 
hydrolysis to occur. Just prior to harvesting the samples, 
52pl of molar HC1 was added to each well to make the pH of 
the wells slightly acidic. The individual wells were then 
harvested and transferred to plastic scintillation vials 
before adding 2ml of acidified scintillation fluid (EP, 
Beckman). Incorporation of 3H-uridine was assessed by
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counting samples in an LKB "Rackbeta" scintillation 
counter.
As well as IFN samples, each plate also containd a 
laboratory IFN-gamma sample and controls. A ''virus" 
control (4 wells) contained challenge virus but no IFN was 
added to the wells, thus giving a measure of maximum 
incorporation of radioactive label. A "cell" control (4 
wells) consisted of wells where neither IFN nor virus was 
added, thus giving a measure of background incorporation 
of 3H-uridine by the AMD-treated cells alone.
Raw results were obtained as readings of counts per 
minute (cpm) for each well, in duplicate. Using the mean 
cpm value for each set of duplicates, the level of 
incorporated label was plotted against logio dilution 
value of the sample (Fig. 7.1). The number of U/ml of IFN 
in a sample is the reciprocal of the dilution causing a 
50% reduction in viral nucleic acid synthesis. The 50% 
reduction value was the midpoint between the virus control 
(Vc = maximum incorporation by the virus) and the cell 
control (Cc = residual incorporation by cells alone). An 
appropriate dilution of virus was used to ensure that the 
virus control was at least 5 times the value of the cell 
control. The IFN titre was thus the reciprocal value of 
the dilution at which the titration curve dissected the 
horizontal 50% endpoint line. A typical IFN assay plot is 
shown in figure 7.1.
Neutralisation assays were carried out by adding 20|il of 
anti-IFN-gamma sera to the WISH cells (final dilution of 
1/300), in addition to the 20pl IFN sample, before making
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Figure 7.1 A TYPICAL INTERFERON ASSAY.
▲  = SEA sample = 2.1 = 120 U/ml 
▼  = A23187 = <0.3 = <2 U/ml
♦  = Mezerein = 1.2 = 16 U/ml
■  = A23187 plus Mezerein = 3.3 = 2000 U/ml
"the dilutions. Any residual IFN activity was then assayed. 
The anti-IFN-gamma antiserum was prepared against 
recombinant IFN-gamma and had no effect on IFNs alpha and 
beta.
A greater than two-fold difference in titre was 
considered to be statistically significant, since in a 
series of replicate titrations of the same standard sample 
95% of the titres obtained lay within a two-fold range. On 
the basis of this assumption, there was a 95% probability 
that the values obtained for a single sample titrated 
twice within the same assay would be within a two-fold 
difference. Thus any greater deviation than this 
constitutes a significant difference between IFN titres.
IL-2 activity was assayed using the IL-2 dependent cell 
line CTLL. These were grown in RPMI 1640/10% FCS plus 10-5 
2-mercaptoethanol, buffered with bicarbonate. Periodic 
addition of IL-2 containing conditioned media (obtained 
from activated PBML) was required to sustain cell growth. 
CTLL were used for an assay three days after the last use 
of conditioned media. They were then resuspended in fresh 
media. IL-2 containing samples were diluted in duplicate, 
usually using half-log dilutions, across a series of 200pl 
microtitre round-bottomed wells containing an appropriate 
volume of medium. CTLL were added after the IL-2 samples, 
2000 CTLL per well. The CTLL were then incubated at 37<>C 
for 24 hours. The stimulatory effects of any IL-2 in the 
samples were determined from the level of 3H-thymidine
158
andincorporation, added at lOpCi/ml to all wells 
incubated for a further 18 hours. The CTLL were then 
harvested using a MASH II cell harvester and
cell-associated radioactivity measured using non-aqueous 
(NA) scintillation fluid. Several wells contained no IL-2 
to measure minimum CTLL proliferation whilst commercial 
IL-2 was added to some wells to stimulate maximal 
proliferation. The number of U/ml of IL-2 in a sample was 
the reciprocal of the dilution causing half maximal 
incorporation.
iii) Assay of RNA and DNA synthesis.
The level of RNA production or cellular proliferation, 
as reflected by the level DNA synthesis, were measured by 
labelling the cells (quadruplicate wells) with 3H-uridine 
or 3 H-thymidine at 2.5pCi/ml for a 24 hour period 3-4 days 
after induction. The cells were then harvested using the 
MASH II cell harvester and cell associated radioactivity 
measured using NA scintillant.
iv) NK cytotoxicity.
K562 cells were used as NK susceptible targets in order 
to measure cytotoxicity. They were incubated with 200pCi 
of 51Cr at 2x10® cells/ml for 2 hours. They were then 
washed 3 times in PBS, left for one hour, and washed once 
more in PBS. The K562 cells were then placed in 200pl 
microtitre wells at 5x10« cells/ml with the cells whose 
cytotoxicity was to be measured at various effector:target 
ratios (usually 30,10, and 3:1), total volume of 200pl.
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After incubation at 37°C for the appropriate time, 15uul 
of supernatant from each well was collected and counted on 
a gamma counter. The percentage of si Cr release was 
calculated by the formula :
%cytotoxicity = Experimental cpm - Spontaneous cam X 100
Total cpm - Spontaneous cpm
Total cpm was determined as the amount released by 
incubating labelled K562 cells with 1M HC1. Spontaneous 
release was measured in wells containing no effector 
cells.
d) IFN-gamma and Interleukin 2 mRNA induction and 
estimation.
i) Induction of mRNA for IFN-gamma and IL-2.
For mRNA preparations much larger numbers of cells 
needed to be processed than required for measuring 
IFN-gamma production. Hence 50ml aliquots of cell 
suspensions (3 x 10® cells/ml), usually pooled from 
several donors, were cultured in large petri dishes (10cm 
diameter; Sterilin Ltd.) with addition of inducers and 
cycloheximide (CHX; Sigma) as appropriate. Crude SEA (used 
in these experiments because of the limited availability 
of pure SEA) was used at 0.5% by volume. A23187 at lpM, 
and mezerein at lOng/ml. CHX (added 1 hour before addition 
of inducers) was used at 200ug/ml, a concentration which 
inhibits protein synthesis by more than 99% in these 
cells, as assessed by 3sS-methionine incorporation.
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ii ) Isolation of RNA
RNA was isolated by the guanidinium 
isothiocyanate-caesium chloride method (Morser et 
al.,1979). Cells were harvested 4 or 24 hours 
post-induction by scraping them off the plate with rubber 
policemen in the presence of PBS, twice. All PBS washes 
and the initial supernatant were spun at 3K for 5 minutes 
in a Chilspin. The cell pellet was then washed once in PBS 
before resuspending it in 3.5ml of lytic buffer 
(guanidinium isothiocyanate) and vortexing to ensure 
complete lysis. This was loaded onto a 1.5ml cushion of 
5.7M caesium chloride (RI=1.405) in MSE (111) 5.5 ml 
polycarbonate ultracentrifuge tubes and centrifuged at
40,000 rpm for 22-24 hours in an MSE "Superspeed 65"
ultracentrifuge , at 210 C, using an MSE 6x5.5 swing-out
rotor. Lysis buffer and caesium chloride were then
aspirated, and each RNA pellet was dissolved into 300ja1 of 
5mM Tris buffer. The RNA was extracted three times with 
equal volumes of a 1:4 mixture of butanol/chloroform, the 
RNA contained in the upper aqueous phase and the caesium 
chloride being discarded with the non-aqueous phase. The 
RNA was then precipitated by adding 30pl of 3M NaCl to the 
300pl of RNA/Tris solution, plus 2.5 volumes of absolute 
ethanol, then placed at -20<>C for at least 20 hours.
All aqueous solutions (apart from the lysis buffer) used 
throughout the RNA extraction were made up in water which 
had been pretreated with diethyl pyrocarbonate (DEPC) in 
order to destroy any contaminating RNases.
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ii) Isolation of RNA
RNA was isolated by the guanidinium 
isothiocyanate-caesium chloride method (Morser et 
Si. ,1979) . Cells were harvested 4 or 24 hours 
post-induction by scraping them off the plate with rubber 
policemen in the presence of PBS, twice. All PBS washes 
and the initial supernatant were spun at 3K for 5 minutes 
in a Chilspin. The cell pellet was then washed once in PBS 
before resuspending it in 3.5ml of lytic buffer 
(guanidinium isothiocyanate) and vortexing to ensure 
complete lysis. This was loaded onto a 1.5ml cushion of 
5.7M caesium chloride (RI=1.405) in MSE (111) 5.5 ml 
polycarbonate ultracentrifuge tubes and centrifuged at 
40,000 rpm for 22-24 hours in an MSE "Superspeed 65" 
ultracentrifuge, at 21° C, using an MSE 6x5.5 swing-out 
rotor. Lysis buffer and caesium chloride were then 
aspirated, and each RNA pellet was dissolved into 300pl of 
5mM Tris buffer. The RNA was extracted three times with 
equal volumes of a 1:4 mixture of butanol/chloroform, the 
RNA contained in the upper aqueous phase and the caesium 
chloride being discarded with the non-aqueous phase. The 
RNA was then precipitated by adding 30pl of 3M NaCl to the 
300pl of RNA/Tris solution, plus 2.5 volumes of absolute 
ethanol, then placed at -20°C for at least 20 hours.
All aqueous solutions (apart from the lysis buffer) used 
throughout the RNA extraction were made up in water which 
had been pretreated with diethyl pyrocarbonate (DEPC) in 
order to destroy any contaminating RNases.
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To measure yields of -total RNA. precipitated RNA was 
pelleted by centrifugation at 10,000g for 10 minutes in an 
Eppendorf "Microfuge". The pellet was washed once in 80% 
ethanol, before repelleting then freeze-drying. The pellet 
was then dissolved in lOOpl of DEPC-treated distilled 
water. A dilution of this was assayed for absorption at 
260nm, in a Unicam SP500 spectrophotometer, in quartz 
cuvettes. An O.D. (optical density) of 1.0 was equivalent 
to 40pg/ml of RNA in the sample. Typically from 150 to 
500pg of RNA was obtained from 1.5x10® lymphocytes. The 
RNA solution could be stored long-term at -70°C.
iii) Quantitation of mRNA levels.
The level of IFN-gamma or IL-2 mRNA in the total RNA of 
each sample was then determined by dot-blot hybridisation 
analysis (Thomas,1980). Nitrocellulose filters were 
presoaked in 20xSSC (lxSSC is 0.15M NaCl, 15mM sodium 
citrate. pH 7.0) for 2 hours and then 20pg duplicates of 
each RNA sample were dotted onto them using a dot-blot 
manifold. Before dotting each RNA sample was made up to 
lOOpl with water and denatured at 65®C for 10 minutes. The 
sample was transferred to an ice/water slurry to prevent 
renaturation and 50pl of cold 20xSSC added per lOOpl of 
sample. After dotting the samples the filter was air-dried 
and then baked at 80<>C for 2 hours in a vacuum oven to fix 
the RNA.
The filter was then soaked in 6xSSC for 5 minutes before 
incubating with a prehybridisation solution, sealed in a 
plastic bag, for 4 hours in a 42°C shaking water bath. The
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prehybridisation solution consists of 50% deionised
formamide (pH 6.8), 5xDenhardt’s solution, 5xSSPE, 0.1% 
SDS, lpg/ml poly A, and heat-denatured salmon sperm DNA at 
lOOng/ml. It was used at 0.3ml per cm2 of nitrocellulose 
filter. This was then changed for a hybridisation 
solution containing heat-denatured, nick-translated cDNA 
probe homologous to IL-2 or IFN-gamma mRNA (Siggens si 
sl.,1984). The IL-2 probe was kindly provided by
Dr.T.Taniguchi (Taniguchi si al.,1983). In all other 
respects the hybridisation mixture was identical to that 
used for prehybridisation, and was used at 0.15ml per cm2 
of filter. Hybridisation was allowed to proceed for 15 
hours at 42°C. The prehybridisation stage helped to block 
any non-specific binding of the labelled probe.
After hybridisation the filters were washed twice in 
3xSSC at room temperature, then once in 0.5xSSC at 65«C 
for 45 minutes in a shaking water bath. Filters were then 
air-dried and the positions of the signals were located by 
autoradiography for 1-3 days, depending on the specific 
activity of the probe used, against Fuji RX X-ray film, 
using a Dupont Cronex "Lighting-plus" intensifying screen, 
at -70°C. The filters were then cut into sections and each 
sample quantitated by liquid scintillation counting.
iv) Preparation_____af_____ radiolabelled_____ Probe------bz
nick-translation.
For both IFN-gamma and IL-2 probes, 50ng of the 
appropriate cDNA in 3-7pl of water was denatured in 
boiling water for 2.5 minutes and immediately quenched in
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ice slurry. The following components were then added on 
ice: 2pl of lOxRP buffer. 2pl of lOxdNTP mix (2mM of each 
unlabelled dNTP), 2pl of OCT primer (prepared as described 
in the Maniatis Cloning Manual pl30), 2pl of water, 4pl 
(40pCi) of 3 2 phosphate dCTP or dGTP, and finally 2pl of 
Klenow enzyme (Amersham). After a brief vortex, the 
mixture was then incubated for at least 8 hours at 19+1®C. 
After this time 0.5ul of 10% SDS and lOpl of salmon sperm 
DNA (2mg/ml) were added, plus lOpl of loading dye. 
Nick-translated DNA was then separated from unincorporated 
label and deoxynucleotide triphosphates by chromatography 
on a Sephadex G-75 column (a slurry equilibrated in TNEt 
run in TNE buffer. The first eight fractions (7 drops 
each) were collected and the 3 or 4 "hottest" fractions 
mixed and used as probe. Typically, the specific activity 
of nick-translated probe prepared in this fashion was in 
the order of 1-5x107 cpm. After denaturing by boiling the 
probe was ready for use in the hybridisation mix. Probe 
was used as soon as possible after preparation, usually 
within 2 days.
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